Imiquimod-Induced Subacute Cutaneous Lupus Erythematosus–like Changes

Article Type
Changed
Thu, 01/10/2019 - 13:23
Display Headline
Imiquimod-Induced Subacute Cutaneous Lupus Erythematosus–like Changes

Drug-induced lupus accounts for up to 10% of lupus erythematosus cases. Subacute cutaneous lupus erythematosus (SCLE) is a distinct clinical variant of lupus erythematosus that typically presents as annular, often scaly, erythematous plaques in photodistributed areas. Subacute cutaneous lupus erythematosus has been reported in association with multiple systemic medications including docetaxel, terbinafine, leuprolide acetate, etanercept, and efalizumab1-5; however, the induction of SCLE by topical agents has not been widely reported. We report a case of local induction of lesions that clinically and histologically resembled SCLE in a 50-year-old woman following treatment with topical imiquimod.

Case Report

A 50-year-old woman presented with an adverse inflammatory reaction on the right side of the upper chest secondary to application of topical imiquimod. Prior to the current presentation the patient was diagnosed with a biopsy-proven superficial basal cell carcinoma (BCC) on the sun-exposed area of the upper right breast, and topical imiquimod therapy was initiated. Several days after starting treatment, the patient began applying imiquimod on areas of clinically normal skin on the upper chest as advised by her dermatologist. After 7 to 10 days of application the patient reported intense erythema, pain, and crusting in the treated area on the right side of the upper chest. She also experienced systemic symptoms including fatigue, arthralgia, malaise, and fever.

Clinical examination revealed erythematous to violaceous annular and polycyclic plaques on the upper chest (Figure 1). Erythema and scaling were noted at the site of the superficial BCC. A biopsy showed a superficial and mid-dermal perivascular and periadnexal lymphocytic infiltrate with overlying vacuolar interface dermatitis and scattered necrotic keratinocytes (Figures 2A and 2B). There was slightly increased dermal edema and mucin. Anti-CD123 immunohistochemical staining revealed nodular aggregates of plasmacytoid dendritic cells (pDCs) accompanying lymphocytes around dermal vessels and adnexa (Figure 2C). The patient’s family history was remarkable for SCLE in her daughter. Antinuclear antibody, anti-Ro (Sjögren syndrome antigen A), and anti-La (Sjögren syndrome antigen B) were negative. On follow-up examination 1 month after discontinuation of imiquimod, the patient’s skin lesions had completely cleared. Two years later, the patient continued to be free of skin lesions.

 


Figure 1. Annular plaques on the upper chest with overlying
scale and focal central clearing. 


 

Figure 2. Vacuolar interface dermatitis with a perivascular and periadnexal lymphocytic infiltrate (A)(H&E, original magnification ×40). Scattered necrotic keratinocytes were evident (B)(H&E, original magnification ×400). Anti-CD123 immunohistochemical staining revealed nodular aggregates of plasmacytoid dendritic cells with accompanying lymphocytes centered around dermal vessels and adnexa (C)(original magnification ×200).

Comment

Imiquimod is a topical immunomodulator used for the treatment of genital warts and cutaneous malignancies. It exerts its effect via induction of proinflammatory cytokines (eg, IFN-a, tumor necrosis factor a [TNF-α]) through activation of toll-like receptor (TLR) 7, an intracytoplasmic receptor that is found on several cell types including pDCs and B cells. When the cell surface receptor is bound by activating ligands (eg, single-stranded RNA, imiquimod), downstream signaling is initiated, resulting in the production of large amounts of IFN-a and TNF-α.6,7 Both IFN-a and TNF-α are upregulated in patient serum and lesional skin in SCLE.8,9 Additionally, pDCs have been shown to accumulate in lesions of cutaneous lupus erythematosus (CLE) in a distinct dermal pattern, as demonstrated by CD123 staining.9,10 This pattern is identical to the one seen in our case. Although pDCs also are present in cutaneous dermatomyositis lesions, the pattern is distinct from CLE.10 These findings indicate that IFN-a produced by pDCs may play an integral role in the pathogenesis of CLE. Several observations implicating TLR signaling in the pathogenesis of lupus have been described. In a lupus-prone mouse model of lupus erythematosus, transgenic overexpression of TLR-7 resulted in increased severity of clinical disease and accelerated mortality. Antimalarials improve lupus erythematosus via blockade of TLR-7 and TLR-9 signaling.11

Imiquimod, which acts as an inducer of IFN-α expression through TLR-7 signaling, may have been an inciting factor in the development of SCLE-like lesions in this genetically predisposed patient. Histopathology of cutaneous malignancies treated with topical imiquimod typically does not show lupuslike features.12 It is possible that a subset of predisposed patients have increased numbers of pDCs primed in their skin or that they exhibit a more robust TLR-7 reaction to imiquimod, resulting in abundant IFN-a production. Other autoimmune diseases, such as pemphigus foliaceus and vitiligo, also have been reported to occur locally after the application of imiquimod,13,14 which suggests that a localized autoimmune reaction can be induced by activation of TLR-7; however, a case of chronic discoid lupus erythematosus of the scalp improving after treatment with imiquimod has been reported.15

 

 

The use of imiquimod in patients with a personal or family history of lupus erythematosus or those with a personal history of an autoimmune blistering disorder should be undertaken with caution until more is known.

References

 

1. Chen M, Crowson AN, Woofter M, et al. Docetaxel (taxotere) induced subacute cutaneous lupus erythematosus: report of 4 cases. J Rheumatol. 2004;31:818-820.

2. Farhi D, Viguier M, Cosnes A, et al. Terbinafine-induced subacute cutaneous lupus erythematosus. Dermatology. 2006;212:59-65.

3. Wiechert A, Tüting T, Bieber T, et al. Subacute cutaneous lupus erythematosus in a leuprorelin-treated patient with prostate carcinoma. Br J Dermatol. 2008;159:231-233.

4. Bleumink GS, ter Borg EJ, Ramselaar CG, et al. Etanercept-induced subcutaneous lupus erythematosus. Rheumatology (Oxford). 2001;40:1317-1319.

5. Bentley DD, Graves JE, Smith DI, et al. Efalizumab-induced subacute cutaneous lupus erythematosus. J Am Acad Dermatol. 2006;54(suppl 5):S242-S243.

6. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol. 2006;6:823-835.

7. Hurwitz DJ, Pincus L, Kupper TS. Imiquimod: a topically applied link between innate and acquired immunity. Arch Dermatol. 2003;139:1347-1350.

8. Zampieri S, Alaibac M, Iaccarino L, et al. Tumour necrosis factor alpha is expressed in refractory skin lesions from patients with subacute cutaneous lupus erythematosus. Ann Rheum Dis. 2006;65:545-548.

9. Farkas L, Beiske K, Lund-Johansen F, et al. Plasmacytoid dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol. 2001;159:237-243.

10. McNiff JM, Kaplan DH. Plasmacytoid dendritic cells are present in cutaneous dermatomyositis lesions in a pattern distinct from lupus erythematosus. J Cutan Pathol. 2008;35:452-456.

11. Pisitkun P, Deane JA, Difilippantonio MJ, et al. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science. 2006;312:1669-1672.

12. Wolf IH, Kodama K, Cerroni L, et al. Nature of inflammatory infiltrate in superficial cutaneous malignancies during topical imiquimod treatment. Am J Dermatopathol. 2007;29:237-241.

13. Lin R, Ladd DJ Jr, Powell DJ, et al. Localized pemphigus foliaceus induced by topical imiquimod treatment. Arch Dermatol. 2004;140:889-890.

14. Brown T, Zirvi M, Cotsarelis G, et al. Vitiligo-like hypopigmentation associated with imiquimod treatment of genital warts. J Am Acad Dermatol. 2005;52:715-716.

15. Gersden R, Wenzel J, Uerlich M, et al. Successful treatment of chronic discoid lupus erythematosus of the scalp with imiquimod. Dermatology. 2002;205:416-418.

Article PDF
Author and Disclosure Information

 

Sheilagh M. Maguiness, MD; Terry T. Farsani, MD; Daniel C. Zedek, MD; Timothy G. Berger, MD

Dr. Maguiness is from the University of Minnesota, Minneapolis. Dr. Farsani is from the Palo Alto Medical Foundation, Mountain View, California. Drs. Zedek and Berger are from the University of California, San Francisco.

The authors report no conflict of interest.

Correspondence: Terry T. Farsani, MD, Palo Alto Medical Foundation, 701 E El Camino Real, Mountain View, CA 94306 (tfarsani@gmail.com).

Issue
Cutis - 95(6)
Publications
Topics
Page Number
349-351
Legacy Keywords
imiquimod, cutaneous lupus, toll-like receptor, autoimmune disease, plasmacytoid dendritic cells, drug-induced lupus
Sections
Author and Disclosure Information

 

Sheilagh M. Maguiness, MD; Terry T. Farsani, MD; Daniel C. Zedek, MD; Timothy G. Berger, MD

Dr. Maguiness is from the University of Minnesota, Minneapolis. Dr. Farsani is from the Palo Alto Medical Foundation, Mountain View, California. Drs. Zedek and Berger are from the University of California, San Francisco.

The authors report no conflict of interest.

Correspondence: Terry T. Farsani, MD, Palo Alto Medical Foundation, 701 E El Camino Real, Mountain View, CA 94306 (tfarsani@gmail.com).

Author and Disclosure Information

 

Sheilagh M. Maguiness, MD; Terry T. Farsani, MD; Daniel C. Zedek, MD; Timothy G. Berger, MD

Dr. Maguiness is from the University of Minnesota, Minneapolis. Dr. Farsani is from the Palo Alto Medical Foundation, Mountain View, California. Drs. Zedek and Berger are from the University of California, San Francisco.

The authors report no conflict of interest.

Correspondence: Terry T. Farsani, MD, Palo Alto Medical Foundation, 701 E El Camino Real, Mountain View, CA 94306 (tfarsani@gmail.com).

Article PDF
Article PDF
Related Articles

Drug-induced lupus accounts for up to 10% of lupus erythematosus cases. Subacute cutaneous lupus erythematosus (SCLE) is a distinct clinical variant of lupus erythematosus that typically presents as annular, often scaly, erythematous plaques in photodistributed areas. Subacute cutaneous lupus erythematosus has been reported in association with multiple systemic medications including docetaxel, terbinafine, leuprolide acetate, etanercept, and efalizumab1-5; however, the induction of SCLE by topical agents has not been widely reported. We report a case of local induction of lesions that clinically and histologically resembled SCLE in a 50-year-old woman following treatment with topical imiquimod.

Case Report

A 50-year-old woman presented with an adverse inflammatory reaction on the right side of the upper chest secondary to application of topical imiquimod. Prior to the current presentation the patient was diagnosed with a biopsy-proven superficial basal cell carcinoma (BCC) on the sun-exposed area of the upper right breast, and topical imiquimod therapy was initiated. Several days after starting treatment, the patient began applying imiquimod on areas of clinically normal skin on the upper chest as advised by her dermatologist. After 7 to 10 days of application the patient reported intense erythema, pain, and crusting in the treated area on the right side of the upper chest. She also experienced systemic symptoms including fatigue, arthralgia, malaise, and fever.

Clinical examination revealed erythematous to violaceous annular and polycyclic plaques on the upper chest (Figure 1). Erythema and scaling were noted at the site of the superficial BCC. A biopsy showed a superficial and mid-dermal perivascular and periadnexal lymphocytic infiltrate with overlying vacuolar interface dermatitis and scattered necrotic keratinocytes (Figures 2A and 2B). There was slightly increased dermal edema and mucin. Anti-CD123 immunohistochemical staining revealed nodular aggregates of plasmacytoid dendritic cells (pDCs) accompanying lymphocytes around dermal vessels and adnexa (Figure 2C). The patient’s family history was remarkable for SCLE in her daughter. Antinuclear antibody, anti-Ro (Sjögren syndrome antigen A), and anti-La (Sjögren syndrome antigen B) were negative. On follow-up examination 1 month after discontinuation of imiquimod, the patient’s skin lesions had completely cleared. Two years later, the patient continued to be free of skin lesions.

 


Figure 1. Annular plaques on the upper chest with overlying
scale and focal central clearing. 


 

Figure 2. Vacuolar interface dermatitis with a perivascular and periadnexal lymphocytic infiltrate (A)(H&E, original magnification ×40). Scattered necrotic keratinocytes were evident (B)(H&E, original magnification ×400). Anti-CD123 immunohistochemical staining revealed nodular aggregates of plasmacytoid dendritic cells with accompanying lymphocytes centered around dermal vessels and adnexa (C)(original magnification ×200).

Comment

Imiquimod is a topical immunomodulator used for the treatment of genital warts and cutaneous malignancies. It exerts its effect via induction of proinflammatory cytokines (eg, IFN-a, tumor necrosis factor a [TNF-α]) through activation of toll-like receptor (TLR) 7, an intracytoplasmic receptor that is found on several cell types including pDCs and B cells. When the cell surface receptor is bound by activating ligands (eg, single-stranded RNA, imiquimod), downstream signaling is initiated, resulting in the production of large amounts of IFN-a and TNF-α.6,7 Both IFN-a and TNF-α are upregulated in patient serum and lesional skin in SCLE.8,9 Additionally, pDCs have been shown to accumulate in lesions of cutaneous lupus erythematosus (CLE) in a distinct dermal pattern, as demonstrated by CD123 staining.9,10 This pattern is identical to the one seen in our case. Although pDCs also are present in cutaneous dermatomyositis lesions, the pattern is distinct from CLE.10 These findings indicate that IFN-a produced by pDCs may play an integral role in the pathogenesis of CLE. Several observations implicating TLR signaling in the pathogenesis of lupus have been described. In a lupus-prone mouse model of lupus erythematosus, transgenic overexpression of TLR-7 resulted in increased severity of clinical disease and accelerated mortality. Antimalarials improve lupus erythematosus via blockade of TLR-7 and TLR-9 signaling.11

Imiquimod, which acts as an inducer of IFN-α expression through TLR-7 signaling, may have been an inciting factor in the development of SCLE-like lesions in this genetically predisposed patient. Histopathology of cutaneous malignancies treated with topical imiquimod typically does not show lupuslike features.12 It is possible that a subset of predisposed patients have increased numbers of pDCs primed in their skin or that they exhibit a more robust TLR-7 reaction to imiquimod, resulting in abundant IFN-a production. Other autoimmune diseases, such as pemphigus foliaceus and vitiligo, also have been reported to occur locally after the application of imiquimod,13,14 which suggests that a localized autoimmune reaction can be induced by activation of TLR-7; however, a case of chronic discoid lupus erythematosus of the scalp improving after treatment with imiquimod has been reported.15

 

 

The use of imiquimod in patients with a personal or family history of lupus erythematosus or those with a personal history of an autoimmune blistering disorder should be undertaken with caution until more is known.

Drug-induced lupus accounts for up to 10% of lupus erythematosus cases. Subacute cutaneous lupus erythematosus (SCLE) is a distinct clinical variant of lupus erythematosus that typically presents as annular, often scaly, erythematous plaques in photodistributed areas. Subacute cutaneous lupus erythematosus has been reported in association with multiple systemic medications including docetaxel, terbinafine, leuprolide acetate, etanercept, and efalizumab1-5; however, the induction of SCLE by topical agents has not been widely reported. We report a case of local induction of lesions that clinically and histologically resembled SCLE in a 50-year-old woman following treatment with topical imiquimod.

Case Report

A 50-year-old woman presented with an adverse inflammatory reaction on the right side of the upper chest secondary to application of topical imiquimod. Prior to the current presentation the patient was diagnosed with a biopsy-proven superficial basal cell carcinoma (BCC) on the sun-exposed area of the upper right breast, and topical imiquimod therapy was initiated. Several days after starting treatment, the patient began applying imiquimod on areas of clinically normal skin on the upper chest as advised by her dermatologist. After 7 to 10 days of application the patient reported intense erythema, pain, and crusting in the treated area on the right side of the upper chest. She also experienced systemic symptoms including fatigue, arthralgia, malaise, and fever.

Clinical examination revealed erythematous to violaceous annular and polycyclic plaques on the upper chest (Figure 1). Erythema and scaling were noted at the site of the superficial BCC. A biopsy showed a superficial and mid-dermal perivascular and periadnexal lymphocytic infiltrate with overlying vacuolar interface dermatitis and scattered necrotic keratinocytes (Figures 2A and 2B). There was slightly increased dermal edema and mucin. Anti-CD123 immunohistochemical staining revealed nodular aggregates of plasmacytoid dendritic cells (pDCs) accompanying lymphocytes around dermal vessels and adnexa (Figure 2C). The patient’s family history was remarkable for SCLE in her daughter. Antinuclear antibody, anti-Ro (Sjögren syndrome antigen A), and anti-La (Sjögren syndrome antigen B) were negative. On follow-up examination 1 month after discontinuation of imiquimod, the patient’s skin lesions had completely cleared. Two years later, the patient continued to be free of skin lesions.

 


Figure 1. Annular plaques on the upper chest with overlying
scale and focal central clearing. 


 

Figure 2. Vacuolar interface dermatitis with a perivascular and periadnexal lymphocytic infiltrate (A)(H&E, original magnification ×40). Scattered necrotic keratinocytes were evident (B)(H&E, original magnification ×400). Anti-CD123 immunohistochemical staining revealed nodular aggregates of plasmacytoid dendritic cells with accompanying lymphocytes centered around dermal vessels and adnexa (C)(original magnification ×200).

Comment

Imiquimod is a topical immunomodulator used for the treatment of genital warts and cutaneous malignancies. It exerts its effect via induction of proinflammatory cytokines (eg, IFN-a, tumor necrosis factor a [TNF-α]) through activation of toll-like receptor (TLR) 7, an intracytoplasmic receptor that is found on several cell types including pDCs and B cells. When the cell surface receptor is bound by activating ligands (eg, single-stranded RNA, imiquimod), downstream signaling is initiated, resulting in the production of large amounts of IFN-a and TNF-α.6,7 Both IFN-a and TNF-α are upregulated in patient serum and lesional skin in SCLE.8,9 Additionally, pDCs have been shown to accumulate in lesions of cutaneous lupus erythematosus (CLE) in a distinct dermal pattern, as demonstrated by CD123 staining.9,10 This pattern is identical to the one seen in our case. Although pDCs also are present in cutaneous dermatomyositis lesions, the pattern is distinct from CLE.10 These findings indicate that IFN-a produced by pDCs may play an integral role in the pathogenesis of CLE. Several observations implicating TLR signaling in the pathogenesis of lupus have been described. In a lupus-prone mouse model of lupus erythematosus, transgenic overexpression of TLR-7 resulted in increased severity of clinical disease and accelerated mortality. Antimalarials improve lupus erythematosus via blockade of TLR-7 and TLR-9 signaling.11

Imiquimod, which acts as an inducer of IFN-α expression through TLR-7 signaling, may have been an inciting factor in the development of SCLE-like lesions in this genetically predisposed patient. Histopathology of cutaneous malignancies treated with topical imiquimod typically does not show lupuslike features.12 It is possible that a subset of predisposed patients have increased numbers of pDCs primed in their skin or that they exhibit a more robust TLR-7 reaction to imiquimod, resulting in abundant IFN-a production. Other autoimmune diseases, such as pemphigus foliaceus and vitiligo, also have been reported to occur locally after the application of imiquimod,13,14 which suggests that a localized autoimmune reaction can be induced by activation of TLR-7; however, a case of chronic discoid lupus erythematosus of the scalp improving after treatment with imiquimod has been reported.15

 

 

The use of imiquimod in patients with a personal or family history of lupus erythematosus or those with a personal history of an autoimmune blistering disorder should be undertaken with caution until more is known.

References

 

1. Chen M, Crowson AN, Woofter M, et al. Docetaxel (taxotere) induced subacute cutaneous lupus erythematosus: report of 4 cases. J Rheumatol. 2004;31:818-820.

2. Farhi D, Viguier M, Cosnes A, et al. Terbinafine-induced subacute cutaneous lupus erythematosus. Dermatology. 2006;212:59-65.

3. Wiechert A, Tüting T, Bieber T, et al. Subacute cutaneous lupus erythematosus in a leuprorelin-treated patient with prostate carcinoma. Br J Dermatol. 2008;159:231-233.

4. Bleumink GS, ter Borg EJ, Ramselaar CG, et al. Etanercept-induced subcutaneous lupus erythematosus. Rheumatology (Oxford). 2001;40:1317-1319.

5. Bentley DD, Graves JE, Smith DI, et al. Efalizumab-induced subacute cutaneous lupus erythematosus. J Am Acad Dermatol. 2006;54(suppl 5):S242-S243.

6. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol. 2006;6:823-835.

7. Hurwitz DJ, Pincus L, Kupper TS. Imiquimod: a topically applied link between innate and acquired immunity. Arch Dermatol. 2003;139:1347-1350.

8. Zampieri S, Alaibac M, Iaccarino L, et al. Tumour necrosis factor alpha is expressed in refractory skin lesions from patients with subacute cutaneous lupus erythematosus. Ann Rheum Dis. 2006;65:545-548.

9. Farkas L, Beiske K, Lund-Johansen F, et al. Plasmacytoid dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol. 2001;159:237-243.

10. McNiff JM, Kaplan DH. Plasmacytoid dendritic cells are present in cutaneous dermatomyositis lesions in a pattern distinct from lupus erythematosus. J Cutan Pathol. 2008;35:452-456.

11. Pisitkun P, Deane JA, Difilippantonio MJ, et al. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science. 2006;312:1669-1672.

12. Wolf IH, Kodama K, Cerroni L, et al. Nature of inflammatory infiltrate in superficial cutaneous malignancies during topical imiquimod treatment. Am J Dermatopathol. 2007;29:237-241.

13. Lin R, Ladd DJ Jr, Powell DJ, et al. Localized pemphigus foliaceus induced by topical imiquimod treatment. Arch Dermatol. 2004;140:889-890.

14. Brown T, Zirvi M, Cotsarelis G, et al. Vitiligo-like hypopigmentation associated with imiquimod treatment of genital warts. J Am Acad Dermatol. 2005;52:715-716.

15. Gersden R, Wenzel J, Uerlich M, et al. Successful treatment of chronic discoid lupus erythematosus of the scalp with imiquimod. Dermatology. 2002;205:416-418.

References

 

1. Chen M, Crowson AN, Woofter M, et al. Docetaxel (taxotere) induced subacute cutaneous lupus erythematosus: report of 4 cases. J Rheumatol. 2004;31:818-820.

2. Farhi D, Viguier M, Cosnes A, et al. Terbinafine-induced subacute cutaneous lupus erythematosus. Dermatology. 2006;212:59-65.

3. Wiechert A, Tüting T, Bieber T, et al. Subacute cutaneous lupus erythematosus in a leuprorelin-treated patient with prostate carcinoma. Br J Dermatol. 2008;159:231-233.

4. Bleumink GS, ter Borg EJ, Ramselaar CG, et al. Etanercept-induced subcutaneous lupus erythematosus. Rheumatology (Oxford). 2001;40:1317-1319.

5. Bentley DD, Graves JE, Smith DI, et al. Efalizumab-induced subacute cutaneous lupus erythematosus. J Am Acad Dermatol. 2006;54(suppl 5):S242-S243.

6. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol. 2006;6:823-835.

7. Hurwitz DJ, Pincus L, Kupper TS. Imiquimod: a topically applied link between innate and acquired immunity. Arch Dermatol. 2003;139:1347-1350.

8. Zampieri S, Alaibac M, Iaccarino L, et al. Tumour necrosis factor alpha is expressed in refractory skin lesions from patients with subacute cutaneous lupus erythematosus. Ann Rheum Dis. 2006;65:545-548.

9. Farkas L, Beiske K, Lund-Johansen F, et al. Plasmacytoid dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol. 2001;159:237-243.

10. McNiff JM, Kaplan DH. Plasmacytoid dendritic cells are present in cutaneous dermatomyositis lesions in a pattern distinct from lupus erythematosus. J Cutan Pathol. 2008;35:452-456.

11. Pisitkun P, Deane JA, Difilippantonio MJ, et al. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science. 2006;312:1669-1672.

12. Wolf IH, Kodama K, Cerroni L, et al. Nature of inflammatory infiltrate in superficial cutaneous malignancies during topical imiquimod treatment. Am J Dermatopathol. 2007;29:237-241.

13. Lin R, Ladd DJ Jr, Powell DJ, et al. Localized pemphigus foliaceus induced by topical imiquimod treatment. Arch Dermatol. 2004;140:889-890.

14. Brown T, Zirvi M, Cotsarelis G, et al. Vitiligo-like hypopigmentation associated with imiquimod treatment of genital warts. J Am Acad Dermatol. 2005;52:715-716.

15. Gersden R, Wenzel J, Uerlich M, et al. Successful treatment of chronic discoid lupus erythematosus of the scalp with imiquimod. Dermatology. 2002;205:416-418.

Issue
Cutis - 95(6)
Issue
Cutis - 95(6)
Page Number
349-351
Page Number
349-351
Publications
Publications
Topics
Article Type
Display Headline
Imiquimod-Induced Subacute Cutaneous Lupus Erythematosus–like Changes
Display Headline
Imiquimod-Induced Subacute Cutaneous Lupus Erythematosus–like Changes
Legacy Keywords
imiquimod, cutaneous lupus, toll-like receptor, autoimmune disease, plasmacytoid dendritic cells, drug-induced lupus
Legacy Keywords
imiquimod, cutaneous lupus, toll-like receptor, autoimmune disease, plasmacytoid dendritic cells, drug-induced lupus
Sections
Inside the Article

   Practice Points

 

  • ­Subacute cutaneous lupus erythematosus has been reported in association with multiple systemic medications; however, association of this disorder with topical agents has not been widely reported.
  • ­The use of topical imiquimod in patients with a personal or family history of lupus erythematosus should be undertaken with caution until more is known.
Disallow All Ads
Article PDF Media

Hidradenitis Suppurativa and Concomitant Pyoderma Gangrenosum Treated With Infliximab

Article Type
Changed
Thu, 12/15/2022 - 15:01
Display Headline
Hidradenitis Suppurativa and Concomitant Pyoderma Gangrenosum Treated With Infliximab

Pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS) are rare chronic inflammatory dermatoses of unknown etiologies that often are refractory to conventional treatments. Multiple case reports have described the coexistence of these 2 diseases in the same patient.1-11 The diagnosis of PG commonly followed the diagnosis of HS by 5 months to 30 years in several of these cases, suggesting that HS may have triggered a possible underlying inflammatory process that resulted in subsequent development of PG. When presenting in the setting of preexisting HS, PG lesions have occurred both in the same sites of the body affected by HS as well as in distinct sites such as the legs.1

Although the treatment of either PG or HS alone can be difficult, the combination of these 2 diseases presents a further therapeutic challenge. Tumor necrosis factor a (TNF-α) has been implicated in the pathogenesis of both of these diseases, and several cases have demonstrated great potential for the use of TNF-α inhibitors, particularly infliximab, in the treatment of resistant cases of each of these conditions.2,12 We report a case of severe concurrent PG and HS in a 51-year-old man that was refractory to other treatments but clinically remitted in response to infliximab therapy.

Case Report

A 51-year-old man was transferred to our institution from an outside hospital where he had presented with fevers and a worsening rash that had prevented him from ambulating for several days secondary to severe pain. At the outside facility, he was noted to have extensive ulcerations with granulation tissue on the scalp, face, sacrum, buttocks, and bilateral legs. A skin biopsy performed at the outside facility revealed a neutrophilic dermal infiltrate with abscesses and granulation tissue consistent with PG. He was transferred to our institution for continued local wound care, corticosteroid administration, and hyperbaric oxygen therapy.

On presentation at our institution, continued ulcerative skin lesions were noted in the previously mentioned areas (Figures 1A and 1B), and deeper purulent sinus tracts were noted in the axillae and extending onto the chest (Figure 1C). A biopsy from the chest showed folliculitis with a prominent plasmacytic infiltrate consistent with HS. Cultures from the sinus tracts showed abundant growth of Enterobacter aerogenes, Klebsiella pneumoniae, Enterobacter cloacae, and Proteus mirabilis. The patient was subsequently treated with intravenous ampicillin-sulbactam and vancomycin as well as oral prednisone 80 mg daily for 2 weeks with only mild improvement of the lesions. The prednisone was gradually tapered to a dose of 10 mg daily in preparation for a trial of infliximab. During the early course of his therapy, subsequent cultures from draining sinus tracts grew Pseudomonas aeruginosa and Acinetobacter baumannii, requiring concomitant treatment with oral antimicrobials including doxycycline, sulfamethoxazole-trimethoprim, ciprofloxacin, and amoxicillin–clavulanic acid for control of the superinfection.

 

 
 
Figure 1. On initial presentation, extensive areas of ulceration with variable amounts of granulation tissue and rusting were noted on the scalp (A) and legs (B). Sinus tract formation also was evident in the neck (A) and axilla (C).

The patient received 3 induction infusions of infliximab at a dosage of 5 mg/kg per treatment at weeks 0, 2, and 6. At the time of the first treatment, he was noted to have numerous crusted draining erosions on the head, neck, and chest. The patient reported no adverse effects during or after each treatment. Following completion of the 3 infliximab infusions, the skin lesions showed considerable improvement, with only 1 draining lesion remaining on the left temple and only erythematous plaques remaining on the scalp, upper back, and axillae. Maintenance infusions were continued every 8 weeks with an increased infliximab dose of 7.5 mg/kg.

After 1 year of treatment, the lesions had healed to form cicatrices with no evidence of erythema, drainage, or infection (Figure 2). Doxycycline and prednisone were discontinued, and the infliximab dose was decreased to 5 mg/kg per infusion every 8 weeks. Following sustained improvement after 2 infusions at this lower dose, infliximab was successfully tapered to 2.5 mg/kg every 8 weeks for 2 doses and then was subsequently discontinued; however, the patient’s disease relapsed approximately 7 months after discontinuation of the infliximab and was immediately resumed at a dose of 5 mg/kg per infusion every 8 weeks. He has remained disease free on this dose to date.

 

 
 
Figure 2. After 11 infusions with infliximab (dose range, 5–7.5 mg/kg), all previously affected areas showed resolution with cicatrices and postinflammatory hyperpigmentation (A–C), with no evidence of ulceration or active sinus tract formation.

Comment

Pyoderma gangrenosum is a chronic inflammatory ulcerative skin condition that most commonly occurs on the lower legs.3 In its most common form, PG lesions typically begin as tender erythematous nodules or pustules that evolve into enlarging painful ulcers with raised, undermined, violaceous borders.13 Biopsy specimens taken from the edges of the lesions typically show a diffuse neutrophilic infiltrate, and pseudoepitheliomatous hyperplasia also may be seen. Lesions tend to persist for months to years, ultimately healing as cribriform scars. The etiology of PG is unknown and its pathogenesis is poorly understood.13 Pyoderma gangrenosum is associated with an underlying systemic disease in approximately 50% of cases, most commonly inflammatory bowel disease, hematologic malignancies, and inflammatory arthritis.3 An underlying immunologic abnormality is therefore postulated to contribute to the pathogenesis of PG, as it is frequently associated with these immune-mediated systemic diseases.

 

 

There is no specific and uniformly effective treatment of PG, but the main therapeutic goals include the reduction of inflammation to promote wound healing, pain reduction, and the treatment of any comorbid diseases that may contribute to the severity of PG, all while minimizing adverse side effects. Systemic corticosteroids and cyclosporine have been reported to produce the most effective results,13 but due to the side effects and toxicities of these drugs, they are often reserved for severe cases in which the benefits of their use outweigh the risks for other comorbidities. Other reported treatments include antimicrobial agents, topical and intralesional corticosteroids, steroid-sparing immunosuppressive agents, colchicine, hyperbaric oxygen therapy, and more recently drugs that function via immune modulation such as TNF-α inhibitors.

Hidradenitis suppurativa is a chronic suppurative inflammatory disease of follicular occlusion in apocrine gland–bearing areas of the skin such as the groin, axillae, and anogenital region. Hidradenitis suppurativa is characterized by recurrent skin abscesses, sinus tract and fistula formation, and subsequent fibrosis with bacterial overgrowth as a common secondary process.14 The pathogenesis of HS remains poorly understood, but histology typically shows a nonspecific inflammatory process with or without concomitant infection.15 Treatment of HS is complex and usually is transiently effective at best.14 In 2012, Rambhatla et al16 discussed the efficacy of various treatments of HS, including systemic and topical antimicrobial agents (eg, clindamycin-rifampicin combination treatment, tetracycline, topical clindamycin phosphate, isotretinoin, dapsone), antiandrogenic agents, biologic agents (eg, infliximab, etanercept, adalimumab, efalizumab), laser surgery (CO2 laser, Nd:YAG laser), and excisional surgery of sinus tracts. Other therapies include cryotherapy, photodynamic therapy, finasteride, zinc gluconate, topical resorcinol, and acitretin.16

Both PG and HS are categorized as chronic inflammatory disorders with nonspecific histopathologic findings. Although the etiologies of these 2 disorders remain poorly understood, several case reports have suggested an association between PG and HS.1,4 In many of the reported cases of concurrent HS and PG, HS preceded the diagnosis of PG by several years and no correlation in disease activity was observed between the 2 conditions.1-4,6-8 Additionally, the clinical triad of PG, acne, and suppurative hidradenitis, known as PASH syndrome, has been described, which may represent a new entity within the spectrum of autoinflammatory syndromes.5 It is not uncommon for either PG or HS to be refractory to conventional therapies, and therefore the management of concomitant PG and HS presents an even further therapeutic challenge.

Recently, biologic agents such as TNF-α inhibitors have been used with increased frequency as novel treatments for severe dermatologic diseases including psoriasis and pemphigus vulgaris, among others.17 Furthermore, several reports have presented convincing results in the off-label use of TNF-α inhibitors in the treatment of isolated PG as well as in the treatment of HS.12,14,17-22 Infliximab, a chimeric anti–TNF-α monoclonal antibody, has been used with particular success in recalcitrant cases of these conditions.12,17,19-21

In a double-blind, placebo-controlled, crossover trial analyzing 38 patients with moderate to severe refractory HS, Grant et al19 found that treatment with infliximab was associated with a significantly greater improvement in pain intensity (P<.001), disease severity (P<.001), and quality of life (P=.003), with concomitant reduction in clinical markers of inflammation compared to placebo. Similarly, a randomized, double-blind, placebo-controlled trial by Brooklyn et al12 evaluated 30 patients with refractory PG. In this study, infliximab was shown to be superior to placebo for rapid clinical response in patients with PG irrespective of the existence of concomitant inflammatory bowel disease.12

On the contrary, lack of efficacy and/or adverse reactions associated with infliximab and other TNF-α inhibitors in the treatment of PG and HS also have been reported in the literature. Fardet et al20 reported that 2 of 7 (28.6%) HS patients treated with at least 3 infusions of infliximab (5 mg/kg) at weeks 0, 2, and 6 had minimal or nonexistent improvement by week 6. Additionally, adverse events occurred in 3 of 7 (42.9%) HS patients, including abdominal pain caused by colon cancer, multifocal motor neuropathy with conduction block, and a severe allergic reaction.20 Usmani et al21 described 1 HS patient who developed an infliximab-induced lupus reaction, 1 who experienced a hypersensitivity reaction to infliximab, and 2 who had poor response to treatment despite 3 infusions. Kleinpenning et al22 reported a case of PG that failed consecutive trials of etanercept and adalimumab. Wolbing et al23 reported a case of septic shock after treatment of PG with infliximab. Shareef et al24 reported progression of IgA gammopathy to myeloma following infliximab treatment for PG in 1 patient.

Of the reported cases of concurrent HS and PG, 3 were treated with TNF-αinhibitors, both alone and in conjunction with other treatment modalities, with varying results. One patient demonstrated a partial response to treatment with etanercept followed by infliximab, 1 was resistant to treatment with infliximab as well as adalimumab, and 1 exhibited clinical improvement following treatment with infliximab.1,2

 

 

Conclusion

In our patient with concurrent PG and HS, both conditions showed dramatic improvement with in-fliximab therapy, and this response has been sustained on 5-mg/kg infliximab maintenance therapy every 8 weeks for the last 3 years. Our case suggests that infliximab may represent an effective therapeutic option for the treatment of concurrent PG and HS that is refractory to conventional therapies. It is yet to be seen whether our patient will continue to experience sustained remission in both his PG and HS permitting the discontinuation of infliximab. Continued study of infliximab and other TNF-α inhibitors is necessary to establish their long-term safety and efficacy for use in patients affected by both HS and PG.

References

 

1. Hsiao JL, Antaya RJ, Berger T, et al. Hidradenitis suppurative and concomitant pyoderma gangrenosum: a case series and literature review. Arch Dermatol. 2010;146:1265-1270.

2. Moschella S. Is there a role for infliximab in the current therapy of hidradenitis suppurativa? a report of three treated cases. Int J Dermatol. 2007;46:1287-1291.

3. Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol. 1996;34:395-409.

4. Ah-Weng A, Langtry JAA, Velangi S, et al. Pyoderma gangrenosum associated with hidradenitis suppurativa. Clin Exp Dermatol. 2005;30:669-671.

5. Braun-Falco M, Kovnerystyy O, Lohse P, et al. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)—a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol. 2012;66:409-415.

6. Buckley DA, Rogers S. Cyclosporin-responsive hidradenitis suppurativa. J R Soc Med. 1995;88:289-290.

7. Shenefelt PD. Pyoderma gangrenosum associated with cystic acne and hidradenitis suppurativa controlled by adding minocycline and sulfasalazine to the treatment regimen. Cutis. 1996;57:315-319. 

8. Raynor A, Askari AD. Behçet’s disease and treatment with colchicine. J Am Acad Dermatol. 1980;2:396-400.

9. Steinhoff JP, Cilursu A, Falasca GF, et al. A study of musculoskeletal manifestations in 12 patients with SAPHO syndrome. J Clin Rheumatol. 2002;8:13-22.

10. Rosner IA, Richter DE, Huettner TL, et al. Spondyloarthropathy associated with hidradenitis suppurative and acne conglobata. Ann Intern Med. 1982;97:520-525.

11. von den Driesch P. Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol. 1997;137:1000-1005.

12. Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomized, double-blind, placebo-controlled trial. Gut. 2006;55:505-509.

13. Ruocco E, Sangiulliano S, Gravina AG, et al. Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol. 2009;23:1008-1017.

14. Mortimer P. Management of hidradenitis suppurativa. Clin Exp Dermatol. 2002;27:328.

15. Blanco R, Martinez-Taboada VM, Villa I, et al. Long-term successful adalimumab therapy in severe hidradenitis suppurativa. Arch Dermatol. 2009;145:580-584.

16. Rambhatla PV, Lim HW, Hamzavi I. A systematic review of treatment for hidradenitis suppurativa. Arch Dermatol. 2012;148:439-446.

17. Alecsandru D, Padilla B, Izquierdo JA, et al. Severe refractory hidradenitis suppurativa in an HIV-positive patient successfully treated with infliximab. Arch Dermatol. 2010;146:1343-1345.

18. Alexis A, Strober B. Off-label dermatologic uses of anti-TNF-a therapies. J Cutan Med Surg. 2006;9:296-301.

19. Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62:205-217.

20. Fardet L, Dupuy A, Kerob D, et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol. 2007;56:624-628.

21. Usmani N, Clayton TH, Everett S, et al. Variable response of hidradenitis suppurativa to infliximab in four patients. Clin Exp Dermatol. 2007;32:204-205.

22. Kleinpenning MM, Langewouters AM, Van De Kerkhof PC, et al. Severe pyoderma gangrenosum unresponsive to etanercept and adalimumab. J Dermatolog Treat. 2011;22:261-265.

23. Wolbing F, Fierlbeck G, Hotzenecker W, et al. Septic shock after treatment of pyoderma gangrenosum with infliximab. Acta Dermato-Venereologica. 2009;89:93-94.

24. Shareef MS, Munro LR, Owen RG, et al. Progression of IgA gammopathy to myeloma following infliximab treatment for pyoderma gangrenosum. Clin Exp Dermatol. 2012;37:146-148.

Article PDF
Author and Disclosure Information

 

Patricia F. Groleau, MD; Anna L. Grossberg, MD; Anthony A. Gaspari, MD

From the Department of Dermatology, University of Maryland School of Medicine, Baltimore.

The authors report no conflict of interest.

Correspondence: Anna L. Grossberg, MD, 419 W Redwood St, Ste 240, Baltimore, MD 21201 (agrossberg@som.umaryland.edu).

Issue
Cutis - 95(6)
Publications
Topics
Page Number
337-342
Legacy Keywords
pyoderma gangrenosum, hidradenitis suppurativa, infliximab, tumor necrosis factor alpha, TNF
Sections
Author and Disclosure Information

 

Patricia F. Groleau, MD; Anna L. Grossberg, MD; Anthony A. Gaspari, MD

From the Department of Dermatology, University of Maryland School of Medicine, Baltimore.

The authors report no conflict of interest.

Correspondence: Anna L. Grossberg, MD, 419 W Redwood St, Ste 240, Baltimore, MD 21201 (agrossberg@som.umaryland.edu).

Author and Disclosure Information

 

Patricia F. Groleau, MD; Anna L. Grossberg, MD; Anthony A. Gaspari, MD

From the Department of Dermatology, University of Maryland School of Medicine, Baltimore.

The authors report no conflict of interest.

Correspondence: Anna L. Grossberg, MD, 419 W Redwood St, Ste 240, Baltimore, MD 21201 (agrossberg@som.umaryland.edu).

Article PDF
Article PDF
Related Articles

Pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS) are rare chronic inflammatory dermatoses of unknown etiologies that often are refractory to conventional treatments. Multiple case reports have described the coexistence of these 2 diseases in the same patient.1-11 The diagnosis of PG commonly followed the diagnosis of HS by 5 months to 30 years in several of these cases, suggesting that HS may have triggered a possible underlying inflammatory process that resulted in subsequent development of PG. When presenting in the setting of preexisting HS, PG lesions have occurred both in the same sites of the body affected by HS as well as in distinct sites such as the legs.1

Although the treatment of either PG or HS alone can be difficult, the combination of these 2 diseases presents a further therapeutic challenge. Tumor necrosis factor a (TNF-α) has been implicated in the pathogenesis of both of these diseases, and several cases have demonstrated great potential for the use of TNF-α inhibitors, particularly infliximab, in the treatment of resistant cases of each of these conditions.2,12 We report a case of severe concurrent PG and HS in a 51-year-old man that was refractory to other treatments but clinically remitted in response to infliximab therapy.

Case Report

A 51-year-old man was transferred to our institution from an outside hospital where he had presented with fevers and a worsening rash that had prevented him from ambulating for several days secondary to severe pain. At the outside facility, he was noted to have extensive ulcerations with granulation tissue on the scalp, face, sacrum, buttocks, and bilateral legs. A skin biopsy performed at the outside facility revealed a neutrophilic dermal infiltrate with abscesses and granulation tissue consistent with PG. He was transferred to our institution for continued local wound care, corticosteroid administration, and hyperbaric oxygen therapy.

On presentation at our institution, continued ulcerative skin lesions were noted in the previously mentioned areas (Figures 1A and 1B), and deeper purulent sinus tracts were noted in the axillae and extending onto the chest (Figure 1C). A biopsy from the chest showed folliculitis with a prominent plasmacytic infiltrate consistent with HS. Cultures from the sinus tracts showed abundant growth of Enterobacter aerogenes, Klebsiella pneumoniae, Enterobacter cloacae, and Proteus mirabilis. The patient was subsequently treated with intravenous ampicillin-sulbactam and vancomycin as well as oral prednisone 80 mg daily for 2 weeks with only mild improvement of the lesions. The prednisone was gradually tapered to a dose of 10 mg daily in preparation for a trial of infliximab. During the early course of his therapy, subsequent cultures from draining sinus tracts grew Pseudomonas aeruginosa and Acinetobacter baumannii, requiring concomitant treatment with oral antimicrobials including doxycycline, sulfamethoxazole-trimethoprim, ciprofloxacin, and amoxicillin–clavulanic acid for control of the superinfection.

 

 
 
Figure 1. On initial presentation, extensive areas of ulceration with variable amounts of granulation tissue and rusting were noted on the scalp (A) and legs (B). Sinus tract formation also was evident in the neck (A) and axilla (C).

The patient received 3 induction infusions of infliximab at a dosage of 5 mg/kg per treatment at weeks 0, 2, and 6. At the time of the first treatment, he was noted to have numerous crusted draining erosions on the head, neck, and chest. The patient reported no adverse effects during or after each treatment. Following completion of the 3 infliximab infusions, the skin lesions showed considerable improvement, with only 1 draining lesion remaining on the left temple and only erythematous plaques remaining on the scalp, upper back, and axillae. Maintenance infusions were continued every 8 weeks with an increased infliximab dose of 7.5 mg/kg.

After 1 year of treatment, the lesions had healed to form cicatrices with no evidence of erythema, drainage, or infection (Figure 2). Doxycycline and prednisone were discontinued, and the infliximab dose was decreased to 5 mg/kg per infusion every 8 weeks. Following sustained improvement after 2 infusions at this lower dose, infliximab was successfully tapered to 2.5 mg/kg every 8 weeks for 2 doses and then was subsequently discontinued; however, the patient’s disease relapsed approximately 7 months after discontinuation of the infliximab and was immediately resumed at a dose of 5 mg/kg per infusion every 8 weeks. He has remained disease free on this dose to date.

 

 
 
Figure 2. After 11 infusions with infliximab (dose range, 5–7.5 mg/kg), all previously affected areas showed resolution with cicatrices and postinflammatory hyperpigmentation (A–C), with no evidence of ulceration or active sinus tract formation.

Comment

Pyoderma gangrenosum is a chronic inflammatory ulcerative skin condition that most commonly occurs on the lower legs.3 In its most common form, PG lesions typically begin as tender erythematous nodules or pustules that evolve into enlarging painful ulcers with raised, undermined, violaceous borders.13 Biopsy specimens taken from the edges of the lesions typically show a diffuse neutrophilic infiltrate, and pseudoepitheliomatous hyperplasia also may be seen. Lesions tend to persist for months to years, ultimately healing as cribriform scars. The etiology of PG is unknown and its pathogenesis is poorly understood.13 Pyoderma gangrenosum is associated with an underlying systemic disease in approximately 50% of cases, most commonly inflammatory bowel disease, hematologic malignancies, and inflammatory arthritis.3 An underlying immunologic abnormality is therefore postulated to contribute to the pathogenesis of PG, as it is frequently associated with these immune-mediated systemic diseases.

 

 

There is no specific and uniformly effective treatment of PG, but the main therapeutic goals include the reduction of inflammation to promote wound healing, pain reduction, and the treatment of any comorbid diseases that may contribute to the severity of PG, all while minimizing adverse side effects. Systemic corticosteroids and cyclosporine have been reported to produce the most effective results,13 but due to the side effects and toxicities of these drugs, they are often reserved for severe cases in which the benefits of their use outweigh the risks for other comorbidities. Other reported treatments include antimicrobial agents, topical and intralesional corticosteroids, steroid-sparing immunosuppressive agents, colchicine, hyperbaric oxygen therapy, and more recently drugs that function via immune modulation such as TNF-α inhibitors.

Hidradenitis suppurativa is a chronic suppurative inflammatory disease of follicular occlusion in apocrine gland–bearing areas of the skin such as the groin, axillae, and anogenital region. Hidradenitis suppurativa is characterized by recurrent skin abscesses, sinus tract and fistula formation, and subsequent fibrosis with bacterial overgrowth as a common secondary process.14 The pathogenesis of HS remains poorly understood, but histology typically shows a nonspecific inflammatory process with or without concomitant infection.15 Treatment of HS is complex and usually is transiently effective at best.14 In 2012, Rambhatla et al16 discussed the efficacy of various treatments of HS, including systemic and topical antimicrobial agents (eg, clindamycin-rifampicin combination treatment, tetracycline, topical clindamycin phosphate, isotretinoin, dapsone), antiandrogenic agents, biologic agents (eg, infliximab, etanercept, adalimumab, efalizumab), laser surgery (CO2 laser, Nd:YAG laser), and excisional surgery of sinus tracts. Other therapies include cryotherapy, photodynamic therapy, finasteride, zinc gluconate, topical resorcinol, and acitretin.16

Both PG and HS are categorized as chronic inflammatory disorders with nonspecific histopathologic findings. Although the etiologies of these 2 disorders remain poorly understood, several case reports have suggested an association between PG and HS.1,4 In many of the reported cases of concurrent HS and PG, HS preceded the diagnosis of PG by several years and no correlation in disease activity was observed between the 2 conditions.1-4,6-8 Additionally, the clinical triad of PG, acne, and suppurative hidradenitis, known as PASH syndrome, has been described, which may represent a new entity within the spectrum of autoinflammatory syndromes.5 It is not uncommon for either PG or HS to be refractory to conventional therapies, and therefore the management of concomitant PG and HS presents an even further therapeutic challenge.

Recently, biologic agents such as TNF-α inhibitors have been used with increased frequency as novel treatments for severe dermatologic diseases including psoriasis and pemphigus vulgaris, among others.17 Furthermore, several reports have presented convincing results in the off-label use of TNF-α inhibitors in the treatment of isolated PG as well as in the treatment of HS.12,14,17-22 Infliximab, a chimeric anti–TNF-α monoclonal antibody, has been used with particular success in recalcitrant cases of these conditions.12,17,19-21

In a double-blind, placebo-controlled, crossover trial analyzing 38 patients with moderate to severe refractory HS, Grant et al19 found that treatment with infliximab was associated with a significantly greater improvement in pain intensity (P<.001), disease severity (P<.001), and quality of life (P=.003), with concomitant reduction in clinical markers of inflammation compared to placebo. Similarly, a randomized, double-blind, placebo-controlled trial by Brooklyn et al12 evaluated 30 patients with refractory PG. In this study, infliximab was shown to be superior to placebo for rapid clinical response in patients with PG irrespective of the existence of concomitant inflammatory bowel disease.12

On the contrary, lack of efficacy and/or adverse reactions associated with infliximab and other TNF-α inhibitors in the treatment of PG and HS also have been reported in the literature. Fardet et al20 reported that 2 of 7 (28.6%) HS patients treated with at least 3 infusions of infliximab (5 mg/kg) at weeks 0, 2, and 6 had minimal or nonexistent improvement by week 6. Additionally, adverse events occurred in 3 of 7 (42.9%) HS patients, including abdominal pain caused by colon cancer, multifocal motor neuropathy with conduction block, and a severe allergic reaction.20 Usmani et al21 described 1 HS patient who developed an infliximab-induced lupus reaction, 1 who experienced a hypersensitivity reaction to infliximab, and 2 who had poor response to treatment despite 3 infusions. Kleinpenning et al22 reported a case of PG that failed consecutive trials of etanercept and adalimumab. Wolbing et al23 reported a case of septic shock after treatment of PG with infliximab. Shareef et al24 reported progression of IgA gammopathy to myeloma following infliximab treatment for PG in 1 patient.

Of the reported cases of concurrent HS and PG, 3 were treated with TNF-αinhibitors, both alone and in conjunction with other treatment modalities, with varying results. One patient demonstrated a partial response to treatment with etanercept followed by infliximab, 1 was resistant to treatment with infliximab as well as adalimumab, and 1 exhibited clinical improvement following treatment with infliximab.1,2

 

 

Conclusion

In our patient with concurrent PG and HS, both conditions showed dramatic improvement with in-fliximab therapy, and this response has been sustained on 5-mg/kg infliximab maintenance therapy every 8 weeks for the last 3 years. Our case suggests that infliximab may represent an effective therapeutic option for the treatment of concurrent PG and HS that is refractory to conventional therapies. It is yet to be seen whether our patient will continue to experience sustained remission in both his PG and HS permitting the discontinuation of infliximab. Continued study of infliximab and other TNF-α inhibitors is necessary to establish their long-term safety and efficacy for use in patients affected by both HS and PG.

Pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS) are rare chronic inflammatory dermatoses of unknown etiologies that often are refractory to conventional treatments. Multiple case reports have described the coexistence of these 2 diseases in the same patient.1-11 The diagnosis of PG commonly followed the diagnosis of HS by 5 months to 30 years in several of these cases, suggesting that HS may have triggered a possible underlying inflammatory process that resulted in subsequent development of PG. When presenting in the setting of preexisting HS, PG lesions have occurred both in the same sites of the body affected by HS as well as in distinct sites such as the legs.1

Although the treatment of either PG or HS alone can be difficult, the combination of these 2 diseases presents a further therapeutic challenge. Tumor necrosis factor a (TNF-α) has been implicated in the pathogenesis of both of these diseases, and several cases have demonstrated great potential for the use of TNF-α inhibitors, particularly infliximab, in the treatment of resistant cases of each of these conditions.2,12 We report a case of severe concurrent PG and HS in a 51-year-old man that was refractory to other treatments but clinically remitted in response to infliximab therapy.

Case Report

A 51-year-old man was transferred to our institution from an outside hospital where he had presented with fevers and a worsening rash that had prevented him from ambulating for several days secondary to severe pain. At the outside facility, he was noted to have extensive ulcerations with granulation tissue on the scalp, face, sacrum, buttocks, and bilateral legs. A skin biopsy performed at the outside facility revealed a neutrophilic dermal infiltrate with abscesses and granulation tissue consistent with PG. He was transferred to our institution for continued local wound care, corticosteroid administration, and hyperbaric oxygen therapy.

On presentation at our institution, continued ulcerative skin lesions were noted in the previously mentioned areas (Figures 1A and 1B), and deeper purulent sinus tracts were noted in the axillae and extending onto the chest (Figure 1C). A biopsy from the chest showed folliculitis with a prominent plasmacytic infiltrate consistent with HS. Cultures from the sinus tracts showed abundant growth of Enterobacter aerogenes, Klebsiella pneumoniae, Enterobacter cloacae, and Proteus mirabilis. The patient was subsequently treated with intravenous ampicillin-sulbactam and vancomycin as well as oral prednisone 80 mg daily for 2 weeks with only mild improvement of the lesions. The prednisone was gradually tapered to a dose of 10 mg daily in preparation for a trial of infliximab. During the early course of his therapy, subsequent cultures from draining sinus tracts grew Pseudomonas aeruginosa and Acinetobacter baumannii, requiring concomitant treatment with oral antimicrobials including doxycycline, sulfamethoxazole-trimethoprim, ciprofloxacin, and amoxicillin–clavulanic acid for control of the superinfection.

 

 
 
Figure 1. On initial presentation, extensive areas of ulceration with variable amounts of granulation tissue and rusting were noted on the scalp (A) and legs (B). Sinus tract formation also was evident in the neck (A) and axilla (C).

The patient received 3 induction infusions of infliximab at a dosage of 5 mg/kg per treatment at weeks 0, 2, and 6. At the time of the first treatment, he was noted to have numerous crusted draining erosions on the head, neck, and chest. The patient reported no adverse effects during or after each treatment. Following completion of the 3 infliximab infusions, the skin lesions showed considerable improvement, with only 1 draining lesion remaining on the left temple and only erythematous plaques remaining on the scalp, upper back, and axillae. Maintenance infusions were continued every 8 weeks with an increased infliximab dose of 7.5 mg/kg.

After 1 year of treatment, the lesions had healed to form cicatrices with no evidence of erythema, drainage, or infection (Figure 2). Doxycycline and prednisone were discontinued, and the infliximab dose was decreased to 5 mg/kg per infusion every 8 weeks. Following sustained improvement after 2 infusions at this lower dose, infliximab was successfully tapered to 2.5 mg/kg every 8 weeks for 2 doses and then was subsequently discontinued; however, the patient’s disease relapsed approximately 7 months after discontinuation of the infliximab and was immediately resumed at a dose of 5 mg/kg per infusion every 8 weeks. He has remained disease free on this dose to date.

 

 
 
Figure 2. After 11 infusions with infliximab (dose range, 5–7.5 mg/kg), all previously affected areas showed resolution with cicatrices and postinflammatory hyperpigmentation (A–C), with no evidence of ulceration or active sinus tract formation.

Comment

Pyoderma gangrenosum is a chronic inflammatory ulcerative skin condition that most commonly occurs on the lower legs.3 In its most common form, PG lesions typically begin as tender erythematous nodules or pustules that evolve into enlarging painful ulcers with raised, undermined, violaceous borders.13 Biopsy specimens taken from the edges of the lesions typically show a diffuse neutrophilic infiltrate, and pseudoepitheliomatous hyperplasia also may be seen. Lesions tend to persist for months to years, ultimately healing as cribriform scars. The etiology of PG is unknown and its pathogenesis is poorly understood.13 Pyoderma gangrenosum is associated with an underlying systemic disease in approximately 50% of cases, most commonly inflammatory bowel disease, hematologic malignancies, and inflammatory arthritis.3 An underlying immunologic abnormality is therefore postulated to contribute to the pathogenesis of PG, as it is frequently associated with these immune-mediated systemic diseases.

 

 

There is no specific and uniformly effective treatment of PG, but the main therapeutic goals include the reduction of inflammation to promote wound healing, pain reduction, and the treatment of any comorbid diseases that may contribute to the severity of PG, all while minimizing adverse side effects. Systemic corticosteroids and cyclosporine have been reported to produce the most effective results,13 but due to the side effects and toxicities of these drugs, they are often reserved for severe cases in which the benefits of their use outweigh the risks for other comorbidities. Other reported treatments include antimicrobial agents, topical and intralesional corticosteroids, steroid-sparing immunosuppressive agents, colchicine, hyperbaric oxygen therapy, and more recently drugs that function via immune modulation such as TNF-α inhibitors.

Hidradenitis suppurativa is a chronic suppurative inflammatory disease of follicular occlusion in apocrine gland–bearing areas of the skin such as the groin, axillae, and anogenital region. Hidradenitis suppurativa is characterized by recurrent skin abscesses, sinus tract and fistula formation, and subsequent fibrosis with bacterial overgrowth as a common secondary process.14 The pathogenesis of HS remains poorly understood, but histology typically shows a nonspecific inflammatory process with or without concomitant infection.15 Treatment of HS is complex and usually is transiently effective at best.14 In 2012, Rambhatla et al16 discussed the efficacy of various treatments of HS, including systemic and topical antimicrobial agents (eg, clindamycin-rifampicin combination treatment, tetracycline, topical clindamycin phosphate, isotretinoin, dapsone), antiandrogenic agents, biologic agents (eg, infliximab, etanercept, adalimumab, efalizumab), laser surgery (CO2 laser, Nd:YAG laser), and excisional surgery of sinus tracts. Other therapies include cryotherapy, photodynamic therapy, finasteride, zinc gluconate, topical resorcinol, and acitretin.16

Both PG and HS are categorized as chronic inflammatory disorders with nonspecific histopathologic findings. Although the etiologies of these 2 disorders remain poorly understood, several case reports have suggested an association between PG and HS.1,4 In many of the reported cases of concurrent HS and PG, HS preceded the diagnosis of PG by several years and no correlation in disease activity was observed between the 2 conditions.1-4,6-8 Additionally, the clinical triad of PG, acne, and suppurative hidradenitis, known as PASH syndrome, has been described, which may represent a new entity within the spectrum of autoinflammatory syndromes.5 It is not uncommon for either PG or HS to be refractory to conventional therapies, and therefore the management of concomitant PG and HS presents an even further therapeutic challenge.

Recently, biologic agents such as TNF-α inhibitors have been used with increased frequency as novel treatments for severe dermatologic diseases including psoriasis and pemphigus vulgaris, among others.17 Furthermore, several reports have presented convincing results in the off-label use of TNF-α inhibitors in the treatment of isolated PG as well as in the treatment of HS.12,14,17-22 Infliximab, a chimeric anti–TNF-α monoclonal antibody, has been used with particular success in recalcitrant cases of these conditions.12,17,19-21

In a double-blind, placebo-controlled, crossover trial analyzing 38 patients with moderate to severe refractory HS, Grant et al19 found that treatment with infliximab was associated with a significantly greater improvement in pain intensity (P<.001), disease severity (P<.001), and quality of life (P=.003), with concomitant reduction in clinical markers of inflammation compared to placebo. Similarly, a randomized, double-blind, placebo-controlled trial by Brooklyn et al12 evaluated 30 patients with refractory PG. In this study, infliximab was shown to be superior to placebo for rapid clinical response in patients with PG irrespective of the existence of concomitant inflammatory bowel disease.12

On the contrary, lack of efficacy and/or adverse reactions associated with infliximab and other TNF-α inhibitors in the treatment of PG and HS also have been reported in the literature. Fardet et al20 reported that 2 of 7 (28.6%) HS patients treated with at least 3 infusions of infliximab (5 mg/kg) at weeks 0, 2, and 6 had minimal or nonexistent improvement by week 6. Additionally, adverse events occurred in 3 of 7 (42.9%) HS patients, including abdominal pain caused by colon cancer, multifocal motor neuropathy with conduction block, and a severe allergic reaction.20 Usmani et al21 described 1 HS patient who developed an infliximab-induced lupus reaction, 1 who experienced a hypersensitivity reaction to infliximab, and 2 who had poor response to treatment despite 3 infusions. Kleinpenning et al22 reported a case of PG that failed consecutive trials of etanercept and adalimumab. Wolbing et al23 reported a case of septic shock after treatment of PG with infliximab. Shareef et al24 reported progression of IgA gammopathy to myeloma following infliximab treatment for PG in 1 patient.

Of the reported cases of concurrent HS and PG, 3 were treated with TNF-αinhibitors, both alone and in conjunction with other treatment modalities, with varying results. One patient demonstrated a partial response to treatment with etanercept followed by infliximab, 1 was resistant to treatment with infliximab as well as adalimumab, and 1 exhibited clinical improvement following treatment with infliximab.1,2

 

 

Conclusion

In our patient with concurrent PG and HS, both conditions showed dramatic improvement with in-fliximab therapy, and this response has been sustained on 5-mg/kg infliximab maintenance therapy every 8 weeks for the last 3 years. Our case suggests that infliximab may represent an effective therapeutic option for the treatment of concurrent PG and HS that is refractory to conventional therapies. It is yet to be seen whether our patient will continue to experience sustained remission in both his PG and HS permitting the discontinuation of infliximab. Continued study of infliximab and other TNF-α inhibitors is necessary to establish their long-term safety and efficacy for use in patients affected by both HS and PG.

References

 

1. Hsiao JL, Antaya RJ, Berger T, et al. Hidradenitis suppurative and concomitant pyoderma gangrenosum: a case series and literature review. Arch Dermatol. 2010;146:1265-1270.

2. Moschella S. Is there a role for infliximab in the current therapy of hidradenitis suppurativa? a report of three treated cases. Int J Dermatol. 2007;46:1287-1291.

3. Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol. 1996;34:395-409.

4. Ah-Weng A, Langtry JAA, Velangi S, et al. Pyoderma gangrenosum associated with hidradenitis suppurativa. Clin Exp Dermatol. 2005;30:669-671.

5. Braun-Falco M, Kovnerystyy O, Lohse P, et al. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)—a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol. 2012;66:409-415.

6. Buckley DA, Rogers S. Cyclosporin-responsive hidradenitis suppurativa. J R Soc Med. 1995;88:289-290.

7. Shenefelt PD. Pyoderma gangrenosum associated with cystic acne and hidradenitis suppurativa controlled by adding minocycline and sulfasalazine to the treatment regimen. Cutis. 1996;57:315-319. 

8. Raynor A, Askari AD. Behçet’s disease and treatment with colchicine. J Am Acad Dermatol. 1980;2:396-400.

9. Steinhoff JP, Cilursu A, Falasca GF, et al. A study of musculoskeletal manifestations in 12 patients with SAPHO syndrome. J Clin Rheumatol. 2002;8:13-22.

10. Rosner IA, Richter DE, Huettner TL, et al. Spondyloarthropathy associated with hidradenitis suppurative and acne conglobata. Ann Intern Med. 1982;97:520-525.

11. von den Driesch P. Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol. 1997;137:1000-1005.

12. Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomized, double-blind, placebo-controlled trial. Gut. 2006;55:505-509.

13. Ruocco E, Sangiulliano S, Gravina AG, et al. Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol. 2009;23:1008-1017.

14. Mortimer P. Management of hidradenitis suppurativa. Clin Exp Dermatol. 2002;27:328.

15. Blanco R, Martinez-Taboada VM, Villa I, et al. Long-term successful adalimumab therapy in severe hidradenitis suppurativa. Arch Dermatol. 2009;145:580-584.

16. Rambhatla PV, Lim HW, Hamzavi I. A systematic review of treatment for hidradenitis suppurativa. Arch Dermatol. 2012;148:439-446.

17. Alecsandru D, Padilla B, Izquierdo JA, et al. Severe refractory hidradenitis suppurativa in an HIV-positive patient successfully treated with infliximab. Arch Dermatol. 2010;146:1343-1345.

18. Alexis A, Strober B. Off-label dermatologic uses of anti-TNF-a therapies. J Cutan Med Surg. 2006;9:296-301.

19. Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62:205-217.

20. Fardet L, Dupuy A, Kerob D, et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol. 2007;56:624-628.

21. Usmani N, Clayton TH, Everett S, et al. Variable response of hidradenitis suppurativa to infliximab in four patients. Clin Exp Dermatol. 2007;32:204-205.

22. Kleinpenning MM, Langewouters AM, Van De Kerkhof PC, et al. Severe pyoderma gangrenosum unresponsive to etanercept and adalimumab. J Dermatolog Treat. 2011;22:261-265.

23. Wolbing F, Fierlbeck G, Hotzenecker W, et al. Septic shock after treatment of pyoderma gangrenosum with infliximab. Acta Dermato-Venereologica. 2009;89:93-94.

24. Shareef MS, Munro LR, Owen RG, et al. Progression of IgA gammopathy to myeloma following infliximab treatment for pyoderma gangrenosum. Clin Exp Dermatol. 2012;37:146-148.

References

 

1. Hsiao JL, Antaya RJ, Berger T, et al. Hidradenitis suppurative and concomitant pyoderma gangrenosum: a case series and literature review. Arch Dermatol. 2010;146:1265-1270.

2. Moschella S. Is there a role for infliximab in the current therapy of hidradenitis suppurativa? a report of three treated cases. Int J Dermatol. 2007;46:1287-1291.

3. Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol. 1996;34:395-409.

4. Ah-Weng A, Langtry JAA, Velangi S, et al. Pyoderma gangrenosum associated with hidradenitis suppurativa. Clin Exp Dermatol. 2005;30:669-671.

5. Braun-Falco M, Kovnerystyy O, Lohse P, et al. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)—a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol. 2012;66:409-415.

6. Buckley DA, Rogers S. Cyclosporin-responsive hidradenitis suppurativa. J R Soc Med. 1995;88:289-290.

7. Shenefelt PD. Pyoderma gangrenosum associated with cystic acne and hidradenitis suppurativa controlled by adding minocycline and sulfasalazine to the treatment regimen. Cutis. 1996;57:315-319. 

8. Raynor A, Askari AD. Behçet’s disease and treatment with colchicine. J Am Acad Dermatol. 1980;2:396-400.

9. Steinhoff JP, Cilursu A, Falasca GF, et al. A study of musculoskeletal manifestations in 12 patients with SAPHO syndrome. J Clin Rheumatol. 2002;8:13-22.

10. Rosner IA, Richter DE, Huettner TL, et al. Spondyloarthropathy associated with hidradenitis suppurative and acne conglobata. Ann Intern Med. 1982;97:520-525.

11. von den Driesch P. Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol. 1997;137:1000-1005.

12. Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomized, double-blind, placebo-controlled trial. Gut. 2006;55:505-509.

13. Ruocco E, Sangiulliano S, Gravina AG, et al. Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol. 2009;23:1008-1017.

14. Mortimer P. Management of hidradenitis suppurativa. Clin Exp Dermatol. 2002;27:328.

15. Blanco R, Martinez-Taboada VM, Villa I, et al. Long-term successful adalimumab therapy in severe hidradenitis suppurativa. Arch Dermatol. 2009;145:580-584.

16. Rambhatla PV, Lim HW, Hamzavi I. A systematic review of treatment for hidradenitis suppurativa. Arch Dermatol. 2012;148:439-446.

17. Alecsandru D, Padilla B, Izquierdo JA, et al. Severe refractory hidradenitis suppurativa in an HIV-positive patient successfully treated with infliximab. Arch Dermatol. 2010;146:1343-1345.

18. Alexis A, Strober B. Off-label dermatologic uses of anti-TNF-a therapies. J Cutan Med Surg. 2006;9:296-301.

19. Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62:205-217.

20. Fardet L, Dupuy A, Kerob D, et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol. 2007;56:624-628.

21. Usmani N, Clayton TH, Everett S, et al. Variable response of hidradenitis suppurativa to infliximab in four patients. Clin Exp Dermatol. 2007;32:204-205.

22. Kleinpenning MM, Langewouters AM, Van De Kerkhof PC, et al. Severe pyoderma gangrenosum unresponsive to etanercept and adalimumab. J Dermatolog Treat. 2011;22:261-265.

23. Wolbing F, Fierlbeck G, Hotzenecker W, et al. Septic shock after treatment of pyoderma gangrenosum with infliximab. Acta Dermato-Venereologica. 2009;89:93-94.

24. Shareef MS, Munro LR, Owen RG, et al. Progression of IgA gammopathy to myeloma following infliximab treatment for pyoderma gangrenosum. Clin Exp Dermatol. 2012;37:146-148.

Issue
Cutis - 95(6)
Issue
Cutis - 95(6)
Page Number
337-342
Page Number
337-342
Publications
Publications
Topics
Article Type
Display Headline
Hidradenitis Suppurativa and Concomitant Pyoderma Gangrenosum Treated With Infliximab
Display Headline
Hidradenitis Suppurativa and Concomitant Pyoderma Gangrenosum Treated With Infliximab
Legacy Keywords
pyoderma gangrenosum, hidradenitis suppurativa, infliximab, tumor necrosis factor alpha, TNF
Legacy Keywords
pyoderma gangrenosum, hidradenitis suppurativa, infliximab, tumor necrosis factor alpha, TNF
Sections
Inside the Article

   Practice Points

 

  • ­Pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS) are rare chronic inflammatory dermatoses that may coexist in the same patient.
  • ­Infliximab may represent an effective therapeutic option for the treatment of concurrent PG and HS that is refractory to conventional therapies.
Disallow All Ads
Article PDF Media

Rare Angioinvasive Fungal Infection in Association With Leukemia Cutis

Article Type
Changed
Thu, 01/10/2019 - 13:23
Display Headline
Rare Angioinvasive Fungal Infection in Association With Leukemia Cutis

Leukemia cutis (LC) is characterized by the infiltration of malignant neoplastic leukocytes or their precursors into the skin, most often in conjunction with systemic leukemia.1 Acute myelogenous leukemia (AML) is the second most common cause of LC and the most common form of leukemia among adults.1 Patients with leukemia often are in a relative or absolute immunocompromised state, which may be secondary to neutropenia, chemotherapy regimens, or immunosuppressive regimens following stem cell transplant (SCT). Thus, when evaluating cutaneous lesions consistent with LC in immunocompromised patients, there must be a high index of suspicion for concomitant opportunistic infections.

We report the case of a 52-year-old man with primary refractory AML following allogeneic SCT with relapse who presented with an LC lesion below the knee with concomitant invasive fungal infection despite being on prophylactic oral antifungal therapy.

Case Report

A 52-year-old man with primary refractory AML (M1) of 1 year’s duration presented for evaluation of a slowly progressing reddish purple nodule on the right knee of 2 to 4 months’ duration. The patient had undergone a matched unrelated donor allogeneic SCT 6 months following diagnosis of AML with subsequent disease progression despite reduction of posttransplant graft-versus-host disease prophylactic immune suppression and a cycle of clofarabine. The patient was hospitalized 2 months after the SCT for neutropenic fever and was found to have vancomycin-resistant enterococcal bacteremia, Clostridium difficile colitis, and possible fungal pneumonia. He was treated with voriconazole 200 mg twice daily, which he continued following discharge for antifungal prophylaxis. At the time of discharge, the patient reported that he noticed an asymptomatic “purple papule” on the right knee but did not seek further workup.

Two months later, the patient presented with a fever (temperature, 38.6°C) and leukocytosis (white blood cell count, 130 cells/mL [increased from 53 cells/mL 1 week prior to admission]). Due to his history of immunosuppression and neutropenia, the patient was placed on a broad-spectrum antibiotic regimen of cefepime, daptomycin, and linezolid on admission. Later, vancomycin and gentamicin were added and voriconazole was switched to caspofungin. The patient also received granulocyte-macrophage colony-stimulating factor for neutropenia. During the current hospitalization, blood cultures demonstrated vancomycin-resistant enterococcemia, and computed tomography of the chest revealed findings consistent with multilobar pneumonia.

 

Figure 1. A large round, reddish purple, centrally ulcerated plaque with dark hemorrhagic crust and a surrounding patch of erythema inferior to the knee on the right lateral lower leg.

Dermatology was consulted to evaluate the purple nodule on the right knee, which had slowly progressed since his last admission. Physical examination revealed a violaceous, 1.5×1.5-cm nodule with central necrosis covered by black eschar with surrounding erythema (Figure 1). Biopsy specimens for routine histology and a tissue culture were obtained. Histopathologic examination revealed a dense diffuse infiltrate of large hyperchromatic mononuclear cells extending through the dermis, which was consistent with the patient’s known AML (Figure 2). Acid-fast bacillus staining was negative for mycobacterial organisms. Grocott-Gomori methenamine-silver stain demonstrated an overwhelming number of septate fungal hyphae with acute-angle branching, concerning for Aspergillus species (Figure 3). Of note, an Aspergillus serum antigen test was performed at this time and was negative. On repeat review of the routine histologic sections, angioinvasion by hyphae was detected amidst the dense lymphocytic infiltrate (Figure 4).

Given the patient’s immunocompromised state, the presence of angioinvasive fungi on the skin biopsy, and unresolved pneumonia, the patient was restarted on voriconazole for treatment of likely Aspergillus infection. He was continued on chemotherapy for the primary refractory AML and received a donor lymphocyte infusion prior to discharge. After the patient was discharged, the tissue culture grew Paecilomyces, a rare fungal species. The patient died 1 week after discharge.

 

Figure 2. A punch biopsy specimen demonstrated a dense interstitial infiltrate of hyperchromatic cells extending through the dermis (A)(H&E, original magnification ×200). Higher-power view of monomorphic cells exhibited elevated nuclear-cytoplasmic ratios (B)(H&E, original magnification ×600).

   

Figure 3. Grocott-Gomori methenamine-silver stain revealed numerous fungal hyphae (A)(original magnification ×200). Higher-power magnification showed septate fungal hyphae (B)(original magnification ×600).

 

Figure 4. Leukemia cutis and numerous fungal hyphae demonstrated angioinvasion (H&amp;E, original magnification ×200).

Comment

Leukemia cutis is an extramedullary manifestation of leukemia that appears in 10% to 15% of patients with AML.2 The frequency of LC differs widely for the various types of AML, with the majority of cases occurring in the acute myelomonocytic leukemia (M4) or acute monocytic leukemia (M5) subtypes.3,4 One large study of AML patients (N=381) demonstrated an incidence of LC in 28.6% of patients with the M4 subtype and 42.9% of those with the M5 subtype, with an incidence of only 7.1% of patients with the M1 subtype.3 It occurs less frequently in chronic myeloproliferative diseases.2,4

 

 

Leukemia cutis has a wide range of cutaneous manifestations and may present with solitary or multiple papular, nodular, or plaquelike lesions that are red-brown, blue, violaceous, or hemorrhagic.4 Leukemia cutis occurs most commonly on the legs, followed by the arms, back, chest, scalp, and face.2,4 Leukemia cutis may be hard to distinguish clinically from other conditions such as cutaneous metastases of visceral malignancies, lymphoma, drug eruptions, and opportunistic infections. Leukemia cutis ulcers often measure only a few centimeters in diameter with a firmly adherent purulent or hemorrhagic crust and may occur in unusual locations. These lesions usually are treatment resistant and their persistence may help to lead to diagnosis.4

Microscopically, most LC lesions show a perivascular or periadnexal pattern of involvement or a dense diffuse, interstitial, or nodular atypical lymphocytic infiltrate involving the dermis and subcutis with sparing of the upper papillary dermis.2 The cytologic appearance of M1 and M2 subtypes of AML are characterized by medium-sized to large mononuclear cells with a light cytoplasm and large basophilic cell nuclei. The M4 and M5 subtypes of AML generally are dominated by medium-sized, round or oval-shaped mononuclear cells that may have eosinophilic cytoplasm and segmented or kidney-shaped basophilic nuclei.4 Immunophenotyping is crucial for diagnosis. In myeloid disorders, there is positive staining with markers of myeloid lineage such as myeloperoxidase, lysozyme, CD34, CD15, CD68, CD43, and CD117.5

In our patient, there was an ulcerated dense diffuse dermal infiltrate of large atypical lymphocytes consistent with LC and positive immunostaining consistent with LC associated with AML. Additionally, septate hyphae with acute-angle branching also were noted in the dermal blood vessels on hematoxylin and eosin and fungal staining, demonstrating concomitant fungal infection. Angioinvasion of organisms demonstrated on skin biopsy and persistent pneumonia noted on chest imaging suggested a disseminated infectious process.       

Invasive fungal infections are an increasing cause of morbidity and mortality in immunocompromised individuals, including those with hematologic malignancies and hematologic SCTs. Despite an increasing number of antifungal therapies, outcomes are frequently suboptimal with mortality rates often greater than 50% depending on the pathogen and disease.6 Thus, there must be a high index of suspicion of infection even when a separate histopathologic diagnosis is available, such as the finding of leukemic infiltrates in this patient’s biopsy specimen. A similar case of LC has been reported with concomitant fungal infection involving Fusarium and Enterococcus.7 Patients with leukemic cells may develop leukemic infiltrates in response to cutaneous infection, and a high index of suspicion for 2 related but distinct processes is necessary.

Paecilomyces species are an emerging cause of opportunistic and usually severe human infections.8-11 The Paecilomyces species are saprophytic filamentous fungi that are found worldwide in soil as well as contaminants in the air and water.12Paecilomyces infection is generally associated with the use of immunosuppressive therapies, implants, or ocular surgery. Among species in this genus, Paecilomyces lilacinus and Paecilomyces variotii are of clinical importance. Most species have high susceptibility to the newer azoles such as voriconazole.6

Conclusion

Despite continued treatment with voriconazole, our patient still developed a rare fungal infection arising in a lesion of LC. He had signs of infection, including an elevated white blood cell count, fever, and malaise, which are nonspecific clinical findings that could have been attributed to known relapse of systemic leukemia or to known enterococcemia. Even in patients on antifungal prophylaxis and with other possible causes of leukocytosis, this case illustrates that there must be a high index of suspicion for angioinvasive fungal infection.

References

 

1. Aquilera SB, Zarraga M, Rosen L. Leukemia cutis in a patient with acute myelogenous leukemia: a case report and review of the literature. Cutis. 2010;85:31-36.

2. Cho-Vega JH, Medeiros J, Prieto VG, et al. Leukemia cutis. Am J Clin Pathol. 2008;129:130.

3. Agis H, Weltermann A, Fonatsch C, et al. A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis. Ann Hematol. 2002;81:90-95.

4. Wagner G, Fenchel K, Back W, et al. Leukemia cutis—epidemiology, clinical presentation, and differential diagnoses. J Dtsch Dermatol Ges. 2012;10:27-36.

5. Hejmadi RK, Thompson D, Shah F, et al. Cutaneous presentation of aleukemic monoblastic leukemia cutis: a case report and review of literature with focus on immunohistochemistry. J Cutan Pathol. 2008;35(suppl 1):46.

6. Kontoyiannis DP. Invasive mycoses: strategies for effective management. Am J Med. 2012;125(suppl 1):25-38.

7. Feramisco JD, Hsiao JL, Fox LP, et al. Angioinvasive Fusarium and concomitant Enterococcus infection arising in association with leukemia cutis. J Cutan Pathol. 2011;38:926-929.

8. Antachopoulos C, Walsh TJ, Roilides E. Fungal infections in primary immunodeficiencies. Eur J Pediatr. 2007;166:1099-1117.

9. Carey J, D’Amico R, Sutton DA, et al. Paecilomyces lilacinus vaginitis in an immuno-competent patient. Emerg Infect Dis. 2003;9:1155-1158.

10. Castro LG, Salebian A, Sotto MN. Hyalohyphomycosis by Paecilomyces lilacinus in a renal transplant patient and a review of human Paecilomyces species infections. J Med Vet Mycol. 1990;28:15-26.

11. Pastor FJ, Guarro J. Clinical manifestations, treatment and outcome of Paecilomyces lilacinus infections. Clin Microbiol Infect. 2006;12:948-960.

12. Castelli MV, Alastruey-Izquierdo A, Cuesta I, et al. Susceptibility testing and molecular classification of Paecilomyces spp. Antimicrob Agents Chemother. 2008;52:2926-2928.

Article PDF
Author and Disclosure Information

 

Yunyoung C. Chang, MD; Campbell Stewart, MD; Emily Y. Chu, MD, PhD; Misha Rosenbach, MD

From the Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia.

The authors report no conflict of interest.

Correspondence: Misha Rosenbach, MD, 3600 Spruce St, 2nd Floor, Maloney Building, University of Pennsylvania, Philadelphia, PA 19104 (Misha.Rosenbach@uphs.upenn.edu).

Issue
Cutis - 95(6)
Publications
Topics
Page Number
332-335
Legacy Keywords
leukemia cutis, acute myelogenous leukemia, angioinvasive fungal infection, paecilomyces
Sections
Author and Disclosure Information

 

Yunyoung C. Chang, MD; Campbell Stewart, MD; Emily Y. Chu, MD, PhD; Misha Rosenbach, MD

From the Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia.

The authors report no conflict of interest.

Correspondence: Misha Rosenbach, MD, 3600 Spruce St, 2nd Floor, Maloney Building, University of Pennsylvania, Philadelphia, PA 19104 (Misha.Rosenbach@uphs.upenn.edu).

Author and Disclosure Information

 

Yunyoung C. Chang, MD; Campbell Stewart, MD; Emily Y. Chu, MD, PhD; Misha Rosenbach, MD

From the Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia.

The authors report no conflict of interest.

Correspondence: Misha Rosenbach, MD, 3600 Spruce St, 2nd Floor, Maloney Building, University of Pennsylvania, Philadelphia, PA 19104 (Misha.Rosenbach@uphs.upenn.edu).

Article PDF
Article PDF
Related Articles

Leukemia cutis (LC) is characterized by the infiltration of malignant neoplastic leukocytes or their precursors into the skin, most often in conjunction with systemic leukemia.1 Acute myelogenous leukemia (AML) is the second most common cause of LC and the most common form of leukemia among adults.1 Patients with leukemia often are in a relative or absolute immunocompromised state, which may be secondary to neutropenia, chemotherapy regimens, or immunosuppressive regimens following stem cell transplant (SCT). Thus, when evaluating cutaneous lesions consistent with LC in immunocompromised patients, there must be a high index of suspicion for concomitant opportunistic infections.

We report the case of a 52-year-old man with primary refractory AML following allogeneic SCT with relapse who presented with an LC lesion below the knee with concomitant invasive fungal infection despite being on prophylactic oral antifungal therapy.

Case Report

A 52-year-old man with primary refractory AML (M1) of 1 year’s duration presented for evaluation of a slowly progressing reddish purple nodule on the right knee of 2 to 4 months’ duration. The patient had undergone a matched unrelated donor allogeneic SCT 6 months following diagnosis of AML with subsequent disease progression despite reduction of posttransplant graft-versus-host disease prophylactic immune suppression and a cycle of clofarabine. The patient was hospitalized 2 months after the SCT for neutropenic fever and was found to have vancomycin-resistant enterococcal bacteremia, Clostridium difficile colitis, and possible fungal pneumonia. He was treated with voriconazole 200 mg twice daily, which he continued following discharge for antifungal prophylaxis. At the time of discharge, the patient reported that he noticed an asymptomatic “purple papule” on the right knee but did not seek further workup.

Two months later, the patient presented with a fever (temperature, 38.6°C) and leukocytosis (white blood cell count, 130 cells/mL [increased from 53 cells/mL 1 week prior to admission]). Due to his history of immunosuppression and neutropenia, the patient was placed on a broad-spectrum antibiotic regimen of cefepime, daptomycin, and linezolid on admission. Later, vancomycin and gentamicin were added and voriconazole was switched to caspofungin. The patient also received granulocyte-macrophage colony-stimulating factor for neutropenia. During the current hospitalization, blood cultures demonstrated vancomycin-resistant enterococcemia, and computed tomography of the chest revealed findings consistent with multilobar pneumonia.

 

Figure 1. A large round, reddish purple, centrally ulcerated plaque with dark hemorrhagic crust and a surrounding patch of erythema inferior to the knee on the right lateral lower leg.

Dermatology was consulted to evaluate the purple nodule on the right knee, which had slowly progressed since his last admission. Physical examination revealed a violaceous, 1.5×1.5-cm nodule with central necrosis covered by black eschar with surrounding erythema (Figure 1). Biopsy specimens for routine histology and a tissue culture were obtained. Histopathologic examination revealed a dense diffuse infiltrate of large hyperchromatic mononuclear cells extending through the dermis, which was consistent with the patient’s known AML (Figure 2). Acid-fast bacillus staining was negative for mycobacterial organisms. Grocott-Gomori methenamine-silver stain demonstrated an overwhelming number of septate fungal hyphae with acute-angle branching, concerning for Aspergillus species (Figure 3). Of note, an Aspergillus serum antigen test was performed at this time and was negative. On repeat review of the routine histologic sections, angioinvasion by hyphae was detected amidst the dense lymphocytic infiltrate (Figure 4).

Given the patient’s immunocompromised state, the presence of angioinvasive fungi on the skin biopsy, and unresolved pneumonia, the patient was restarted on voriconazole for treatment of likely Aspergillus infection. He was continued on chemotherapy for the primary refractory AML and received a donor lymphocyte infusion prior to discharge. After the patient was discharged, the tissue culture grew Paecilomyces, a rare fungal species. The patient died 1 week after discharge.

 

Figure 2. A punch biopsy specimen demonstrated a dense interstitial infiltrate of hyperchromatic cells extending through the dermis (A)(H&E, original magnification ×200). Higher-power view of monomorphic cells exhibited elevated nuclear-cytoplasmic ratios (B)(H&E, original magnification ×600).

   

Figure 3. Grocott-Gomori methenamine-silver stain revealed numerous fungal hyphae (A)(original magnification ×200). Higher-power magnification showed septate fungal hyphae (B)(original magnification ×600).

 

Figure 4. Leukemia cutis and numerous fungal hyphae demonstrated angioinvasion (H&amp;E, original magnification ×200).

Comment

Leukemia cutis is an extramedullary manifestation of leukemia that appears in 10% to 15% of patients with AML.2 The frequency of LC differs widely for the various types of AML, with the majority of cases occurring in the acute myelomonocytic leukemia (M4) or acute monocytic leukemia (M5) subtypes.3,4 One large study of AML patients (N=381) demonstrated an incidence of LC in 28.6% of patients with the M4 subtype and 42.9% of those with the M5 subtype, with an incidence of only 7.1% of patients with the M1 subtype.3 It occurs less frequently in chronic myeloproliferative diseases.2,4

 

 

Leukemia cutis has a wide range of cutaneous manifestations and may present with solitary or multiple papular, nodular, or plaquelike lesions that are red-brown, blue, violaceous, or hemorrhagic.4 Leukemia cutis occurs most commonly on the legs, followed by the arms, back, chest, scalp, and face.2,4 Leukemia cutis may be hard to distinguish clinically from other conditions such as cutaneous metastases of visceral malignancies, lymphoma, drug eruptions, and opportunistic infections. Leukemia cutis ulcers often measure only a few centimeters in diameter with a firmly adherent purulent or hemorrhagic crust and may occur in unusual locations. These lesions usually are treatment resistant and their persistence may help to lead to diagnosis.4

Microscopically, most LC lesions show a perivascular or periadnexal pattern of involvement or a dense diffuse, interstitial, or nodular atypical lymphocytic infiltrate involving the dermis and subcutis with sparing of the upper papillary dermis.2 The cytologic appearance of M1 and M2 subtypes of AML are characterized by medium-sized to large mononuclear cells with a light cytoplasm and large basophilic cell nuclei. The M4 and M5 subtypes of AML generally are dominated by medium-sized, round or oval-shaped mononuclear cells that may have eosinophilic cytoplasm and segmented or kidney-shaped basophilic nuclei.4 Immunophenotyping is crucial for diagnosis. In myeloid disorders, there is positive staining with markers of myeloid lineage such as myeloperoxidase, lysozyme, CD34, CD15, CD68, CD43, and CD117.5

In our patient, there was an ulcerated dense diffuse dermal infiltrate of large atypical lymphocytes consistent with LC and positive immunostaining consistent with LC associated with AML. Additionally, septate hyphae with acute-angle branching also were noted in the dermal blood vessels on hematoxylin and eosin and fungal staining, demonstrating concomitant fungal infection. Angioinvasion of organisms demonstrated on skin biopsy and persistent pneumonia noted on chest imaging suggested a disseminated infectious process.       

Invasive fungal infections are an increasing cause of morbidity and mortality in immunocompromised individuals, including those with hematologic malignancies and hematologic SCTs. Despite an increasing number of antifungal therapies, outcomes are frequently suboptimal with mortality rates often greater than 50% depending on the pathogen and disease.6 Thus, there must be a high index of suspicion of infection even when a separate histopathologic diagnosis is available, such as the finding of leukemic infiltrates in this patient’s biopsy specimen. A similar case of LC has been reported with concomitant fungal infection involving Fusarium and Enterococcus.7 Patients with leukemic cells may develop leukemic infiltrates in response to cutaneous infection, and a high index of suspicion for 2 related but distinct processes is necessary.

Paecilomyces species are an emerging cause of opportunistic and usually severe human infections.8-11 The Paecilomyces species are saprophytic filamentous fungi that are found worldwide in soil as well as contaminants in the air and water.12Paecilomyces infection is generally associated with the use of immunosuppressive therapies, implants, or ocular surgery. Among species in this genus, Paecilomyces lilacinus and Paecilomyces variotii are of clinical importance. Most species have high susceptibility to the newer azoles such as voriconazole.6

Conclusion

Despite continued treatment with voriconazole, our patient still developed a rare fungal infection arising in a lesion of LC. He had signs of infection, including an elevated white blood cell count, fever, and malaise, which are nonspecific clinical findings that could have been attributed to known relapse of systemic leukemia or to known enterococcemia. Even in patients on antifungal prophylaxis and with other possible causes of leukocytosis, this case illustrates that there must be a high index of suspicion for angioinvasive fungal infection.

Leukemia cutis (LC) is characterized by the infiltration of malignant neoplastic leukocytes or their precursors into the skin, most often in conjunction with systemic leukemia.1 Acute myelogenous leukemia (AML) is the second most common cause of LC and the most common form of leukemia among adults.1 Patients with leukemia often are in a relative or absolute immunocompromised state, which may be secondary to neutropenia, chemotherapy regimens, or immunosuppressive regimens following stem cell transplant (SCT). Thus, when evaluating cutaneous lesions consistent with LC in immunocompromised patients, there must be a high index of suspicion for concomitant opportunistic infections.

We report the case of a 52-year-old man with primary refractory AML following allogeneic SCT with relapse who presented with an LC lesion below the knee with concomitant invasive fungal infection despite being on prophylactic oral antifungal therapy.

Case Report

A 52-year-old man with primary refractory AML (M1) of 1 year’s duration presented for evaluation of a slowly progressing reddish purple nodule on the right knee of 2 to 4 months’ duration. The patient had undergone a matched unrelated donor allogeneic SCT 6 months following diagnosis of AML with subsequent disease progression despite reduction of posttransplant graft-versus-host disease prophylactic immune suppression and a cycle of clofarabine. The patient was hospitalized 2 months after the SCT for neutropenic fever and was found to have vancomycin-resistant enterococcal bacteremia, Clostridium difficile colitis, and possible fungal pneumonia. He was treated with voriconazole 200 mg twice daily, which he continued following discharge for antifungal prophylaxis. At the time of discharge, the patient reported that he noticed an asymptomatic “purple papule” on the right knee but did not seek further workup.

Two months later, the patient presented with a fever (temperature, 38.6°C) and leukocytosis (white blood cell count, 130 cells/mL [increased from 53 cells/mL 1 week prior to admission]). Due to his history of immunosuppression and neutropenia, the patient was placed on a broad-spectrum antibiotic regimen of cefepime, daptomycin, and linezolid on admission. Later, vancomycin and gentamicin were added and voriconazole was switched to caspofungin. The patient also received granulocyte-macrophage colony-stimulating factor for neutropenia. During the current hospitalization, blood cultures demonstrated vancomycin-resistant enterococcemia, and computed tomography of the chest revealed findings consistent with multilobar pneumonia.

 

Figure 1. A large round, reddish purple, centrally ulcerated plaque with dark hemorrhagic crust and a surrounding patch of erythema inferior to the knee on the right lateral lower leg.

Dermatology was consulted to evaluate the purple nodule on the right knee, which had slowly progressed since his last admission. Physical examination revealed a violaceous, 1.5×1.5-cm nodule with central necrosis covered by black eschar with surrounding erythema (Figure 1). Biopsy specimens for routine histology and a tissue culture were obtained. Histopathologic examination revealed a dense diffuse infiltrate of large hyperchromatic mononuclear cells extending through the dermis, which was consistent with the patient’s known AML (Figure 2). Acid-fast bacillus staining was negative for mycobacterial organisms. Grocott-Gomori methenamine-silver stain demonstrated an overwhelming number of septate fungal hyphae with acute-angle branching, concerning for Aspergillus species (Figure 3). Of note, an Aspergillus serum antigen test was performed at this time and was negative. On repeat review of the routine histologic sections, angioinvasion by hyphae was detected amidst the dense lymphocytic infiltrate (Figure 4).

Given the patient’s immunocompromised state, the presence of angioinvasive fungi on the skin biopsy, and unresolved pneumonia, the patient was restarted on voriconazole for treatment of likely Aspergillus infection. He was continued on chemotherapy for the primary refractory AML and received a donor lymphocyte infusion prior to discharge. After the patient was discharged, the tissue culture grew Paecilomyces, a rare fungal species. The patient died 1 week after discharge.

 

Figure 2. A punch biopsy specimen demonstrated a dense interstitial infiltrate of hyperchromatic cells extending through the dermis (A)(H&E, original magnification ×200). Higher-power view of monomorphic cells exhibited elevated nuclear-cytoplasmic ratios (B)(H&E, original magnification ×600).

   

Figure 3. Grocott-Gomori methenamine-silver stain revealed numerous fungal hyphae (A)(original magnification ×200). Higher-power magnification showed septate fungal hyphae (B)(original magnification ×600).

 

Figure 4. Leukemia cutis and numerous fungal hyphae demonstrated angioinvasion (H&amp;E, original magnification ×200).

Comment

Leukemia cutis is an extramedullary manifestation of leukemia that appears in 10% to 15% of patients with AML.2 The frequency of LC differs widely for the various types of AML, with the majority of cases occurring in the acute myelomonocytic leukemia (M4) or acute monocytic leukemia (M5) subtypes.3,4 One large study of AML patients (N=381) demonstrated an incidence of LC in 28.6% of patients with the M4 subtype and 42.9% of those with the M5 subtype, with an incidence of only 7.1% of patients with the M1 subtype.3 It occurs less frequently in chronic myeloproliferative diseases.2,4

 

 

Leukemia cutis has a wide range of cutaneous manifestations and may present with solitary or multiple papular, nodular, or plaquelike lesions that are red-brown, blue, violaceous, or hemorrhagic.4 Leukemia cutis occurs most commonly on the legs, followed by the arms, back, chest, scalp, and face.2,4 Leukemia cutis may be hard to distinguish clinically from other conditions such as cutaneous metastases of visceral malignancies, lymphoma, drug eruptions, and opportunistic infections. Leukemia cutis ulcers often measure only a few centimeters in diameter with a firmly adherent purulent or hemorrhagic crust and may occur in unusual locations. These lesions usually are treatment resistant and their persistence may help to lead to diagnosis.4

Microscopically, most LC lesions show a perivascular or periadnexal pattern of involvement or a dense diffuse, interstitial, or nodular atypical lymphocytic infiltrate involving the dermis and subcutis with sparing of the upper papillary dermis.2 The cytologic appearance of M1 and M2 subtypes of AML are characterized by medium-sized to large mononuclear cells with a light cytoplasm and large basophilic cell nuclei. The M4 and M5 subtypes of AML generally are dominated by medium-sized, round or oval-shaped mononuclear cells that may have eosinophilic cytoplasm and segmented or kidney-shaped basophilic nuclei.4 Immunophenotyping is crucial for diagnosis. In myeloid disorders, there is positive staining with markers of myeloid lineage such as myeloperoxidase, lysozyme, CD34, CD15, CD68, CD43, and CD117.5

In our patient, there was an ulcerated dense diffuse dermal infiltrate of large atypical lymphocytes consistent with LC and positive immunostaining consistent with LC associated with AML. Additionally, septate hyphae with acute-angle branching also were noted in the dermal blood vessels on hematoxylin and eosin and fungal staining, demonstrating concomitant fungal infection. Angioinvasion of organisms demonstrated on skin biopsy and persistent pneumonia noted on chest imaging suggested a disseminated infectious process.       

Invasive fungal infections are an increasing cause of morbidity and mortality in immunocompromised individuals, including those with hematologic malignancies and hematologic SCTs. Despite an increasing number of antifungal therapies, outcomes are frequently suboptimal with mortality rates often greater than 50% depending on the pathogen and disease.6 Thus, there must be a high index of suspicion of infection even when a separate histopathologic diagnosis is available, such as the finding of leukemic infiltrates in this patient’s biopsy specimen. A similar case of LC has been reported with concomitant fungal infection involving Fusarium and Enterococcus.7 Patients with leukemic cells may develop leukemic infiltrates in response to cutaneous infection, and a high index of suspicion for 2 related but distinct processes is necessary.

Paecilomyces species are an emerging cause of opportunistic and usually severe human infections.8-11 The Paecilomyces species are saprophytic filamentous fungi that are found worldwide in soil as well as contaminants in the air and water.12Paecilomyces infection is generally associated with the use of immunosuppressive therapies, implants, or ocular surgery. Among species in this genus, Paecilomyces lilacinus and Paecilomyces variotii are of clinical importance. Most species have high susceptibility to the newer azoles such as voriconazole.6

Conclusion

Despite continued treatment with voriconazole, our patient still developed a rare fungal infection arising in a lesion of LC. He had signs of infection, including an elevated white blood cell count, fever, and malaise, which are nonspecific clinical findings that could have been attributed to known relapse of systemic leukemia or to known enterococcemia. Even in patients on antifungal prophylaxis and with other possible causes of leukocytosis, this case illustrates that there must be a high index of suspicion for angioinvasive fungal infection.

References

 

1. Aquilera SB, Zarraga M, Rosen L. Leukemia cutis in a patient with acute myelogenous leukemia: a case report and review of the literature. Cutis. 2010;85:31-36.

2. Cho-Vega JH, Medeiros J, Prieto VG, et al. Leukemia cutis. Am J Clin Pathol. 2008;129:130.

3. Agis H, Weltermann A, Fonatsch C, et al. A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis. Ann Hematol. 2002;81:90-95.

4. Wagner G, Fenchel K, Back W, et al. Leukemia cutis—epidemiology, clinical presentation, and differential diagnoses. J Dtsch Dermatol Ges. 2012;10:27-36.

5. Hejmadi RK, Thompson D, Shah F, et al. Cutaneous presentation of aleukemic monoblastic leukemia cutis: a case report and review of literature with focus on immunohistochemistry. J Cutan Pathol. 2008;35(suppl 1):46.

6. Kontoyiannis DP. Invasive mycoses: strategies for effective management. Am J Med. 2012;125(suppl 1):25-38.

7. Feramisco JD, Hsiao JL, Fox LP, et al. Angioinvasive Fusarium and concomitant Enterococcus infection arising in association with leukemia cutis. J Cutan Pathol. 2011;38:926-929.

8. Antachopoulos C, Walsh TJ, Roilides E. Fungal infections in primary immunodeficiencies. Eur J Pediatr. 2007;166:1099-1117.

9. Carey J, D’Amico R, Sutton DA, et al. Paecilomyces lilacinus vaginitis in an immuno-competent patient. Emerg Infect Dis. 2003;9:1155-1158.

10. Castro LG, Salebian A, Sotto MN. Hyalohyphomycosis by Paecilomyces lilacinus in a renal transplant patient and a review of human Paecilomyces species infections. J Med Vet Mycol. 1990;28:15-26.

11. Pastor FJ, Guarro J. Clinical manifestations, treatment and outcome of Paecilomyces lilacinus infections. Clin Microbiol Infect. 2006;12:948-960.

12. Castelli MV, Alastruey-Izquierdo A, Cuesta I, et al. Susceptibility testing and molecular classification of Paecilomyces spp. Antimicrob Agents Chemother. 2008;52:2926-2928.

References

 

1. Aquilera SB, Zarraga M, Rosen L. Leukemia cutis in a patient with acute myelogenous leukemia: a case report and review of the literature. Cutis. 2010;85:31-36.

2. Cho-Vega JH, Medeiros J, Prieto VG, et al. Leukemia cutis. Am J Clin Pathol. 2008;129:130.

3. Agis H, Weltermann A, Fonatsch C, et al. A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis. Ann Hematol. 2002;81:90-95.

4. Wagner G, Fenchel K, Back W, et al. Leukemia cutis—epidemiology, clinical presentation, and differential diagnoses. J Dtsch Dermatol Ges. 2012;10:27-36.

5. Hejmadi RK, Thompson D, Shah F, et al. Cutaneous presentation of aleukemic monoblastic leukemia cutis: a case report and review of literature with focus on immunohistochemistry. J Cutan Pathol. 2008;35(suppl 1):46.

6. Kontoyiannis DP. Invasive mycoses: strategies for effective management. Am J Med. 2012;125(suppl 1):25-38.

7. Feramisco JD, Hsiao JL, Fox LP, et al. Angioinvasive Fusarium and concomitant Enterococcus infection arising in association with leukemia cutis. J Cutan Pathol. 2011;38:926-929.

8. Antachopoulos C, Walsh TJ, Roilides E. Fungal infections in primary immunodeficiencies. Eur J Pediatr. 2007;166:1099-1117.

9. Carey J, D’Amico R, Sutton DA, et al. Paecilomyces lilacinus vaginitis in an immuno-competent patient. Emerg Infect Dis. 2003;9:1155-1158.

10. Castro LG, Salebian A, Sotto MN. Hyalohyphomycosis by Paecilomyces lilacinus in a renal transplant patient and a review of human Paecilomyces species infections. J Med Vet Mycol. 1990;28:15-26.

11. Pastor FJ, Guarro J. Clinical manifestations, treatment and outcome of Paecilomyces lilacinus infections. Clin Microbiol Infect. 2006;12:948-960.

12. Castelli MV, Alastruey-Izquierdo A, Cuesta I, et al. Susceptibility testing and molecular classification of Paecilomyces spp. Antimicrob Agents Chemother. 2008;52:2926-2928.

Issue
Cutis - 95(6)
Issue
Cutis - 95(6)
Page Number
332-335
Page Number
332-335
Publications
Publications
Topics
Article Type
Display Headline
Rare Angioinvasive Fungal Infection in Association With Leukemia Cutis
Display Headline
Rare Angioinvasive Fungal Infection in Association With Leukemia Cutis
Legacy Keywords
leukemia cutis, acute myelogenous leukemia, angioinvasive fungal infection, paecilomyces
Legacy Keywords
leukemia cutis, acute myelogenous leukemia, angioinvasive fungal infection, paecilomyces
Sections
Inside the Article

   Practice Points

 

  • ­Immunosuppressed patients are at risk for atypical presentations of common infections as well as infection with rare pathogens.
  • ­Skin biopsy and tissue culture play an important role in identifying infectious agents in immunosuppressed patients.
  • ­Leukemic infiltrates may mask pathogens, and pathologists should strongly consider additional stains when indicated.
Disallow All Ads
Article PDF Media

Primary Localized Cutaneous Nodular Amyloidosis of the Thighs

Article Type
Changed
Thu, 01/10/2019 - 13:23
Display Headline
Primary Localized Cutaneous Nodular Amyloidosis of the Thighs

Case Report

Clinical Findings

A 65-year-old woman presented with multiple asymptomatic discrete nodules and atrophic plaques on the thighs of 4 years’ duration. The lesions had started as 2 small, asymptomatic, madder red plaques symmetrically located on the anterior aspect of each thigh that had gradually increased in number and size, particularly on the right thigh. Two years later, 2 new atrophic plaques appeared on the anterior aspect of each. The lesions developed slowly but never remitted and had been misdiagnosed as primary macular atrophy of skin by several outpatient clinics. The patient’s general health was good and her personal and family history was unremarkable.

Physical examination revealed multiple madder red plaques and nodules of various shapes and sizes (ie, 1–3 cm in diameter) on the anterior aspect of the right thigh. The lesions were slightly elevated with a waxy surface, firm, and painless to palpation. One similar lesion was noted on the anterior aspect of the left thigh. Two 2-cm, brown-red, atrophic plaques also were noted in a symmetrical distribution on the anterior aspect of each thigh. The plaque surfaces were slightly crinkly and shiny, and anetodermalike lesions produced a buttonhole sign identical to a neurofibroma on palpation (Figure 1).

 

Figure 1. Multiple madder red plaques, nodules, and atrophic plaques in various shapes and sizes were seen on the anterior aspect of both thighs.

Histopathologic Findings

Two biopsy specimens were taken from a nodule and an atrophic plaque on the right thigh. Microscopic examination revealed deposition of homogeneous eosinophilic material in the reticular dermis and subcutis as well as around the fine vessels (Figure 2A). There was mild cellular infiltration of lymphocytes, plasma cells, and giant cells in the dermis, especially adjacent to deposits and around the vessels (Figure 2B). The homogeneous material appeared salmon pink on Congo red staining and bright green by thioflavin T staining using a fluorescent microscope (Figures 3 and 4). These results suggested the characteristic features of cutaneous nodular amyloidosis.

 

 

Figure 2. Histopathologically, homogeneous eosinophilic material deposited in the reticular dermis and subcutis was noted (A)(H&E, original magnification ×25). Microscopic examination showed lymphocytes and plasma cells infiltrated in the dermis, especially adjacent to deposits and around the vessels (B)(H&E, original magnification ×200).

 

Figure 3. Congo red staining showed salmon pink homogeneous material (original magnification ×25).
Figure 4. Thioflavin T staining showed bright green homogeneous material (original magnification ×100).

 

Laboratory Findings

Laboratory studies showed normal results for complete blood cell count, urinalysis, liver and renal function tests, blood glucose levels, lipid panel, and erythrocyte sedimentation rate. Serum protein electrophoresis was normal and no Bence Jones proteins were detected. Serum IgA, IgG, and IgM levels showed no abnormalities. Electrocardiogram, chest radiography, and abdominal ultrasound were normal.

A diagnosis of primary localized cutaneous nodular amyloidosis (PLCNA) was made based on clinical, histopathologic, and laboratory findings. Although surgical excision in stages was proposed, the patient refused treatment because the lesions were asymptomatic. There was no obvious progression of the skin lesions and no abnormal systemic findings during 2.5 years’ follow-up.

Comment

Amyloidosis is a spectrum of diseases consisting of deposition of amyloid proteins in various tissues. Clinically, amyloidosis is divided into both primary and secondary forms of systemic amyloidosis, hemodialysis-associated amyloidosis, heredofamilial amyloidosis, and cutaneous amyloidosis. Primary cutaneous amyloidosis is localized to the skin without other organ involvement and does not occur in systemic amyloidosis. Secondary cutaneous involvement in systemic amyloidosis is rare. Most cases of primary localized cutaneous amyloidosis (PLCA) are sporadic but approximately 10% of cases may be familial.1 There are 3 main forms of localized cutaneous amyloidosis: macular, lichen, and nodular amyloidosis. Nodular cutaneous amyloidosis is the rarest form of PLCA.

Nodular amyloidosis was first described by Gottron in 1950.2 Its cutaneous lesions may present as single or multiple nodules, occasionally with overlying atrophic plaques. The lesions consist of firm, smooth-surfaced, waxy or rubbery, pink to tan papules, plaques, or nodules measuring up to several centimeters. On some lesions, surface telangiectasia may be seen. Bullous-appearing and anetodermalike lesions have been reported.3 The acral region is the most common location, followed by the legs, head, trunk, arms, and genitalia, respectively.4 In some cases the lesions can spontaneously improve over time. In our patient, the lesions were composed of both multiple nodules and atrophic plaques, which is uncommon.

The pathogenesis of amyloid deposition is still unknown. Cutaneous macular and lichen amyloidosis may originate from degenerated keratinocyte intermediate filaments. Nodular amyloidosis may represent a localized plasma cell dyscrasia that can be associated with a monoclonal gammopathy or multiple myeloma.5 Some components of amyloid in some cases of PLCNA may consist of κ and λ immunoglobulin light chains, with most reported cases being of the l subtype.6 The results of one study indicated that β2-microglobulin was another major component of amyloid fibrils and that β2-microglobulin was partly subjected to the modification of advanced glycation end product in PLCNA.7

 

 

The histopathologic examination of PLCNA is characterized by large deposits of amorphous, sometimes fissured, pale, eosinophilic material in the papillary dermis, reticular dermis, and subcutaneous fat. The overlying epidermis may exhibit flattened rete ridges. Amyloid may occur within vessel walls and adnexal structures, sometimes in a ring surrounding individual fat cells. Clinically, the lesions of PLCNA may be indistinguishable from nodular deposits of amyloid occurring in primary systemic amyloidosis or myeloma-associated amyloidosis. Histopathologically, PLCNA usually has a variable infiltrate of plasma cells and lymphocytes at the periphery or within the amyloid deposits,6 but no single stain is highly sensitive and specific. Congo red–stained deposits showed salmon pink amorphous material or apple green birefringence with polarizing microscopy.8 Amyloid derived from immunoglobulin light chains, including cutaneous nodular amyloid, also stain positive for anti-human λ light chain antibody on immunohistochemistry. Additionally, amyloid can stain positively with methyl violet and crystal violet Gram stains, Picrosirius red, thioflavin T, Dylon, and periodic acid–Schiff stains.

Clinically, some PLCNA lesions can be removed via surgical excision or laser if they are cosmetically disfiguring or symptomatic. Other methods have been attempted to improve the appearance of the lesions, such as intralesional corticosteroids, cryotherapy, and dermabrasion,9 but they usually are not helpful and have a high rate of recurrence. Although PLCNA often is a benign cutaneous disorder and some cases of PLCNA could be reactive diseases rather than neoplastic ones, some patients may develop underlying systemic amyloidosis or even paraproteinemia.10 Northcutt and Vanover11 indicated that systemic amyloidosis may be expected in less than 15% of 47 patients with localized cutaneous amyloidosis during follow-up by reviewing most of the related literature. Some cases may be associated with Sjögren syndrome (SJS), CREST (calcinosis, Raynaud phenomenon, esophageal motility disorders, sclerodactyly, and telangiectasia) syndrome, dermatomyositis, and diabetes mellitus.12-14 Polyclonal immunoglobulin amyloid has been reported only in PLCNA with SJS, which may be due to the fact that a certain population of SJS develops polyclonal B-cell proliferation and hyperglobulinemia.12 Woollons and Black15 estimated the rate of progression of PLCNA to systemic amyloidosis to be only 7%, which is much lower than the rate in the literature by a large clinical follow-up study on PLCNA.16 However, all patients with PLCNA should have a systemic evaluation and should be advised to undergo long-term clinical follow-up to help prevent progression to systemic amyloidosis or plasma cell dyscrasia.

References

 

1. Sakuma TH, Hans-Filho G, Arita K, et al. Familial primary localized cutaneous amyloidosis in Brazil. Arch Dermatol. 2009;145:695-699.

2. Rodermund OE. On amyloidosis cutis nodularis atrophicans (Gottron 1950). at the same time a contribution to the classification of amyloidosis [in German]. Arch Klin Exp Dermatol. 1967;230:153-171.

3. Chapel TA, Birmingham DJ, Malinowski YE. Nodular primary localized cutaneous amyloidosis. Arch Dermatol. 1977;113:1248-1249.

4. Criado PR, Silva CS, Vasconcellos C, et al. Extensive nodular cutaneous amyloidosis: an unusual presentation. J Eur Acad Dermatol Venereol. 2005;19:481-483.

5. Touart DM, Sau P. Cutaneous deposition diseases. part I [published correction appears in J Am Acad Dermatol. 1998;39:1042]. J Am Acad Dermatol. 1998;39(2, pt 1):149-171; quiz 172-174.

6. Borrowman TA, Lutz ME, Walsh JS. Cutaneous nodular amyloidosis masquerading as a foot callus. J Am Acad Dermatol. 2003;49:307-310.

7. Fujimoto N, Yajima M, Ohnishi Y, et al. Advanced glycation end product-modified beta2-microglobulin is a component of amyloid fibrils of primary localized cutaneous nodular amyloidosis. J Invest Dermatol. 2002;118:479-484.

8. Clement CG, Truong LD. An evaluation of Congo red fluorescence for the diagnosis of amyloidosis. Hum Pathol. 2014;45:1766-1772.

9. Lien MH, Railan D, Nelson BR. The efficacy of dermabrasion in the treatment of nodular amyloidosis. J Am Acad Dermatol. 1997;36(2, pt 2):315-316.

10. Taylor SC, Baker E, Grossman ME. Nodular vulvar amyloid as a presentation of systemic amyloidosis. J Am Acad Dermatol. 1991;24:139.

11. Northcutt AD, Vanover MJ. Nodular cutaneous amyloidosis involving the vulva. case report and literature review. Arch Dermatol. 1985;121:518-521.

12. Yoneyama K, Tochigi N, Oikawa A, et al. Primary localized cutaneous nodular amyloidosis in a patient with Sjögren’s syndrome: a review of the literature. J Dermatol. 2005;32:120-123.

13. Summers EM, Kendrick CG. Primary localized cutaneous nodular amyloidosis and CREST syndrome: a case report and review of the literature. Cutis. 2008;82:55-59.

14. Taniguchi Y, Horino T, Terada Y. Cutaneous amyloidosis associated with amyopathic dermatomyositis. J Rheumatol. 2009;36:1088-1089.

15. Woollons A, Black MM. Nodular localized primary cutaneous amyloidosis: a long-term follow-up study. Br J Dermatol. 2001;145:105-109.

16. Brownstein MH, Helwig EB. The cutaneous amyloidoses. I. localized forms. Arch Dermatol. 1970;102:8-19.

Article PDF
Author and Disclosure Information

 

Zhifang Zhai, PhD; Fei Hao, PhD; Zhiqiang Song, PhD; Xichuan Yang, PhD

From the Department of Dermatology, Southwest Hospital, Third Military Medical University, Chongqing, China.

The authors report no conflict of interest.

Correspondence: Zhifang Zhai, PhD, Department of Dermatology, Southwest Hospital, Third Military Medical University, Chongqing, 400038 China (zhaizf1004@163.com).

Issue
Cutis - 95(6)
Publications
Topics
Page Number
E24-E27
Legacy Keywords
cutaneous amyloidosis, primary localized, nodular, atrophic plaque
Sections
Author and Disclosure Information

 

Zhifang Zhai, PhD; Fei Hao, PhD; Zhiqiang Song, PhD; Xichuan Yang, PhD

From the Department of Dermatology, Southwest Hospital, Third Military Medical University, Chongqing, China.

The authors report no conflict of interest.

Correspondence: Zhifang Zhai, PhD, Department of Dermatology, Southwest Hospital, Third Military Medical University, Chongqing, 400038 China (zhaizf1004@163.com).

Author and Disclosure Information

 

Zhifang Zhai, PhD; Fei Hao, PhD; Zhiqiang Song, PhD; Xichuan Yang, PhD

From the Department of Dermatology, Southwest Hospital, Third Military Medical University, Chongqing, China.

The authors report no conflict of interest.

Correspondence: Zhifang Zhai, PhD, Department of Dermatology, Southwest Hospital, Third Military Medical University, Chongqing, 400038 China (zhaizf1004@163.com).

Article PDF
Article PDF
Related Articles

Case Report

Clinical Findings

A 65-year-old woman presented with multiple asymptomatic discrete nodules and atrophic plaques on the thighs of 4 years’ duration. The lesions had started as 2 small, asymptomatic, madder red plaques symmetrically located on the anterior aspect of each thigh that had gradually increased in number and size, particularly on the right thigh. Two years later, 2 new atrophic plaques appeared on the anterior aspect of each. The lesions developed slowly but never remitted and had been misdiagnosed as primary macular atrophy of skin by several outpatient clinics. The patient’s general health was good and her personal and family history was unremarkable.

Physical examination revealed multiple madder red plaques and nodules of various shapes and sizes (ie, 1–3 cm in diameter) on the anterior aspect of the right thigh. The lesions were slightly elevated with a waxy surface, firm, and painless to palpation. One similar lesion was noted on the anterior aspect of the left thigh. Two 2-cm, brown-red, atrophic plaques also were noted in a symmetrical distribution on the anterior aspect of each thigh. The plaque surfaces were slightly crinkly and shiny, and anetodermalike lesions produced a buttonhole sign identical to a neurofibroma on palpation (Figure 1).

 

Figure 1. Multiple madder red plaques, nodules, and atrophic plaques in various shapes and sizes were seen on the anterior aspect of both thighs.

Histopathologic Findings

Two biopsy specimens were taken from a nodule and an atrophic plaque on the right thigh. Microscopic examination revealed deposition of homogeneous eosinophilic material in the reticular dermis and subcutis as well as around the fine vessels (Figure 2A). There was mild cellular infiltration of lymphocytes, plasma cells, and giant cells in the dermis, especially adjacent to deposits and around the vessels (Figure 2B). The homogeneous material appeared salmon pink on Congo red staining and bright green by thioflavin T staining using a fluorescent microscope (Figures 3 and 4). These results suggested the characteristic features of cutaneous nodular amyloidosis.

 

 

Figure 2. Histopathologically, homogeneous eosinophilic material deposited in the reticular dermis and subcutis was noted (A)(H&E, original magnification ×25). Microscopic examination showed lymphocytes and plasma cells infiltrated in the dermis, especially adjacent to deposits and around the vessels (B)(H&E, original magnification ×200).

 

Figure 3. Congo red staining showed salmon pink homogeneous material (original magnification ×25).
Figure 4. Thioflavin T staining showed bright green homogeneous material (original magnification ×100).

 

Laboratory Findings

Laboratory studies showed normal results for complete blood cell count, urinalysis, liver and renal function tests, blood glucose levels, lipid panel, and erythrocyte sedimentation rate. Serum protein electrophoresis was normal and no Bence Jones proteins were detected. Serum IgA, IgG, and IgM levels showed no abnormalities. Electrocardiogram, chest radiography, and abdominal ultrasound were normal.

A diagnosis of primary localized cutaneous nodular amyloidosis (PLCNA) was made based on clinical, histopathologic, and laboratory findings. Although surgical excision in stages was proposed, the patient refused treatment because the lesions were asymptomatic. There was no obvious progression of the skin lesions and no abnormal systemic findings during 2.5 years’ follow-up.

Comment

Amyloidosis is a spectrum of diseases consisting of deposition of amyloid proteins in various tissues. Clinically, amyloidosis is divided into both primary and secondary forms of systemic amyloidosis, hemodialysis-associated amyloidosis, heredofamilial amyloidosis, and cutaneous amyloidosis. Primary cutaneous amyloidosis is localized to the skin without other organ involvement and does not occur in systemic amyloidosis. Secondary cutaneous involvement in systemic amyloidosis is rare. Most cases of primary localized cutaneous amyloidosis (PLCA) are sporadic but approximately 10% of cases may be familial.1 There are 3 main forms of localized cutaneous amyloidosis: macular, lichen, and nodular amyloidosis. Nodular cutaneous amyloidosis is the rarest form of PLCA.

Nodular amyloidosis was first described by Gottron in 1950.2 Its cutaneous lesions may present as single or multiple nodules, occasionally with overlying atrophic plaques. The lesions consist of firm, smooth-surfaced, waxy or rubbery, pink to tan papules, plaques, or nodules measuring up to several centimeters. On some lesions, surface telangiectasia may be seen. Bullous-appearing and anetodermalike lesions have been reported.3 The acral region is the most common location, followed by the legs, head, trunk, arms, and genitalia, respectively.4 In some cases the lesions can spontaneously improve over time. In our patient, the lesions were composed of both multiple nodules and atrophic plaques, which is uncommon.

The pathogenesis of amyloid deposition is still unknown. Cutaneous macular and lichen amyloidosis may originate from degenerated keratinocyte intermediate filaments. Nodular amyloidosis may represent a localized plasma cell dyscrasia that can be associated with a monoclonal gammopathy or multiple myeloma.5 Some components of amyloid in some cases of PLCNA may consist of κ and λ immunoglobulin light chains, with most reported cases being of the l subtype.6 The results of one study indicated that β2-microglobulin was another major component of amyloid fibrils and that β2-microglobulin was partly subjected to the modification of advanced glycation end product in PLCNA.7

 

 

The histopathologic examination of PLCNA is characterized by large deposits of amorphous, sometimes fissured, pale, eosinophilic material in the papillary dermis, reticular dermis, and subcutaneous fat. The overlying epidermis may exhibit flattened rete ridges. Amyloid may occur within vessel walls and adnexal structures, sometimes in a ring surrounding individual fat cells. Clinically, the lesions of PLCNA may be indistinguishable from nodular deposits of amyloid occurring in primary systemic amyloidosis or myeloma-associated amyloidosis. Histopathologically, PLCNA usually has a variable infiltrate of plasma cells and lymphocytes at the periphery or within the amyloid deposits,6 but no single stain is highly sensitive and specific. Congo red–stained deposits showed salmon pink amorphous material or apple green birefringence with polarizing microscopy.8 Amyloid derived from immunoglobulin light chains, including cutaneous nodular amyloid, also stain positive for anti-human λ light chain antibody on immunohistochemistry. Additionally, amyloid can stain positively with methyl violet and crystal violet Gram stains, Picrosirius red, thioflavin T, Dylon, and periodic acid–Schiff stains.

Clinically, some PLCNA lesions can be removed via surgical excision or laser if they are cosmetically disfiguring or symptomatic. Other methods have been attempted to improve the appearance of the lesions, such as intralesional corticosteroids, cryotherapy, and dermabrasion,9 but they usually are not helpful and have a high rate of recurrence. Although PLCNA often is a benign cutaneous disorder and some cases of PLCNA could be reactive diseases rather than neoplastic ones, some patients may develop underlying systemic amyloidosis or even paraproteinemia.10 Northcutt and Vanover11 indicated that systemic amyloidosis may be expected in less than 15% of 47 patients with localized cutaneous amyloidosis during follow-up by reviewing most of the related literature. Some cases may be associated with Sjögren syndrome (SJS), CREST (calcinosis, Raynaud phenomenon, esophageal motility disorders, sclerodactyly, and telangiectasia) syndrome, dermatomyositis, and diabetes mellitus.12-14 Polyclonal immunoglobulin amyloid has been reported only in PLCNA with SJS, which may be due to the fact that a certain population of SJS develops polyclonal B-cell proliferation and hyperglobulinemia.12 Woollons and Black15 estimated the rate of progression of PLCNA to systemic amyloidosis to be only 7%, which is much lower than the rate in the literature by a large clinical follow-up study on PLCNA.16 However, all patients with PLCNA should have a systemic evaluation and should be advised to undergo long-term clinical follow-up to help prevent progression to systemic amyloidosis or plasma cell dyscrasia.

Case Report

Clinical Findings

A 65-year-old woman presented with multiple asymptomatic discrete nodules and atrophic plaques on the thighs of 4 years’ duration. The lesions had started as 2 small, asymptomatic, madder red plaques symmetrically located on the anterior aspect of each thigh that had gradually increased in number and size, particularly on the right thigh. Two years later, 2 new atrophic plaques appeared on the anterior aspect of each. The lesions developed slowly but never remitted and had been misdiagnosed as primary macular atrophy of skin by several outpatient clinics. The patient’s general health was good and her personal and family history was unremarkable.

Physical examination revealed multiple madder red plaques and nodules of various shapes and sizes (ie, 1–3 cm in diameter) on the anterior aspect of the right thigh. The lesions were slightly elevated with a waxy surface, firm, and painless to palpation. One similar lesion was noted on the anterior aspect of the left thigh. Two 2-cm, brown-red, atrophic plaques also were noted in a symmetrical distribution on the anterior aspect of each thigh. The plaque surfaces were slightly crinkly and shiny, and anetodermalike lesions produced a buttonhole sign identical to a neurofibroma on palpation (Figure 1).

 

Figure 1. Multiple madder red plaques, nodules, and atrophic plaques in various shapes and sizes were seen on the anterior aspect of both thighs.

Histopathologic Findings

Two biopsy specimens were taken from a nodule and an atrophic plaque on the right thigh. Microscopic examination revealed deposition of homogeneous eosinophilic material in the reticular dermis and subcutis as well as around the fine vessels (Figure 2A). There was mild cellular infiltration of lymphocytes, plasma cells, and giant cells in the dermis, especially adjacent to deposits and around the vessels (Figure 2B). The homogeneous material appeared salmon pink on Congo red staining and bright green by thioflavin T staining using a fluorescent microscope (Figures 3 and 4). These results suggested the characteristic features of cutaneous nodular amyloidosis.

 

 

Figure 2. Histopathologically, homogeneous eosinophilic material deposited in the reticular dermis and subcutis was noted (A)(H&E, original magnification ×25). Microscopic examination showed lymphocytes and plasma cells infiltrated in the dermis, especially adjacent to deposits and around the vessels (B)(H&E, original magnification ×200).

 

Figure 3. Congo red staining showed salmon pink homogeneous material (original magnification ×25).
Figure 4. Thioflavin T staining showed bright green homogeneous material (original magnification ×100).

 

Laboratory Findings

Laboratory studies showed normal results for complete blood cell count, urinalysis, liver and renal function tests, blood glucose levels, lipid panel, and erythrocyte sedimentation rate. Serum protein electrophoresis was normal and no Bence Jones proteins were detected. Serum IgA, IgG, and IgM levels showed no abnormalities. Electrocardiogram, chest radiography, and abdominal ultrasound were normal.

A diagnosis of primary localized cutaneous nodular amyloidosis (PLCNA) was made based on clinical, histopathologic, and laboratory findings. Although surgical excision in stages was proposed, the patient refused treatment because the lesions were asymptomatic. There was no obvious progression of the skin lesions and no abnormal systemic findings during 2.5 years’ follow-up.

Comment

Amyloidosis is a spectrum of diseases consisting of deposition of amyloid proteins in various tissues. Clinically, amyloidosis is divided into both primary and secondary forms of systemic amyloidosis, hemodialysis-associated amyloidosis, heredofamilial amyloidosis, and cutaneous amyloidosis. Primary cutaneous amyloidosis is localized to the skin without other organ involvement and does not occur in systemic amyloidosis. Secondary cutaneous involvement in systemic amyloidosis is rare. Most cases of primary localized cutaneous amyloidosis (PLCA) are sporadic but approximately 10% of cases may be familial.1 There are 3 main forms of localized cutaneous amyloidosis: macular, lichen, and nodular amyloidosis. Nodular cutaneous amyloidosis is the rarest form of PLCA.

Nodular amyloidosis was first described by Gottron in 1950.2 Its cutaneous lesions may present as single or multiple nodules, occasionally with overlying atrophic plaques. The lesions consist of firm, smooth-surfaced, waxy or rubbery, pink to tan papules, plaques, or nodules measuring up to several centimeters. On some lesions, surface telangiectasia may be seen. Bullous-appearing and anetodermalike lesions have been reported.3 The acral region is the most common location, followed by the legs, head, trunk, arms, and genitalia, respectively.4 In some cases the lesions can spontaneously improve over time. In our patient, the lesions were composed of both multiple nodules and atrophic plaques, which is uncommon.

The pathogenesis of amyloid deposition is still unknown. Cutaneous macular and lichen amyloidosis may originate from degenerated keratinocyte intermediate filaments. Nodular amyloidosis may represent a localized plasma cell dyscrasia that can be associated with a monoclonal gammopathy or multiple myeloma.5 Some components of amyloid in some cases of PLCNA may consist of κ and λ immunoglobulin light chains, with most reported cases being of the l subtype.6 The results of one study indicated that β2-microglobulin was another major component of amyloid fibrils and that β2-microglobulin was partly subjected to the modification of advanced glycation end product in PLCNA.7

 

 

The histopathologic examination of PLCNA is characterized by large deposits of amorphous, sometimes fissured, pale, eosinophilic material in the papillary dermis, reticular dermis, and subcutaneous fat. The overlying epidermis may exhibit flattened rete ridges. Amyloid may occur within vessel walls and adnexal structures, sometimes in a ring surrounding individual fat cells. Clinically, the lesions of PLCNA may be indistinguishable from nodular deposits of amyloid occurring in primary systemic amyloidosis or myeloma-associated amyloidosis. Histopathologically, PLCNA usually has a variable infiltrate of plasma cells and lymphocytes at the periphery or within the amyloid deposits,6 but no single stain is highly sensitive and specific. Congo red–stained deposits showed salmon pink amorphous material or apple green birefringence with polarizing microscopy.8 Amyloid derived from immunoglobulin light chains, including cutaneous nodular amyloid, also stain positive for anti-human λ light chain antibody on immunohistochemistry. Additionally, amyloid can stain positively with methyl violet and crystal violet Gram stains, Picrosirius red, thioflavin T, Dylon, and periodic acid–Schiff stains.

Clinically, some PLCNA lesions can be removed via surgical excision or laser if they are cosmetically disfiguring or symptomatic. Other methods have been attempted to improve the appearance of the lesions, such as intralesional corticosteroids, cryotherapy, and dermabrasion,9 but they usually are not helpful and have a high rate of recurrence. Although PLCNA often is a benign cutaneous disorder and some cases of PLCNA could be reactive diseases rather than neoplastic ones, some patients may develop underlying systemic amyloidosis or even paraproteinemia.10 Northcutt and Vanover11 indicated that systemic amyloidosis may be expected in less than 15% of 47 patients with localized cutaneous amyloidosis during follow-up by reviewing most of the related literature. Some cases may be associated with Sjögren syndrome (SJS), CREST (calcinosis, Raynaud phenomenon, esophageal motility disorders, sclerodactyly, and telangiectasia) syndrome, dermatomyositis, and diabetes mellitus.12-14 Polyclonal immunoglobulin amyloid has been reported only in PLCNA with SJS, which may be due to the fact that a certain population of SJS develops polyclonal B-cell proliferation and hyperglobulinemia.12 Woollons and Black15 estimated the rate of progression of PLCNA to systemic amyloidosis to be only 7%, which is much lower than the rate in the literature by a large clinical follow-up study on PLCNA.16 However, all patients with PLCNA should have a systemic evaluation and should be advised to undergo long-term clinical follow-up to help prevent progression to systemic amyloidosis or plasma cell dyscrasia.

References

 

1. Sakuma TH, Hans-Filho G, Arita K, et al. Familial primary localized cutaneous amyloidosis in Brazil. Arch Dermatol. 2009;145:695-699.

2. Rodermund OE. On amyloidosis cutis nodularis atrophicans (Gottron 1950). at the same time a contribution to the classification of amyloidosis [in German]. Arch Klin Exp Dermatol. 1967;230:153-171.

3. Chapel TA, Birmingham DJ, Malinowski YE. Nodular primary localized cutaneous amyloidosis. Arch Dermatol. 1977;113:1248-1249.

4. Criado PR, Silva CS, Vasconcellos C, et al. Extensive nodular cutaneous amyloidosis: an unusual presentation. J Eur Acad Dermatol Venereol. 2005;19:481-483.

5. Touart DM, Sau P. Cutaneous deposition diseases. part I [published correction appears in J Am Acad Dermatol. 1998;39:1042]. J Am Acad Dermatol. 1998;39(2, pt 1):149-171; quiz 172-174.

6. Borrowman TA, Lutz ME, Walsh JS. Cutaneous nodular amyloidosis masquerading as a foot callus. J Am Acad Dermatol. 2003;49:307-310.

7. Fujimoto N, Yajima M, Ohnishi Y, et al. Advanced glycation end product-modified beta2-microglobulin is a component of amyloid fibrils of primary localized cutaneous nodular amyloidosis. J Invest Dermatol. 2002;118:479-484.

8. Clement CG, Truong LD. An evaluation of Congo red fluorescence for the diagnosis of amyloidosis. Hum Pathol. 2014;45:1766-1772.

9. Lien MH, Railan D, Nelson BR. The efficacy of dermabrasion in the treatment of nodular amyloidosis. J Am Acad Dermatol. 1997;36(2, pt 2):315-316.

10. Taylor SC, Baker E, Grossman ME. Nodular vulvar amyloid as a presentation of systemic amyloidosis. J Am Acad Dermatol. 1991;24:139.

11. Northcutt AD, Vanover MJ. Nodular cutaneous amyloidosis involving the vulva. case report and literature review. Arch Dermatol. 1985;121:518-521.

12. Yoneyama K, Tochigi N, Oikawa A, et al. Primary localized cutaneous nodular amyloidosis in a patient with Sjögren’s syndrome: a review of the literature. J Dermatol. 2005;32:120-123.

13. Summers EM, Kendrick CG. Primary localized cutaneous nodular amyloidosis and CREST syndrome: a case report and review of the literature. Cutis. 2008;82:55-59.

14. Taniguchi Y, Horino T, Terada Y. Cutaneous amyloidosis associated with amyopathic dermatomyositis. J Rheumatol. 2009;36:1088-1089.

15. Woollons A, Black MM. Nodular localized primary cutaneous amyloidosis: a long-term follow-up study. Br J Dermatol. 2001;145:105-109.

16. Brownstein MH, Helwig EB. The cutaneous amyloidoses. I. localized forms. Arch Dermatol. 1970;102:8-19.

References

 

1. Sakuma TH, Hans-Filho G, Arita K, et al. Familial primary localized cutaneous amyloidosis in Brazil. Arch Dermatol. 2009;145:695-699.

2. Rodermund OE. On amyloidosis cutis nodularis atrophicans (Gottron 1950). at the same time a contribution to the classification of amyloidosis [in German]. Arch Klin Exp Dermatol. 1967;230:153-171.

3. Chapel TA, Birmingham DJ, Malinowski YE. Nodular primary localized cutaneous amyloidosis. Arch Dermatol. 1977;113:1248-1249.

4. Criado PR, Silva CS, Vasconcellos C, et al. Extensive nodular cutaneous amyloidosis: an unusual presentation. J Eur Acad Dermatol Venereol. 2005;19:481-483.

5. Touart DM, Sau P. Cutaneous deposition diseases. part I [published correction appears in J Am Acad Dermatol. 1998;39:1042]. J Am Acad Dermatol. 1998;39(2, pt 1):149-171; quiz 172-174.

6. Borrowman TA, Lutz ME, Walsh JS. Cutaneous nodular amyloidosis masquerading as a foot callus. J Am Acad Dermatol. 2003;49:307-310.

7. Fujimoto N, Yajima M, Ohnishi Y, et al. Advanced glycation end product-modified beta2-microglobulin is a component of amyloid fibrils of primary localized cutaneous nodular amyloidosis. J Invest Dermatol. 2002;118:479-484.

8. Clement CG, Truong LD. An evaluation of Congo red fluorescence for the diagnosis of amyloidosis. Hum Pathol. 2014;45:1766-1772.

9. Lien MH, Railan D, Nelson BR. The efficacy of dermabrasion in the treatment of nodular amyloidosis. J Am Acad Dermatol. 1997;36(2, pt 2):315-316.

10. Taylor SC, Baker E, Grossman ME. Nodular vulvar amyloid as a presentation of systemic amyloidosis. J Am Acad Dermatol. 1991;24:139.

11. Northcutt AD, Vanover MJ. Nodular cutaneous amyloidosis involving the vulva. case report and literature review. Arch Dermatol. 1985;121:518-521.

12. Yoneyama K, Tochigi N, Oikawa A, et al. Primary localized cutaneous nodular amyloidosis in a patient with Sjögren’s syndrome: a review of the literature. J Dermatol. 2005;32:120-123.

13. Summers EM, Kendrick CG. Primary localized cutaneous nodular amyloidosis and CREST syndrome: a case report and review of the literature. Cutis. 2008;82:55-59.

14. Taniguchi Y, Horino T, Terada Y. Cutaneous amyloidosis associated with amyopathic dermatomyositis. J Rheumatol. 2009;36:1088-1089.

15. Woollons A, Black MM. Nodular localized primary cutaneous amyloidosis: a long-term follow-up study. Br J Dermatol. 2001;145:105-109.

16. Brownstein MH, Helwig EB. The cutaneous amyloidoses. I. localized forms. Arch Dermatol. 1970;102:8-19.

Issue
Cutis - 95(6)
Issue
Cutis - 95(6)
Page Number
E24-E27
Page Number
E24-E27
Publications
Publications
Topics
Article Type
Display Headline
Primary Localized Cutaneous Nodular Amyloidosis of the Thighs
Display Headline
Primary Localized Cutaneous Nodular Amyloidosis of the Thighs
Legacy Keywords
cutaneous amyloidosis, primary localized, nodular, atrophic plaque
Legacy Keywords
cutaneous amyloidosis, primary localized, nodular, atrophic plaque
Sections
Inside the Article

   Practice Points

 

  • ­The cutaneous lesions of primary localized cutaneous nodular amyloidosis (PLCNA) may present as single or multiple nodules, occasionally with overlying atrophic plaques and some with surface telangiectasia.
  • ­Primary localized cutaneous nodular amyloidosis may represent a localized plasma cell dyscrasia that can be associated with a monoclonal gammopathy or multiple myeloma.
  • ­Although PLCNA often is a benign cutaneous disorder, some patients can develop underlying systemic amyloidosis or even paraproteinemia.
Disallow All Ads
Article PDF Media

Burning pain from chest to back • allodynia and hyperesthesia • extreme sensitivity at the left T5 dermatome • Dx?

Article Type
Changed
Mon, 01/14/2019 - 13:59
Display Headline
Burning pain from chest to back • allodynia and hyperesthesia • extreme sensitivity at the left T5 dermatome • Dx?

THE CASE

A 27-year-old woman in the 21st week of her first pregnancy came to our clinic complaining of a constant burning pain that spread around her left chest wall to her back. She graded the pain as a 10 on a 0 to 10 visual analog scale. The pain, which began 3 months earlier, became worse when she took a deep breath, ate, or walked, but was alleviated by applying warm compresses. Our patient hadn’t slept well since the pain began. Her medical history was noteworthy for chickenpox at age 5.

During the physical examination, palpating her left upper abdominal quadrant and left lower chest wall elicited tenderness. We noted allodynia and hyperesthesia in these regions, and the left T5 dermatome revealed extreme sensitivity.

THE DIAGNOSIS

We decided to test for antibodies to the varicella-zoster virus (VZV) based on the location of the pain along a dermatome. A serum anti-VZV immunoglobulin G (IgG) level was high at 1.9. Since our patient hadn’t been vaccinated against VZV, her high IgG level may have been the result of reactivation of the virus. Based on this test result and our patient’s history and physical exam findings (ie, neuropathic pain along a dermatome without a typical herpes zoster rash), we diagnosed zoster sine herpete (ZSH).

DISCUSSION

One million new cases of herpes zoster (shingles) are diagnosed in the United States each year, with a rate of 3 to 4 cases per 1000 people.1 One in 3 patients develops postherpetic neuralgia, depending on age and immunocompetence.1

In ZSH, the neuropathic pain of herpes zoster occurs without the typical zoster rash.2 Since the rash is absent, the diagnosis is often missed. The incidence of ZSH is unknown.

Although many pregnant women suffer from thoracic and/or abdominal neuropathic pain, there are no reports in the literature that describe ZSH in pregnant women.3

Suspect zoster sine herpete in a patient who has neuropathic radicular pain but no rash.

The appropriate diagnostic tests for ZSH are polymerase chain reaction for VZV DNA and anti-VZV IgG.2,4-7 A definitive diagnosis can be reached by identifying herpes zoster DNA in cerebrospinal fluid (CSF) and organism-specific immunoglobulins. However, a high titer of serum IgG antibodies or a positive IgM antibodies test typically provides a high degree of certainty for the diagnosis.8 For our patient, we decided not to test her CSF because we felt that her clinical course and positive IgG test were sufficient to establish the diagnosis.

The differential diagnosis of radicular pain during pregnancy includes cutaneous nerve entrapment. The expanding uterus could increase pressure on cutaneous nerves in the abdominal wall and cause pain. Although nerve entrapment would be expected to cause impingement and sometimes hypoesthesia, ZSH usually causes allodynia and hyperesthesia, as was the case in our patient.3

Pregnancy affects choice of treatment

Treatments for ZSH include acyclovir and local anesthesia.8 A single injection of lidocaine (8 cc) may completely eliminate the ZSH pain by affecting the nerve action potential.9 Corticosteroids are used to suppress inflammation and decrease erythema, swelling, warmth at the site, and local tenderness.

Our patient. We decided to treat our patient with only a nerve block because the potential adverse effects of acyclovir in the second trimester of pregnancy are unclear.10 She received 1 cc of betamethasone acetate (3 mg) and betamethasone sodium phosphate (3 mg) and 8 cc of 2% lidocaine. The patient reported immediate pain relief, which lasted until delivery.

THE TAKEAWAY

ZSH is characterized by neuropathic pain along a dermatome that’s associated with herpes zoster and is not accompanied by the characteristic rash. Many pregnant women suffer from thoracic and abdominal wall neuropathic pain. Neuropathic radicular pain in the absence of a rash should raise suspicion of ZSH. Considering this syndrome at an early stage can avert unnecessary testing and reduce the patient’s pain.

References

1. Cohen JI. Clinical practice: Herpes zoster. N Engl J Med. 2013;369:255-263.

2. Nagel MA, Gilden DH. The protean neurologic manifestations of varicella-zoster virus infection. Cleve Clin J Med. 2007;74:489-504.

3. Peleg R, Gohar J, Koretz M, et al. Abdominal wall pain in pregnant women caused by thoracic lateral cutaneous nerve entrapment. Eur J Obstet Gynecol Reprod Biol. 1997;74:169-171.

4. Gilden DH, Wright RR, Schneck SA, et al. Zoster sine herpete, a clinical variant. Ann Neurol. 1994;35:530-533.

5. Amlie-Lefond C, Mackin GA, Ferguson M, et al. Another case of virologically confirmed zoster sine herpete, with electrophysiologic correlation. J Neurovirol. 1996;2:136-138.

6. Blumenthal DT, Shacham-Shmueli E, Bokstein F, et al. Zoster sine herpete: virologic verification by detection of anti-VZV IgG antibody in CSF. Neurology. 2011;76:484-485.

7. Lewis GW. Zoster sine herpete. Br Med J. 1958;2:418-421.

8. Kennedy PG. Zoster sine herpete: it would be rash to ignore it. Neurology. 2011;76:416-417.

9. Baranowski AP, De Courcey J, Bonello E. A trial of intravenous lidocaine on the pain and allodynia of postherpetic neuralgia. J Pain Symptom Manage. 1999;17:429-433.

10. Stone KM, Reiff-Eldridge R, White AD, et al. Pregnancy outcomes following systemic prenatal acyclovir exposure: Conclusions from the international acyclovir pregnancy registry, 1984-1999. Birth Defects Res A Clin Mol Teratol. 2004;70:201-207.

Article PDF
Author and Disclosure Information

Belle Tamir, BA
Roni Peleg, MD

The Department of Family Medicine, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel

pelegr@bgu.ac.il

The authors reported no potential conflict of interest relevant to this article.

Issue
The Journal of Family Practice - 64(6)
Publications
Topics
Page Number
E1-E2
Legacy Keywords
Belle Tamir, BA; Roni Peleg, MD; pain; herpes zoster; shingles; zoster sine herpete; ZSH
Sections
Author and Disclosure Information

Belle Tamir, BA
Roni Peleg, MD

The Department of Family Medicine, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel

pelegr@bgu.ac.il

The authors reported no potential conflict of interest relevant to this article.

Author and Disclosure Information

Belle Tamir, BA
Roni Peleg, MD

The Department of Family Medicine, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel

pelegr@bgu.ac.il

The authors reported no potential conflict of interest relevant to this article.

Article PDF
Article PDF
Related Articles

THE CASE

A 27-year-old woman in the 21st week of her first pregnancy came to our clinic complaining of a constant burning pain that spread around her left chest wall to her back. She graded the pain as a 10 on a 0 to 10 visual analog scale. The pain, which began 3 months earlier, became worse when she took a deep breath, ate, or walked, but was alleviated by applying warm compresses. Our patient hadn’t slept well since the pain began. Her medical history was noteworthy for chickenpox at age 5.

During the physical examination, palpating her left upper abdominal quadrant and left lower chest wall elicited tenderness. We noted allodynia and hyperesthesia in these regions, and the left T5 dermatome revealed extreme sensitivity.

THE DIAGNOSIS

We decided to test for antibodies to the varicella-zoster virus (VZV) based on the location of the pain along a dermatome. A serum anti-VZV immunoglobulin G (IgG) level was high at 1.9. Since our patient hadn’t been vaccinated against VZV, her high IgG level may have been the result of reactivation of the virus. Based on this test result and our patient’s history and physical exam findings (ie, neuropathic pain along a dermatome without a typical herpes zoster rash), we diagnosed zoster sine herpete (ZSH).

DISCUSSION

One million new cases of herpes zoster (shingles) are diagnosed in the United States each year, with a rate of 3 to 4 cases per 1000 people.1 One in 3 patients develops postherpetic neuralgia, depending on age and immunocompetence.1

In ZSH, the neuropathic pain of herpes zoster occurs without the typical zoster rash.2 Since the rash is absent, the diagnosis is often missed. The incidence of ZSH is unknown.

Although many pregnant women suffer from thoracic and/or abdominal neuropathic pain, there are no reports in the literature that describe ZSH in pregnant women.3

Suspect zoster sine herpete in a patient who has neuropathic radicular pain but no rash.

The appropriate diagnostic tests for ZSH are polymerase chain reaction for VZV DNA and anti-VZV IgG.2,4-7 A definitive diagnosis can be reached by identifying herpes zoster DNA in cerebrospinal fluid (CSF) and organism-specific immunoglobulins. However, a high titer of serum IgG antibodies or a positive IgM antibodies test typically provides a high degree of certainty for the diagnosis.8 For our patient, we decided not to test her CSF because we felt that her clinical course and positive IgG test were sufficient to establish the diagnosis.

The differential diagnosis of radicular pain during pregnancy includes cutaneous nerve entrapment. The expanding uterus could increase pressure on cutaneous nerves in the abdominal wall and cause pain. Although nerve entrapment would be expected to cause impingement and sometimes hypoesthesia, ZSH usually causes allodynia and hyperesthesia, as was the case in our patient.3

Pregnancy affects choice of treatment

Treatments for ZSH include acyclovir and local anesthesia.8 A single injection of lidocaine (8 cc) may completely eliminate the ZSH pain by affecting the nerve action potential.9 Corticosteroids are used to suppress inflammation and decrease erythema, swelling, warmth at the site, and local tenderness.

Our patient. We decided to treat our patient with only a nerve block because the potential adverse effects of acyclovir in the second trimester of pregnancy are unclear.10 She received 1 cc of betamethasone acetate (3 mg) and betamethasone sodium phosphate (3 mg) and 8 cc of 2% lidocaine. The patient reported immediate pain relief, which lasted until delivery.

THE TAKEAWAY

ZSH is characterized by neuropathic pain along a dermatome that’s associated with herpes zoster and is not accompanied by the characteristic rash. Many pregnant women suffer from thoracic and abdominal wall neuropathic pain. Neuropathic radicular pain in the absence of a rash should raise suspicion of ZSH. Considering this syndrome at an early stage can avert unnecessary testing and reduce the patient’s pain.

THE CASE

A 27-year-old woman in the 21st week of her first pregnancy came to our clinic complaining of a constant burning pain that spread around her left chest wall to her back. She graded the pain as a 10 on a 0 to 10 visual analog scale. The pain, which began 3 months earlier, became worse when she took a deep breath, ate, or walked, but was alleviated by applying warm compresses. Our patient hadn’t slept well since the pain began. Her medical history was noteworthy for chickenpox at age 5.

During the physical examination, palpating her left upper abdominal quadrant and left lower chest wall elicited tenderness. We noted allodynia and hyperesthesia in these regions, and the left T5 dermatome revealed extreme sensitivity.

THE DIAGNOSIS

We decided to test for antibodies to the varicella-zoster virus (VZV) based on the location of the pain along a dermatome. A serum anti-VZV immunoglobulin G (IgG) level was high at 1.9. Since our patient hadn’t been vaccinated against VZV, her high IgG level may have been the result of reactivation of the virus. Based on this test result and our patient’s history and physical exam findings (ie, neuropathic pain along a dermatome without a typical herpes zoster rash), we diagnosed zoster sine herpete (ZSH).

DISCUSSION

One million new cases of herpes zoster (shingles) are diagnosed in the United States each year, with a rate of 3 to 4 cases per 1000 people.1 One in 3 patients develops postherpetic neuralgia, depending on age and immunocompetence.1

In ZSH, the neuropathic pain of herpes zoster occurs without the typical zoster rash.2 Since the rash is absent, the diagnosis is often missed. The incidence of ZSH is unknown.

Although many pregnant women suffer from thoracic and/or abdominal neuropathic pain, there are no reports in the literature that describe ZSH in pregnant women.3

Suspect zoster sine herpete in a patient who has neuropathic radicular pain but no rash.

The appropriate diagnostic tests for ZSH are polymerase chain reaction for VZV DNA and anti-VZV IgG.2,4-7 A definitive diagnosis can be reached by identifying herpes zoster DNA in cerebrospinal fluid (CSF) and organism-specific immunoglobulins. However, a high titer of serum IgG antibodies or a positive IgM antibodies test typically provides a high degree of certainty for the diagnosis.8 For our patient, we decided not to test her CSF because we felt that her clinical course and positive IgG test were sufficient to establish the diagnosis.

The differential diagnosis of radicular pain during pregnancy includes cutaneous nerve entrapment. The expanding uterus could increase pressure on cutaneous nerves in the abdominal wall and cause pain. Although nerve entrapment would be expected to cause impingement and sometimes hypoesthesia, ZSH usually causes allodynia and hyperesthesia, as was the case in our patient.3

Pregnancy affects choice of treatment

Treatments for ZSH include acyclovir and local anesthesia.8 A single injection of lidocaine (8 cc) may completely eliminate the ZSH pain by affecting the nerve action potential.9 Corticosteroids are used to suppress inflammation and decrease erythema, swelling, warmth at the site, and local tenderness.

Our patient. We decided to treat our patient with only a nerve block because the potential adverse effects of acyclovir in the second trimester of pregnancy are unclear.10 She received 1 cc of betamethasone acetate (3 mg) and betamethasone sodium phosphate (3 mg) and 8 cc of 2% lidocaine. The patient reported immediate pain relief, which lasted until delivery.

THE TAKEAWAY

ZSH is characterized by neuropathic pain along a dermatome that’s associated with herpes zoster and is not accompanied by the characteristic rash. Many pregnant women suffer from thoracic and abdominal wall neuropathic pain. Neuropathic radicular pain in the absence of a rash should raise suspicion of ZSH. Considering this syndrome at an early stage can avert unnecessary testing and reduce the patient’s pain.

References

1. Cohen JI. Clinical practice: Herpes zoster. N Engl J Med. 2013;369:255-263.

2. Nagel MA, Gilden DH. The protean neurologic manifestations of varicella-zoster virus infection. Cleve Clin J Med. 2007;74:489-504.

3. Peleg R, Gohar J, Koretz M, et al. Abdominal wall pain in pregnant women caused by thoracic lateral cutaneous nerve entrapment. Eur J Obstet Gynecol Reprod Biol. 1997;74:169-171.

4. Gilden DH, Wright RR, Schneck SA, et al. Zoster sine herpete, a clinical variant. Ann Neurol. 1994;35:530-533.

5. Amlie-Lefond C, Mackin GA, Ferguson M, et al. Another case of virologically confirmed zoster sine herpete, with electrophysiologic correlation. J Neurovirol. 1996;2:136-138.

6. Blumenthal DT, Shacham-Shmueli E, Bokstein F, et al. Zoster sine herpete: virologic verification by detection of anti-VZV IgG antibody in CSF. Neurology. 2011;76:484-485.

7. Lewis GW. Zoster sine herpete. Br Med J. 1958;2:418-421.

8. Kennedy PG. Zoster sine herpete: it would be rash to ignore it. Neurology. 2011;76:416-417.

9. Baranowski AP, De Courcey J, Bonello E. A trial of intravenous lidocaine on the pain and allodynia of postherpetic neuralgia. J Pain Symptom Manage. 1999;17:429-433.

10. Stone KM, Reiff-Eldridge R, White AD, et al. Pregnancy outcomes following systemic prenatal acyclovir exposure: Conclusions from the international acyclovir pregnancy registry, 1984-1999. Birth Defects Res A Clin Mol Teratol. 2004;70:201-207.

References

1. Cohen JI. Clinical practice: Herpes zoster. N Engl J Med. 2013;369:255-263.

2. Nagel MA, Gilden DH. The protean neurologic manifestations of varicella-zoster virus infection. Cleve Clin J Med. 2007;74:489-504.

3. Peleg R, Gohar J, Koretz M, et al. Abdominal wall pain in pregnant women caused by thoracic lateral cutaneous nerve entrapment. Eur J Obstet Gynecol Reprod Biol. 1997;74:169-171.

4. Gilden DH, Wright RR, Schneck SA, et al. Zoster sine herpete, a clinical variant. Ann Neurol. 1994;35:530-533.

5. Amlie-Lefond C, Mackin GA, Ferguson M, et al. Another case of virologically confirmed zoster sine herpete, with electrophysiologic correlation. J Neurovirol. 1996;2:136-138.

6. Blumenthal DT, Shacham-Shmueli E, Bokstein F, et al. Zoster sine herpete: virologic verification by detection of anti-VZV IgG antibody in CSF. Neurology. 2011;76:484-485.

7. Lewis GW. Zoster sine herpete. Br Med J. 1958;2:418-421.

8. Kennedy PG. Zoster sine herpete: it would be rash to ignore it. Neurology. 2011;76:416-417.

9. Baranowski AP, De Courcey J, Bonello E. A trial of intravenous lidocaine on the pain and allodynia of postherpetic neuralgia. J Pain Symptom Manage. 1999;17:429-433.

10. Stone KM, Reiff-Eldridge R, White AD, et al. Pregnancy outcomes following systemic prenatal acyclovir exposure: Conclusions from the international acyclovir pregnancy registry, 1984-1999. Birth Defects Res A Clin Mol Teratol. 2004;70:201-207.

Issue
The Journal of Family Practice - 64(6)
Issue
The Journal of Family Practice - 64(6)
Page Number
E1-E2
Page Number
E1-E2
Publications
Publications
Topics
Article Type
Display Headline
Burning pain from chest to back • allodynia and hyperesthesia • extreme sensitivity at the left T5 dermatome • Dx?
Display Headline
Burning pain from chest to back • allodynia and hyperesthesia • extreme sensitivity at the left T5 dermatome • Dx?
Legacy Keywords
Belle Tamir, BA; Roni Peleg, MD; pain; herpes zoster; shingles; zoster sine herpete; ZSH
Legacy Keywords
Belle Tamir, BA; Roni Peleg, MD; pain; herpes zoster; shingles; zoster sine herpete; ZSH
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Bifrontal headache • blurred vision • vomiting • Dx?

Article Type
Changed
Mon, 01/14/2019 - 13:59
Display Headline
Bifrontal headache • blurred vision • vomiting • Dx?

THE CASE

A 55-year-old woman presented to the emergency department (ED) with a bifrontal headache that she’d had for one day. She also had blurred vision and was vomiting shortly before coming to the hospital. The patient had no history of hypertension, migraine headaches, seizure disorder, autoimmune disorders, or cerebrovascular disease.

Her vital signs, including a blood pressure of 114/63 mm Hg, were normal, but a physical examination revealed subjective vision loss. She was only able to see objects moving on a horizontal plane. Her finger-to-nose exam, pupillary reflexes, and extra-ocular movements were normal, but peripheral vision was limited on her left side. No other neurologic deficits were noted.

The patient was admitted to the hospital and most of her laboratory work-up was normal, including a basic metabolic panel, complete blood count, coagulation studies, brain natriuretic peptide test, and cardiac enzymes. Her white blood cell count was 19,700/mcL, but no source of infection was found. A computed tomography (CT) scan of her head without contrast showed low-density, patchy areas in the subcortical regions of the parietal and occipital lobes bilaterally (FIGURE 1, arrows), with relative sparing of the cortex.

THE DIAGNOSIS

Based on our patient’s presentation and radiologic findings, we made a diagnosis of posterior reversible encephalopathy syndrome (PRES). However, because we could not rule out an ischemic cerebrovascular event at the time of presentation, we started the patient on aspirin and clopidogrel 75 mg to prevent possible future ischemic events. The next day, we ordered magnetic resonance imaging (MRI) of the head and neck, which documented the edema and confirmed the diagnosis of PRES (FIGURE 2).

DISCUSSION

PRES is a neurotoxic state associated with a unique pattern of brain vasogenic edema seen on CT or MRI. The edema is often widespread but is predominantly found in the parietal and occipital regions.1 PRES is seen in patients with a variety of conditions, including hypertension and bone marrow or organ transplantation, as well as in those receiving immunosuppressive or cytotoxic medications.1 Patients with PRES typically present with headaches and seizures.2 Visual abnormalities (most commonly cortical blindness), occur in 15% to 20% of patients with PRES.2-4

Hinchey et al3 first described reversible posterior leukoencephalopathy syndrome (which later became known as PRES) in 1996. Most of the 15 patients included in this original report had a history of hypertension or immunosuppression. These cases were associated with cerebral edema in portions of the posterior cerebral white matter. It is thought that hypertension alters the blood-brain barrier and causes the acute changes that occur in PRES.3

Besides hypertension and immunosuppression, the risk factors most commonly associated with PRES include preeclampsia/eclampsia; sepsis, particularly due to grampositive organisms; Wegener’s granulomatosis, scleroderma, and polyarteritis nodosa; cancer chemotherapy; bone marrow or stem cell transplantation; and renal disease.1,4-6

Although a clear cause of PRES has not yet been established, researchers have proposed 2 theories. The first postulates that a sudden increase in systemic blood pressure causes vasoconstriction, which leads to ischemia and edema.1-4,7,8 However, several studies have also described cases of PRES in patients with mild elevations in blood pressure,1,5-7 and mild edema has been observed even in normotensive patients1,5 (as was the case with our patient).

The second theory links PRES to the loss of brain autoregulation, a function that maintains steady blood flow when blood pressure fluctuates.6 A loss of this regulatory mechanism causes endothelial dysfunction, capillary leakage, and disruption in the blood-brain barrier.1,2,4,6-8 These changes then lead to cerebral vasodilatation and edema.2 Immunotherapy has also been associated with increased endothelial dysfunction.2

The evidence on the link between the severity of PRES and clinical outcomes is conflicting.

One study that followed 113 PRES patients over 6 years did not find an association between the severity of clinical presentation and the extent of vasogenic edema found on imaging studies.5 Of these 113 patients, 69 had PRES primarily due to hypertension, and 21 were receiving cytotoxic medications.5 In contrast, a larger retrospective study that followed patients with PRES for 12 years found that severe cases, which included patients with severe cerebral edema and altered mental status, had poor outcomes.4 Small studies have reported that 14% of patients with PRES develop cerebral hemorrhage.8

When to suspect this condition. PRES should be part of the differential diagnosis for any patient who presents with headache and vision loss. It is important to distinguish PRES from an acute cerebrovascular accident (CVA) because the 2 conditions are managed differently.2 In addition, PRES lesions can be misdiagnosed as tumors, especially in a patient with a history of malignant disease in whom the condition appears after chemotherapy.9

 

 

Treatment targets the underlying causes

Treatment options for PRES are limited. Hypertension in a patient with PRES requires prompt intervention to avoid progression of the disease.2 The use of intravenous (IV) calcium-channel blockers or IV beta-blockers for these patients is common.2,8

Patients with seizures should be treated with anticonvulsant medication, but longterm antiepileptic treatment usually is not required.2 Patients who take immunosuppressant or cytotoxic drugs should stop them indefinitely upon presenting with PRES.2

PRES lesions can be misdiagnosed as tumors—especially in patients with a history of malignant disease who have undergone chemotherapy.

For a pregnant woman with preeclampsia/eclampsia, delivery of the placenta, which is considered to be the cause of PRES in these cases, is curative.1 However, women can develop PRES several weeks after delivery.1

In most cases, the symptoms associated with PRES will resolve once treatment is initiated, and neurologic recovery can be expected within 2 weeks.2

Our patient regained her sight the following morning and was discharged home 2 days after admission. Her blood pressure remained normal. She returned to the hospital unresponsive the day after she had been discharged. Family members stated that she had taken 15 packets of an aspirin/caffeine combination to control a new headache.

Her blood pressure was elevated at 159/79 mm Hg. A CT of the brain showed a hemorrhagic stroke within the left occipital lobe and posterior parietal lobe with a midline shift of 8 mm. We don’t know if the aspirin use contributed to the hemorrhagic event or if it was a sequela of PRES.

The patient died 4 days later.

THE TAKEAWAY

PRES is a neurotoxic condition that causes headache, seizures, and vision loss. Most patients will present with elevated blood pressure and imaging studies will reveal a specific pattern of vasogenic edema that is predominately found in the parietal and occipital regions.

Treating the hypertension may result in a more favorable recovery. Normotensive patients are harder to treat because there is no specific therapy for PRES. Follow-up imaging may help to assess the resolution of the syndrome.

References

1. Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol. 2008;29:1036-1042.

2. Stott VL, Hurrell MA, Anderson TJ. Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed. Intern Med J. 2005;35:83-90.

3. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334:494-500.

4. Liman TG, Bohner G, Endres M, et al. Discharge status and in-hospital mortality in posterior reversible encephalopathy syndrome. Acta Neurol Scand. 2014;130:34-39.

5. Fugate JE, Claassen DO, Cloft HJ, et al. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc. 2010;85:427-432.

6. Bartynski WS. Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol. 2008;29:1043-1049.

7. Ay H, Buonanno FS, Schaefer PW, et al. Posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI. Neurology. 1998;51:1369-1376.

8. Legriel S, Schraub O, Azoulay E, et al; Critically III Posterior Reversible Encephalopathy Syndrome Study Group (CYPRESS). Determinants of recovery from severe posterior reversible encephalopathy syndrome. PLoS ONE. 2012;7:e44534.

9. Morina D, Ntoulias G, Maslehaty H, et al. Posterior reversible encephalopathy syndrome mimicking cerebral metastasis: contraindication for biopsy. Clin Pract. 2014;4:632.

Article PDF
Author and Disclosure Information

W. Michael Hughes, DO, MS
Jose M. Villalon-Gomez, MD, MPH

Floyd Medical Center Family Medicine Residency, Rome, Ga

mhughes@floyd.org

The authors reported no potential conflict of interest relevant to this article.

Issue
The Journal of Family Practice - 64(6)
Publications
Topics
Page Number
358-360
Legacy Keywords
W. Michael Hughes, DO, MS; Jose M. Villalon-Gomez, MD, MPH; headache; PRES; posterior reversible encephalopathy syndrome; hypertension
Sections
Author and Disclosure Information

W. Michael Hughes, DO, MS
Jose M. Villalon-Gomez, MD, MPH

Floyd Medical Center Family Medicine Residency, Rome, Ga

mhughes@floyd.org

The authors reported no potential conflict of interest relevant to this article.

Author and Disclosure Information

W. Michael Hughes, DO, MS
Jose M. Villalon-Gomez, MD, MPH

Floyd Medical Center Family Medicine Residency, Rome, Ga

mhughes@floyd.org

The authors reported no potential conflict of interest relevant to this article.

Article PDF
Article PDF

THE CASE

A 55-year-old woman presented to the emergency department (ED) with a bifrontal headache that she’d had for one day. She also had blurred vision and was vomiting shortly before coming to the hospital. The patient had no history of hypertension, migraine headaches, seizure disorder, autoimmune disorders, or cerebrovascular disease.

Her vital signs, including a blood pressure of 114/63 mm Hg, were normal, but a physical examination revealed subjective vision loss. She was only able to see objects moving on a horizontal plane. Her finger-to-nose exam, pupillary reflexes, and extra-ocular movements were normal, but peripheral vision was limited on her left side. No other neurologic deficits were noted.

The patient was admitted to the hospital and most of her laboratory work-up was normal, including a basic metabolic panel, complete blood count, coagulation studies, brain natriuretic peptide test, and cardiac enzymes. Her white blood cell count was 19,700/mcL, but no source of infection was found. A computed tomography (CT) scan of her head without contrast showed low-density, patchy areas in the subcortical regions of the parietal and occipital lobes bilaterally (FIGURE 1, arrows), with relative sparing of the cortex.

THE DIAGNOSIS

Based on our patient’s presentation and radiologic findings, we made a diagnosis of posterior reversible encephalopathy syndrome (PRES). However, because we could not rule out an ischemic cerebrovascular event at the time of presentation, we started the patient on aspirin and clopidogrel 75 mg to prevent possible future ischemic events. The next day, we ordered magnetic resonance imaging (MRI) of the head and neck, which documented the edema and confirmed the diagnosis of PRES (FIGURE 2).

DISCUSSION

PRES is a neurotoxic state associated with a unique pattern of brain vasogenic edema seen on CT or MRI. The edema is often widespread but is predominantly found in the parietal and occipital regions.1 PRES is seen in patients with a variety of conditions, including hypertension and bone marrow or organ transplantation, as well as in those receiving immunosuppressive or cytotoxic medications.1 Patients with PRES typically present with headaches and seizures.2 Visual abnormalities (most commonly cortical blindness), occur in 15% to 20% of patients with PRES.2-4

Hinchey et al3 first described reversible posterior leukoencephalopathy syndrome (which later became known as PRES) in 1996. Most of the 15 patients included in this original report had a history of hypertension or immunosuppression. These cases were associated with cerebral edema in portions of the posterior cerebral white matter. It is thought that hypertension alters the blood-brain barrier and causes the acute changes that occur in PRES.3

Besides hypertension and immunosuppression, the risk factors most commonly associated with PRES include preeclampsia/eclampsia; sepsis, particularly due to grampositive organisms; Wegener’s granulomatosis, scleroderma, and polyarteritis nodosa; cancer chemotherapy; bone marrow or stem cell transplantation; and renal disease.1,4-6

Although a clear cause of PRES has not yet been established, researchers have proposed 2 theories. The first postulates that a sudden increase in systemic blood pressure causes vasoconstriction, which leads to ischemia and edema.1-4,7,8 However, several studies have also described cases of PRES in patients with mild elevations in blood pressure,1,5-7 and mild edema has been observed even in normotensive patients1,5 (as was the case with our patient).

The second theory links PRES to the loss of brain autoregulation, a function that maintains steady blood flow when blood pressure fluctuates.6 A loss of this regulatory mechanism causes endothelial dysfunction, capillary leakage, and disruption in the blood-brain barrier.1,2,4,6-8 These changes then lead to cerebral vasodilatation and edema.2 Immunotherapy has also been associated with increased endothelial dysfunction.2

The evidence on the link between the severity of PRES and clinical outcomes is conflicting.

One study that followed 113 PRES patients over 6 years did not find an association between the severity of clinical presentation and the extent of vasogenic edema found on imaging studies.5 Of these 113 patients, 69 had PRES primarily due to hypertension, and 21 were receiving cytotoxic medications.5 In contrast, a larger retrospective study that followed patients with PRES for 12 years found that severe cases, which included patients with severe cerebral edema and altered mental status, had poor outcomes.4 Small studies have reported that 14% of patients with PRES develop cerebral hemorrhage.8

When to suspect this condition. PRES should be part of the differential diagnosis for any patient who presents with headache and vision loss. It is important to distinguish PRES from an acute cerebrovascular accident (CVA) because the 2 conditions are managed differently.2 In addition, PRES lesions can be misdiagnosed as tumors, especially in a patient with a history of malignant disease in whom the condition appears after chemotherapy.9

 

 

Treatment targets the underlying causes

Treatment options for PRES are limited. Hypertension in a patient with PRES requires prompt intervention to avoid progression of the disease.2 The use of intravenous (IV) calcium-channel blockers or IV beta-blockers for these patients is common.2,8

Patients with seizures should be treated with anticonvulsant medication, but longterm antiepileptic treatment usually is not required.2 Patients who take immunosuppressant or cytotoxic drugs should stop them indefinitely upon presenting with PRES.2

PRES lesions can be misdiagnosed as tumors—especially in patients with a history of malignant disease who have undergone chemotherapy.

For a pregnant woman with preeclampsia/eclampsia, delivery of the placenta, which is considered to be the cause of PRES in these cases, is curative.1 However, women can develop PRES several weeks after delivery.1

In most cases, the symptoms associated with PRES will resolve once treatment is initiated, and neurologic recovery can be expected within 2 weeks.2

Our patient regained her sight the following morning and was discharged home 2 days after admission. Her blood pressure remained normal. She returned to the hospital unresponsive the day after she had been discharged. Family members stated that she had taken 15 packets of an aspirin/caffeine combination to control a new headache.

Her blood pressure was elevated at 159/79 mm Hg. A CT of the brain showed a hemorrhagic stroke within the left occipital lobe and posterior parietal lobe with a midline shift of 8 mm. We don’t know if the aspirin use contributed to the hemorrhagic event or if it was a sequela of PRES.

The patient died 4 days later.

THE TAKEAWAY

PRES is a neurotoxic condition that causes headache, seizures, and vision loss. Most patients will present with elevated blood pressure and imaging studies will reveal a specific pattern of vasogenic edema that is predominately found in the parietal and occipital regions.

Treating the hypertension may result in a more favorable recovery. Normotensive patients are harder to treat because there is no specific therapy for PRES. Follow-up imaging may help to assess the resolution of the syndrome.

THE CASE

A 55-year-old woman presented to the emergency department (ED) with a bifrontal headache that she’d had for one day. She also had blurred vision and was vomiting shortly before coming to the hospital. The patient had no history of hypertension, migraine headaches, seizure disorder, autoimmune disorders, or cerebrovascular disease.

Her vital signs, including a blood pressure of 114/63 mm Hg, were normal, but a physical examination revealed subjective vision loss. She was only able to see objects moving on a horizontal plane. Her finger-to-nose exam, pupillary reflexes, and extra-ocular movements were normal, but peripheral vision was limited on her left side. No other neurologic deficits were noted.

The patient was admitted to the hospital and most of her laboratory work-up was normal, including a basic metabolic panel, complete blood count, coagulation studies, brain natriuretic peptide test, and cardiac enzymes. Her white blood cell count was 19,700/mcL, but no source of infection was found. A computed tomography (CT) scan of her head without contrast showed low-density, patchy areas in the subcortical regions of the parietal and occipital lobes bilaterally (FIGURE 1, arrows), with relative sparing of the cortex.

THE DIAGNOSIS

Based on our patient’s presentation and radiologic findings, we made a diagnosis of posterior reversible encephalopathy syndrome (PRES). However, because we could not rule out an ischemic cerebrovascular event at the time of presentation, we started the patient on aspirin and clopidogrel 75 mg to prevent possible future ischemic events. The next day, we ordered magnetic resonance imaging (MRI) of the head and neck, which documented the edema and confirmed the diagnosis of PRES (FIGURE 2).

DISCUSSION

PRES is a neurotoxic state associated with a unique pattern of brain vasogenic edema seen on CT or MRI. The edema is often widespread but is predominantly found in the parietal and occipital regions.1 PRES is seen in patients with a variety of conditions, including hypertension and bone marrow or organ transplantation, as well as in those receiving immunosuppressive or cytotoxic medications.1 Patients with PRES typically present with headaches and seizures.2 Visual abnormalities (most commonly cortical blindness), occur in 15% to 20% of patients with PRES.2-4

Hinchey et al3 first described reversible posterior leukoencephalopathy syndrome (which later became known as PRES) in 1996. Most of the 15 patients included in this original report had a history of hypertension or immunosuppression. These cases were associated with cerebral edema in portions of the posterior cerebral white matter. It is thought that hypertension alters the blood-brain barrier and causes the acute changes that occur in PRES.3

Besides hypertension and immunosuppression, the risk factors most commonly associated with PRES include preeclampsia/eclampsia; sepsis, particularly due to grampositive organisms; Wegener’s granulomatosis, scleroderma, and polyarteritis nodosa; cancer chemotherapy; bone marrow or stem cell transplantation; and renal disease.1,4-6

Although a clear cause of PRES has not yet been established, researchers have proposed 2 theories. The first postulates that a sudden increase in systemic blood pressure causes vasoconstriction, which leads to ischemia and edema.1-4,7,8 However, several studies have also described cases of PRES in patients with mild elevations in blood pressure,1,5-7 and mild edema has been observed even in normotensive patients1,5 (as was the case with our patient).

The second theory links PRES to the loss of brain autoregulation, a function that maintains steady blood flow when blood pressure fluctuates.6 A loss of this regulatory mechanism causes endothelial dysfunction, capillary leakage, and disruption in the blood-brain barrier.1,2,4,6-8 These changes then lead to cerebral vasodilatation and edema.2 Immunotherapy has also been associated with increased endothelial dysfunction.2

The evidence on the link between the severity of PRES and clinical outcomes is conflicting.

One study that followed 113 PRES patients over 6 years did not find an association between the severity of clinical presentation and the extent of vasogenic edema found on imaging studies.5 Of these 113 patients, 69 had PRES primarily due to hypertension, and 21 were receiving cytotoxic medications.5 In contrast, a larger retrospective study that followed patients with PRES for 12 years found that severe cases, which included patients with severe cerebral edema and altered mental status, had poor outcomes.4 Small studies have reported that 14% of patients with PRES develop cerebral hemorrhage.8

When to suspect this condition. PRES should be part of the differential diagnosis for any patient who presents with headache and vision loss. It is important to distinguish PRES from an acute cerebrovascular accident (CVA) because the 2 conditions are managed differently.2 In addition, PRES lesions can be misdiagnosed as tumors, especially in a patient with a history of malignant disease in whom the condition appears after chemotherapy.9

 

 

Treatment targets the underlying causes

Treatment options for PRES are limited. Hypertension in a patient with PRES requires prompt intervention to avoid progression of the disease.2 The use of intravenous (IV) calcium-channel blockers or IV beta-blockers for these patients is common.2,8

Patients with seizures should be treated with anticonvulsant medication, but longterm antiepileptic treatment usually is not required.2 Patients who take immunosuppressant or cytotoxic drugs should stop them indefinitely upon presenting with PRES.2

PRES lesions can be misdiagnosed as tumors—especially in patients with a history of malignant disease who have undergone chemotherapy.

For a pregnant woman with preeclampsia/eclampsia, delivery of the placenta, which is considered to be the cause of PRES in these cases, is curative.1 However, women can develop PRES several weeks after delivery.1

In most cases, the symptoms associated with PRES will resolve once treatment is initiated, and neurologic recovery can be expected within 2 weeks.2

Our patient regained her sight the following morning and was discharged home 2 days after admission. Her blood pressure remained normal. She returned to the hospital unresponsive the day after she had been discharged. Family members stated that she had taken 15 packets of an aspirin/caffeine combination to control a new headache.

Her blood pressure was elevated at 159/79 mm Hg. A CT of the brain showed a hemorrhagic stroke within the left occipital lobe and posterior parietal lobe with a midline shift of 8 mm. We don’t know if the aspirin use contributed to the hemorrhagic event or if it was a sequela of PRES.

The patient died 4 days later.

THE TAKEAWAY

PRES is a neurotoxic condition that causes headache, seizures, and vision loss. Most patients will present with elevated blood pressure and imaging studies will reveal a specific pattern of vasogenic edema that is predominately found in the parietal and occipital regions.

Treating the hypertension may result in a more favorable recovery. Normotensive patients are harder to treat because there is no specific therapy for PRES. Follow-up imaging may help to assess the resolution of the syndrome.

References

1. Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol. 2008;29:1036-1042.

2. Stott VL, Hurrell MA, Anderson TJ. Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed. Intern Med J. 2005;35:83-90.

3. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334:494-500.

4. Liman TG, Bohner G, Endres M, et al. Discharge status and in-hospital mortality in posterior reversible encephalopathy syndrome. Acta Neurol Scand. 2014;130:34-39.

5. Fugate JE, Claassen DO, Cloft HJ, et al. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc. 2010;85:427-432.

6. Bartynski WS. Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol. 2008;29:1043-1049.

7. Ay H, Buonanno FS, Schaefer PW, et al. Posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI. Neurology. 1998;51:1369-1376.

8. Legriel S, Schraub O, Azoulay E, et al; Critically III Posterior Reversible Encephalopathy Syndrome Study Group (CYPRESS). Determinants of recovery from severe posterior reversible encephalopathy syndrome. PLoS ONE. 2012;7:e44534.

9. Morina D, Ntoulias G, Maslehaty H, et al. Posterior reversible encephalopathy syndrome mimicking cerebral metastasis: contraindication for biopsy. Clin Pract. 2014;4:632.

References

1. Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol. 2008;29:1036-1042.

2. Stott VL, Hurrell MA, Anderson TJ. Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed. Intern Med J. 2005;35:83-90.

3. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334:494-500.

4. Liman TG, Bohner G, Endres M, et al. Discharge status and in-hospital mortality in posterior reversible encephalopathy syndrome. Acta Neurol Scand. 2014;130:34-39.

5. Fugate JE, Claassen DO, Cloft HJ, et al. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc. 2010;85:427-432.

6. Bartynski WS. Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol. 2008;29:1043-1049.

7. Ay H, Buonanno FS, Schaefer PW, et al. Posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI. Neurology. 1998;51:1369-1376.

8. Legriel S, Schraub O, Azoulay E, et al; Critically III Posterior Reversible Encephalopathy Syndrome Study Group (CYPRESS). Determinants of recovery from severe posterior reversible encephalopathy syndrome. PLoS ONE. 2012;7:e44534.

9. Morina D, Ntoulias G, Maslehaty H, et al. Posterior reversible encephalopathy syndrome mimicking cerebral metastasis: contraindication for biopsy. Clin Pract. 2014;4:632.

Issue
The Journal of Family Practice - 64(6)
Issue
The Journal of Family Practice - 64(6)
Page Number
358-360
Page Number
358-360
Publications
Publications
Topics
Article Type
Display Headline
Bifrontal headache • blurred vision • vomiting • Dx?
Display Headline
Bifrontal headache • blurred vision • vomiting • Dx?
Legacy Keywords
W. Michael Hughes, DO, MS; Jose M. Villalon-Gomez, MD, MPH; headache; PRES; posterior reversible encephalopathy syndrome; hypertension
Legacy Keywords
W. Michael Hughes, DO, MS; Jose M. Villalon-Gomez, MD, MPH; headache; PRES; posterior reversible encephalopathy syndrome; hypertension
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Case Report: High-Pressure Injection Hand Injury

Article Type
Changed
Wed, 12/12/2018 - 20:34
Display Headline
Case Report: High-Pressure Injection Hand Injury

Case

A 42-year-old healthy man presented to the ED 3 hours after sustaining an injury to the tip of his left index finger from a pressurized washer. He stated that while at work, he had touched the jet nozzle of the washer to “test” its pressure, and had experienced immediate pain in his entire finger as well as blanching in his mid-finger. He took a picture of his finger with his cell phone approximately 5 minutes postinjury, which showed cynanosis at the distal volar pad (Figure 1).

On presentation to the ED, physical examination revealed only an innocuous 1-mm puncture wound to the middle of the volar pad of the distal phalanx of his left index finger, with mild tenderness along the length of the finger but no swelling. The rest of the finger and hand appeared intact with normal color and sensation.   


The patient’s workup included a radiograph, which revealed subcutaneous radiolucencies in the tissue plains of the finger without bony involvement (Figure 2). After being treated with cefazolin 1 g every 6 hours IV and given a tetanus immunization, he was admitted to the hand surgery service where he was observed for 48 hours; thereafter, he was discharged with a 10-day course of oral cephalexin 500 mg every 6 hours and a follow-up appointment with hand surgery services.

Three weeks after discharge, however, the patient developed pain, diffuse swelling, and purulent drainage from the same injured finger and presented again to the ED. He was immediately taken to the operating room where a broad dissection was performed and drains were placed. Two months later, he reported a complete resolution of the infection and was still working on regaining full functioning of his finger by attending physical therapy.

High-Pressure Injection injuries

Diagnosis
At the time of presentation, most high-pressure injection injuries to the hand appear innocuous but frequently result in severe sequelae, including functional disability and amputation. High-pressure injuries occur when soft tissues are placed in contact or near the opening of a high-pressure device or malfunctioning equipment (eg, pinhole rupture in a hydraulic hose).

While the literature reports that 100 psi or greater is required to break the skin,1 patients presenting to the ED typically report operating machinery shooting between 2,000 and 12,000 psi.2,3 Case-report reviews of patients with high-pressure injection injuries by Schoo et al4 and Hogan and Ruland5 found this type of  injury most often occurred in the nondominant hand of male laborers—primarily in the index finger—with 30% to 48% of such injuries resulting in amputation of the digit.

Mechanical and Chemical Injuries

High-pressure injection injuries can be both mechanical as well as chemical. A mechanical high-pressure injury depends upon the magnitude of the injection force, with higher pressures associated with increased dysfunction and incidence of amputation. A chemical-related injury depends upon the duration of exposure and the volume of the material injected.

A high-pressure injury results from a tearing of the soft tissues, with shearing and dissection within and among the tissue plains down the finger and into the palm and proximal tissues.4,6 In this type of injury, there is often direct injury to the neurovascular bundles.

Along with the mechanical aspect of injury, a concurrent chemical injury depends upon the type of material injected (ie, gas or liquid), cytotoxicity, concentration, and inflammatory properties.6 Hogan and Ruland5 described the incidence of amputation associated with injected materials to be greater than 40% with diesel fuel, paint thinner, oil, and paint; 20% to 40% with undercoating, hydraulic fluid, and grease; and 0% with air and water. Oil-based paint injections were associated with a 58% amputation rate comapred to only 6% for latex paints.5

In general, evaluation of high-pressure-related injuries begins with a thorough history to identify the injected material and its attributes, pressure of injection, mechanism of exposure, time elapsed since the event, and the patient’s tetanus immunization status. Interventions include radiographs to evaluate for proximal spread of injected material; tetanus immunization, if required; prophylactic antibiotic therapy7; analgesia; and often emergency surgical consultation. The use of corticosteroid therapy has not been shown to impact the amputation rate or the incidence of infection.5 

Type of Injury and Treatment

Wong et al8 developed the following guidelines categorizing the type and recommended treatment of mild, moderate, and severe high-pressure injection injuries:

Mild Injuries. In mild high-pressure injection injuries, patients tend to seek immediate treatment. These types of injuries typically involve oil or water, with a relatively low-pressure exposure, and preserved circulation in the injured area.8 Treatment includes conservative management with an option for surgery.5,8

 

 

Moderate Injuries. In moderate injection injuries, there is more significant tissue damage from any of the aforementioned materials, but with preserved neurovascular structures. Treatment often includes debridement in addition to antibiotic therapy.

Severe Injuries. These types of injection injuries often involve paints and solvents, high-pressure exposure, and usually present with an abnormal neurovasculature. The best chance for salvage injuries involves rapid surgical intervention for debridement and reconstruction.9,10

Surgical Evaluation and Debridement

Despite optimal care, amputation and dysfunction rates with high-risk injection injuries (due to higher psi, organic solvents, and/or delayed definitive care) have been reported from 48% to 80%.10-13 Immediate surgical evaluation is often recommended when injection injuries are encountered.10,13 Patients who receive immediate surgical debridement (ie, within 6 hours from injury), specifically those injected with organic solvents, have a lower amputation rate than those who do not have immediate surgical intervention.13

In some reports, more than 80% of those injected with organic solvents who did not have immediate washout and debridement required amputation.4 Other effects of postponed debridement include delayed return to work time and decreased functionality of the hand.13,14

Conclusion

Although high-pressure injection injuries often appear mild at initial presentation since the immediate symptoms of the neurovascular injury often resolves, patients often experience severe sequelae including infection, disability, or amputation. The severity of the injury not only depends upon the psi, but also the type and amount of chemical injected. Because of the high morbidity, it is imperative that emergency physicians are aware of and identify these types of injuries and their sequelae.10,11,13,14

Dr Wilson is a third year resident in the department of emergency medicine at the Alpert Medical School, Brown University, Providence, Rhode Island. Dr Hack is the director for the division of medical toxicology at Brown University and the director of the educational program in medical toxicology.  He is an associate professor at Warren Alpert Medical School; and an attending physician in the department of emergency medicine at Brown University, Rhode Island Hospital, Miriam Hospital, Providence.

Disclosure: The authors report no conflicts of interest.

References

  1. Scott AR. Occupational high-pressure injection injuries: pathogenesis and prevention. J Soc Occup Med. 1983;33(2):56-59.
  2. Pappou IP, Deal DN. High-pressure injection injuries. J Hand Surg Am. 2012;37(11):2404-2407.
  3. Soyuncu S, Bektas F, Dinc S. High-pressure air injection injury to the upper extremity. J Emerg Med. 2013;45(1):96-98.
  4. Schoo MJ, Scott FA, Boswick JA Jr. High-pressure injection injuries of the hand. J Trauma. 1980;20(3):229-238.
  5. Hogan CJ, Ruland RT. High-pressure injection injuries to the upper extremity: a review of the literature. J Orthop Trauma. 2006;20(7):503-511.
  6. Rosenwasser MP, Wei DH. High-pressure injection injuries to the hand. J Am Acad Orthop Surg. 2014;22(1):38-45.
  7. Mirzayan R, Schnall SB, Chon JH, Holtom PD, Pazakis MJ, Stevanovic MV.  Culture results and amputation rates in high-pressure paint gun injuries of the hand. Orthopedics. 2001;24(6):587-589.
  8. Wong TC, Ip FK, Wu WC. High-pressure injection injuries of the hand in a Chinese population. J Hand Surg Br. 2005;30(6):588-592.
  9. Pinto MR, Turkula-Pinto LD, Cooney WP, Wood MB, Dobyns JH: High-pressure injection injuries of the hand: review of 25 patients managed by open wound technique. J Hand Surg Am. 1993;18(1):125-130.
  10. Kaufman, HD. High pressure injection injuries, the problems, pathogenesis and management. Hand. 1970;2(1);63-73.
  11. Vasilevski D, Noorbergen M, Depierreux M, Lafontaine M. High-pressure injection injuries to the hand. Am J Emerg Med. 2000;18(7):820-824.
  12. Bekler H, Gokce A, Beyzadeoglu T, Parmaksizoglu F. The surgical treatment and outcomes of high pressure injection injuries of the hand. J Hand Surg Eur Vol. 2007;32(4):394-399.
  13. Amsdell SL, Hammert WC. High-pressure injection injuries in the hand: current treatment concepts. Plast Reconstr Surg. 2013;132(4):586e-591e.
  14. Hart RG, Smith GD, Haq A. Prevention of high-pressure injection injuries to the hand. Am J Emerg Med. 2005;24(1):73-76.
Author and Disclosure Information

Issue
Emergency Medicine - 47(6)
Publications
Page Number
261-263
Sections
Author and Disclosure Information

Author and Disclosure Information

Case

A 42-year-old healthy man presented to the ED 3 hours after sustaining an injury to the tip of his left index finger from a pressurized washer. He stated that while at work, he had touched the jet nozzle of the washer to “test” its pressure, and had experienced immediate pain in his entire finger as well as blanching in his mid-finger. He took a picture of his finger with his cell phone approximately 5 minutes postinjury, which showed cynanosis at the distal volar pad (Figure 1).

On presentation to the ED, physical examination revealed only an innocuous 1-mm puncture wound to the middle of the volar pad of the distal phalanx of his left index finger, with mild tenderness along the length of the finger but no swelling. The rest of the finger and hand appeared intact with normal color and sensation.   


The patient’s workup included a radiograph, which revealed subcutaneous radiolucencies in the tissue plains of the finger without bony involvement (Figure 2). After being treated with cefazolin 1 g every 6 hours IV and given a tetanus immunization, he was admitted to the hand surgery service where he was observed for 48 hours; thereafter, he was discharged with a 10-day course of oral cephalexin 500 mg every 6 hours and a follow-up appointment with hand surgery services.

Three weeks after discharge, however, the patient developed pain, diffuse swelling, and purulent drainage from the same injured finger and presented again to the ED. He was immediately taken to the operating room where a broad dissection was performed and drains were placed. Two months later, he reported a complete resolution of the infection and was still working on regaining full functioning of his finger by attending physical therapy.

High-Pressure Injection injuries

Diagnosis
At the time of presentation, most high-pressure injection injuries to the hand appear innocuous but frequently result in severe sequelae, including functional disability and amputation. High-pressure injuries occur when soft tissues are placed in contact or near the opening of a high-pressure device or malfunctioning equipment (eg, pinhole rupture in a hydraulic hose).

While the literature reports that 100 psi or greater is required to break the skin,1 patients presenting to the ED typically report operating machinery shooting between 2,000 and 12,000 psi.2,3 Case-report reviews of patients with high-pressure injection injuries by Schoo et al4 and Hogan and Ruland5 found this type of  injury most often occurred in the nondominant hand of male laborers—primarily in the index finger—with 30% to 48% of such injuries resulting in amputation of the digit.

Mechanical and Chemical Injuries

High-pressure injection injuries can be both mechanical as well as chemical. A mechanical high-pressure injury depends upon the magnitude of the injection force, with higher pressures associated with increased dysfunction and incidence of amputation. A chemical-related injury depends upon the duration of exposure and the volume of the material injected.

A high-pressure injury results from a tearing of the soft tissues, with shearing and dissection within and among the tissue plains down the finger and into the palm and proximal tissues.4,6 In this type of injury, there is often direct injury to the neurovascular bundles.

Along with the mechanical aspect of injury, a concurrent chemical injury depends upon the type of material injected (ie, gas or liquid), cytotoxicity, concentration, and inflammatory properties.6 Hogan and Ruland5 described the incidence of amputation associated with injected materials to be greater than 40% with diesel fuel, paint thinner, oil, and paint; 20% to 40% with undercoating, hydraulic fluid, and grease; and 0% with air and water. Oil-based paint injections were associated with a 58% amputation rate comapred to only 6% for latex paints.5

In general, evaluation of high-pressure-related injuries begins with a thorough history to identify the injected material and its attributes, pressure of injection, mechanism of exposure, time elapsed since the event, and the patient’s tetanus immunization status. Interventions include radiographs to evaluate for proximal spread of injected material; tetanus immunization, if required; prophylactic antibiotic therapy7; analgesia; and often emergency surgical consultation. The use of corticosteroid therapy has not been shown to impact the amputation rate or the incidence of infection.5 

Type of Injury and Treatment

Wong et al8 developed the following guidelines categorizing the type and recommended treatment of mild, moderate, and severe high-pressure injection injuries:

Mild Injuries. In mild high-pressure injection injuries, patients tend to seek immediate treatment. These types of injuries typically involve oil or water, with a relatively low-pressure exposure, and preserved circulation in the injured area.8 Treatment includes conservative management with an option for surgery.5,8

 

 

Moderate Injuries. In moderate injection injuries, there is more significant tissue damage from any of the aforementioned materials, but with preserved neurovascular structures. Treatment often includes debridement in addition to antibiotic therapy.

Severe Injuries. These types of injection injuries often involve paints and solvents, high-pressure exposure, and usually present with an abnormal neurovasculature. The best chance for salvage injuries involves rapid surgical intervention for debridement and reconstruction.9,10

Surgical Evaluation and Debridement

Despite optimal care, amputation and dysfunction rates with high-risk injection injuries (due to higher psi, organic solvents, and/or delayed definitive care) have been reported from 48% to 80%.10-13 Immediate surgical evaluation is often recommended when injection injuries are encountered.10,13 Patients who receive immediate surgical debridement (ie, within 6 hours from injury), specifically those injected with organic solvents, have a lower amputation rate than those who do not have immediate surgical intervention.13

In some reports, more than 80% of those injected with organic solvents who did not have immediate washout and debridement required amputation.4 Other effects of postponed debridement include delayed return to work time and decreased functionality of the hand.13,14

Conclusion

Although high-pressure injection injuries often appear mild at initial presentation since the immediate symptoms of the neurovascular injury often resolves, patients often experience severe sequelae including infection, disability, or amputation. The severity of the injury not only depends upon the psi, but also the type and amount of chemical injected. Because of the high morbidity, it is imperative that emergency physicians are aware of and identify these types of injuries and their sequelae.10,11,13,14

Dr Wilson is a third year resident in the department of emergency medicine at the Alpert Medical School, Brown University, Providence, Rhode Island. Dr Hack is the director for the division of medical toxicology at Brown University and the director of the educational program in medical toxicology.  He is an associate professor at Warren Alpert Medical School; and an attending physician in the department of emergency medicine at Brown University, Rhode Island Hospital, Miriam Hospital, Providence.

Disclosure: The authors report no conflicts of interest.

Case

A 42-year-old healthy man presented to the ED 3 hours after sustaining an injury to the tip of his left index finger from a pressurized washer. He stated that while at work, he had touched the jet nozzle of the washer to “test” its pressure, and had experienced immediate pain in his entire finger as well as blanching in his mid-finger. He took a picture of his finger with his cell phone approximately 5 minutes postinjury, which showed cynanosis at the distal volar pad (Figure 1).

On presentation to the ED, physical examination revealed only an innocuous 1-mm puncture wound to the middle of the volar pad of the distal phalanx of his left index finger, with mild tenderness along the length of the finger but no swelling. The rest of the finger and hand appeared intact with normal color and sensation.   


The patient’s workup included a radiograph, which revealed subcutaneous radiolucencies in the tissue plains of the finger without bony involvement (Figure 2). After being treated with cefazolin 1 g every 6 hours IV and given a tetanus immunization, he was admitted to the hand surgery service where he was observed for 48 hours; thereafter, he was discharged with a 10-day course of oral cephalexin 500 mg every 6 hours and a follow-up appointment with hand surgery services.

Three weeks after discharge, however, the patient developed pain, diffuse swelling, and purulent drainage from the same injured finger and presented again to the ED. He was immediately taken to the operating room where a broad dissection was performed and drains were placed. Two months later, he reported a complete resolution of the infection and was still working on regaining full functioning of his finger by attending physical therapy.

High-Pressure Injection injuries

Diagnosis
At the time of presentation, most high-pressure injection injuries to the hand appear innocuous but frequently result in severe sequelae, including functional disability and amputation. High-pressure injuries occur when soft tissues are placed in contact or near the opening of a high-pressure device or malfunctioning equipment (eg, pinhole rupture in a hydraulic hose).

While the literature reports that 100 psi or greater is required to break the skin,1 patients presenting to the ED typically report operating machinery shooting between 2,000 and 12,000 psi.2,3 Case-report reviews of patients with high-pressure injection injuries by Schoo et al4 and Hogan and Ruland5 found this type of  injury most often occurred in the nondominant hand of male laborers—primarily in the index finger—with 30% to 48% of such injuries resulting in amputation of the digit.

Mechanical and Chemical Injuries

High-pressure injection injuries can be both mechanical as well as chemical. A mechanical high-pressure injury depends upon the magnitude of the injection force, with higher pressures associated with increased dysfunction and incidence of amputation. A chemical-related injury depends upon the duration of exposure and the volume of the material injected.

A high-pressure injury results from a tearing of the soft tissues, with shearing and dissection within and among the tissue plains down the finger and into the palm and proximal tissues.4,6 In this type of injury, there is often direct injury to the neurovascular bundles.

Along with the mechanical aspect of injury, a concurrent chemical injury depends upon the type of material injected (ie, gas or liquid), cytotoxicity, concentration, and inflammatory properties.6 Hogan and Ruland5 described the incidence of amputation associated with injected materials to be greater than 40% with diesel fuel, paint thinner, oil, and paint; 20% to 40% with undercoating, hydraulic fluid, and grease; and 0% with air and water. Oil-based paint injections were associated with a 58% amputation rate comapred to only 6% for latex paints.5

In general, evaluation of high-pressure-related injuries begins with a thorough history to identify the injected material and its attributes, pressure of injection, mechanism of exposure, time elapsed since the event, and the patient’s tetanus immunization status. Interventions include radiographs to evaluate for proximal spread of injected material; tetanus immunization, if required; prophylactic antibiotic therapy7; analgesia; and often emergency surgical consultation. The use of corticosteroid therapy has not been shown to impact the amputation rate or the incidence of infection.5 

Type of Injury and Treatment

Wong et al8 developed the following guidelines categorizing the type and recommended treatment of mild, moderate, and severe high-pressure injection injuries:

Mild Injuries. In mild high-pressure injection injuries, patients tend to seek immediate treatment. These types of injuries typically involve oil or water, with a relatively low-pressure exposure, and preserved circulation in the injured area.8 Treatment includes conservative management with an option for surgery.5,8

 

 

Moderate Injuries. In moderate injection injuries, there is more significant tissue damage from any of the aforementioned materials, but with preserved neurovascular structures. Treatment often includes debridement in addition to antibiotic therapy.

Severe Injuries. These types of injection injuries often involve paints and solvents, high-pressure exposure, and usually present with an abnormal neurovasculature. The best chance for salvage injuries involves rapid surgical intervention for debridement and reconstruction.9,10

Surgical Evaluation and Debridement

Despite optimal care, amputation and dysfunction rates with high-risk injection injuries (due to higher psi, organic solvents, and/or delayed definitive care) have been reported from 48% to 80%.10-13 Immediate surgical evaluation is often recommended when injection injuries are encountered.10,13 Patients who receive immediate surgical debridement (ie, within 6 hours from injury), specifically those injected with organic solvents, have a lower amputation rate than those who do not have immediate surgical intervention.13

In some reports, more than 80% of those injected with organic solvents who did not have immediate washout and debridement required amputation.4 Other effects of postponed debridement include delayed return to work time and decreased functionality of the hand.13,14

Conclusion

Although high-pressure injection injuries often appear mild at initial presentation since the immediate symptoms of the neurovascular injury often resolves, patients often experience severe sequelae including infection, disability, or amputation. The severity of the injury not only depends upon the psi, but also the type and amount of chemical injected. Because of the high morbidity, it is imperative that emergency physicians are aware of and identify these types of injuries and their sequelae.10,11,13,14

Dr Wilson is a third year resident in the department of emergency medicine at the Alpert Medical School, Brown University, Providence, Rhode Island. Dr Hack is the director for the division of medical toxicology at Brown University and the director of the educational program in medical toxicology.  He is an associate professor at Warren Alpert Medical School; and an attending physician in the department of emergency medicine at Brown University, Rhode Island Hospital, Miriam Hospital, Providence.

Disclosure: The authors report no conflicts of interest.

References

  1. Scott AR. Occupational high-pressure injection injuries: pathogenesis and prevention. J Soc Occup Med. 1983;33(2):56-59.
  2. Pappou IP, Deal DN. High-pressure injection injuries. J Hand Surg Am. 2012;37(11):2404-2407.
  3. Soyuncu S, Bektas F, Dinc S. High-pressure air injection injury to the upper extremity. J Emerg Med. 2013;45(1):96-98.
  4. Schoo MJ, Scott FA, Boswick JA Jr. High-pressure injection injuries of the hand. J Trauma. 1980;20(3):229-238.
  5. Hogan CJ, Ruland RT. High-pressure injection injuries to the upper extremity: a review of the literature. J Orthop Trauma. 2006;20(7):503-511.
  6. Rosenwasser MP, Wei DH. High-pressure injection injuries to the hand. J Am Acad Orthop Surg. 2014;22(1):38-45.
  7. Mirzayan R, Schnall SB, Chon JH, Holtom PD, Pazakis MJ, Stevanovic MV.  Culture results and amputation rates in high-pressure paint gun injuries of the hand. Orthopedics. 2001;24(6):587-589.
  8. Wong TC, Ip FK, Wu WC. High-pressure injection injuries of the hand in a Chinese population. J Hand Surg Br. 2005;30(6):588-592.
  9. Pinto MR, Turkula-Pinto LD, Cooney WP, Wood MB, Dobyns JH: High-pressure injection injuries of the hand: review of 25 patients managed by open wound technique. J Hand Surg Am. 1993;18(1):125-130.
  10. Kaufman, HD. High pressure injection injuries, the problems, pathogenesis and management. Hand. 1970;2(1);63-73.
  11. Vasilevski D, Noorbergen M, Depierreux M, Lafontaine M. High-pressure injection injuries to the hand. Am J Emerg Med. 2000;18(7):820-824.
  12. Bekler H, Gokce A, Beyzadeoglu T, Parmaksizoglu F. The surgical treatment and outcomes of high pressure injection injuries of the hand. J Hand Surg Eur Vol. 2007;32(4):394-399.
  13. Amsdell SL, Hammert WC. High-pressure injection injuries in the hand: current treatment concepts. Plast Reconstr Surg. 2013;132(4):586e-591e.
  14. Hart RG, Smith GD, Haq A. Prevention of high-pressure injection injuries to the hand. Am J Emerg Med. 2005;24(1):73-76.
References

  1. Scott AR. Occupational high-pressure injection injuries: pathogenesis and prevention. J Soc Occup Med. 1983;33(2):56-59.
  2. Pappou IP, Deal DN. High-pressure injection injuries. J Hand Surg Am. 2012;37(11):2404-2407.
  3. Soyuncu S, Bektas F, Dinc S. High-pressure air injection injury to the upper extremity. J Emerg Med. 2013;45(1):96-98.
  4. Schoo MJ, Scott FA, Boswick JA Jr. High-pressure injection injuries of the hand. J Trauma. 1980;20(3):229-238.
  5. Hogan CJ, Ruland RT. High-pressure injection injuries to the upper extremity: a review of the literature. J Orthop Trauma. 2006;20(7):503-511.
  6. Rosenwasser MP, Wei DH. High-pressure injection injuries to the hand. J Am Acad Orthop Surg. 2014;22(1):38-45.
  7. Mirzayan R, Schnall SB, Chon JH, Holtom PD, Pazakis MJ, Stevanovic MV.  Culture results and amputation rates in high-pressure paint gun injuries of the hand. Orthopedics. 2001;24(6):587-589.
  8. Wong TC, Ip FK, Wu WC. High-pressure injection injuries of the hand in a Chinese population. J Hand Surg Br. 2005;30(6):588-592.
  9. Pinto MR, Turkula-Pinto LD, Cooney WP, Wood MB, Dobyns JH: High-pressure injection injuries of the hand: review of 25 patients managed by open wound technique. J Hand Surg Am. 1993;18(1):125-130.
  10. Kaufman, HD. High pressure injection injuries, the problems, pathogenesis and management. Hand. 1970;2(1);63-73.
  11. Vasilevski D, Noorbergen M, Depierreux M, Lafontaine M. High-pressure injection injuries to the hand. Am J Emerg Med. 2000;18(7):820-824.
  12. Bekler H, Gokce A, Beyzadeoglu T, Parmaksizoglu F. The surgical treatment and outcomes of high pressure injection injuries of the hand. J Hand Surg Eur Vol. 2007;32(4):394-399.
  13. Amsdell SL, Hammert WC. High-pressure injection injuries in the hand: current treatment concepts. Plast Reconstr Surg. 2013;132(4):586e-591e.
  14. Hart RG, Smith GD, Haq A. Prevention of high-pressure injection injuries to the hand. Am J Emerg Med. 2005;24(1):73-76.
Issue
Emergency Medicine - 47(6)
Issue
Emergency Medicine - 47(6)
Page Number
261-263
Page Number
261-263
Publications
Publications
Article Type
Display Headline
Case Report: High-Pressure Injection Hand Injury
Display Headline
Case Report: High-Pressure Injection Hand Injury
Sections
Article Source

PURLs Copyright

Inside the Article

Case Studies in Toxicology: Babies and Booze—Pediatric Considerations in the Management of Ethanol Intoxication

Article Type
Changed
Wed, 12/12/2018 - 20:34
Display Headline
Case Studies in Toxicology: Babies and Booze—Pediatric Considerations in the Management of Ethanol Intoxication
A 4-month-old infant was brought to the ED by her father after a reported unintentional ethanol exposure.

Case

A previously healthy 4-month-old girl was brought into the ED for concerns of alcohol ingestion. Reportedly, the infant’s father reconstituted 4 ounces of powdered formula using what he thought was water from an unmarked bottle in his refrigerator. He later realized that the bottle contained rum, although he still let the child finish the 4 ounces of formula in the hopes that she would vomit—which did not occur.

Upon arrival to the ED, the infant’s vital signs were: blood pressure, 100/61 mm Hg; heart rate, 155 beats/minute; respiratory rate, 36 breaths/minute; and temperature, normal. Oxygen saturation was 98% on room air. A rapid bedside blood glucose test was 89 mg/dL. The infant’s physical examination was unremarkable. She appeared active but hungry, had a strong cry, and had a developmentally appropriate gross neurological examination.

How does ethanol exposure in children typically occur?

Recent reports from the American Association of Poison Control Centers’ National Poison Data System demonstrate that ethanol exposures comprise 1% to 3% of total exposures in children aged ≤5 years.

The most common sources are ethanol-containing beverages, mouthwash, and cologne/perfume.1 Ethanol can also be found as a solvent for certain pediatric liquid medications (eg, ranitidine) or in flavor extracts (eg, vanilla extract, orange extract). Any clear alcohol (eg, vodka, gin, rum) stored in an accessible site, such as a refrigerator, may be mistaken for water. In many reports, a caregiver unintentionally used the alcohol to reconstitute formula; however, intentional provision of alcohol to toddlers, usually as a sedative, is a recurring concern.2

What are the clinical concerns in children with ethanol intoxication?

An understanding of the pathways of ethanol metabolism frames the key issues surrounding ethanol exposure in small children. Ethanol is metabolized in the liver primarily through sequential oxidation by alcohol-dehydrogenase (ADH) and aldehyde-dehydrogenase (ALDH), which reduce nicotinamide adenine dinucleotide (NAD+) to NAD plus hydrogen (NADH) in each step. The final product of this pathway, acetate, is then converted to acetyl coenzyme A (acetyl-CoA), which enters into the Krebs cycle for thiamine-dependent metabolism to carbon dioxide and water (Figure). With substantial exposures to ethanol, the accumulation of NADH creates an imbalance in the body’s reducing potential, resulting in metabolic disturbances such as alcoholic ketoacidosis.

Under usual conditions, a normal serum glucose concentration is maintained from ingested carbohydrates and via glycogenolysis of hepatic glycogen stores. Such glycogen reserves can sustain normal blood glucose concentrations for several hours in adults but for a shorter period in children. Once glycogen is depleted, as is common after an overnight fast, glucose can be generated through gluconeogenesis.

However, in the presence of ethanol (Figure), the excessive reducing potential (ie, NADH) that results from ethanol metabolism shunts pyruvate away from the gluconeogenic pathway (toward lactate), inhibiting glucose production. Unlike adults, children and infants, who have relatively low glycogen reserves, are at significant risk for hypoglycemia following ethanol exposure. This represents the largest contributor to morbidity and mortality of children with ethanol intoxication.3 Patients with hypoglycemia can have a highly variable clinical presentation including agitation, seizures, focality, or coma.4

Case Continuation

Intravenous (IV) access was obtained, and the patient was placed on a dextrose-containing fluid at 1.5 times the maintenance flow rate. Pertinent laboratory studies revealed a serum glucose level of 90 mg/dL, normal electrolyte panel, and an initial blood alcohol concentration of 337 mg/dL (approximately 30 minutes postingestion).

How do children with ethanol intoxication present?

While there is some variation in clinical effects among nontolerant adults, acute ethanol intoxication with a serum concentration >250 mg/dL is frequently associated with stupor, respiratory depression, and hypotension. A concentration >400 mg/dL may be associated with coma or apnea. Although similar clinical effects are expected in adolescents and children, infants often have counterintuitive clinical findings.

To date, eight cases of significant infant ethanol exposure exist in the literature (age range, 29 days to 9 months; ethanol concentration, 183-524 mg/dL). Respiratory depression was absent in all cases.5-9 In all but two cases, the neurological examination revealed only subtle decreases in interaction or tone. The remaining two children were described as obtunded and flaccid (ethanol levels, 405 mg/dL and 524 mg/dL, respectively) and were intubated for airway protection despite normal respiratory rates.7,10

The incongruence between the clinical findings (both the neurological examination and respiratory effects) and the ethanol concentration is difficult to explain. It may be due to age-related neurological immaturity or a limited ability to perform the required detailed neurological examinations in children. In particular, the relatively preserved level of consciousness, despite an otherwise coma-inducing ethanol concentration, is unique to infants. Accordingly, there should be a low threshold to check ethanol concentrations in infants presenting with apparent life-threatening events, altered mental status, decreased tone, or unexplained hypoglycemia or hypothermia.

 

 

What is the estimated time to sobriety in infants?

Ethanol is eliminated via a hepatic enzymatic oxidation pathway that becomes saturated at low serum levels. In nontolerant adults, this results in a zero-order kinetic elimination pattern with an ethanol elimination rate of approximately 20 mg/dL per hour. Anecdotally, it had been thought that children clear ethanol at roughly double this rate via unclear mechanisms. However, a review of published kinetic data suggests the actual rate of clearance may not differ substantially from adults (range, 19-34 mg/dL per hour).5-7,10,11

Case Conclusion

The patient was transferred to a tertiary care pediatric hospital for continued management, where the markedly elevated serum ethanol concentration was confirmed.  She was maintained on a dextrose-containing IV fluid and observed overnight without development of any complications. Serial serum ethanol concentrations were performed and complete clearance was achieved approximately 20 hours postingestion, suggesting a metabolic rate of 16 mg/dL per hour. The infant was discharged home with supervision by child protective services.

Dr Boroughf is a toxicology fellow, department of emergency medicine, Albert Einstein Medical Center, Philadelphia, Pennsylvania. Dr Nelson, editor of “Case Studies in Toxicology,” is a professor in the department of emergency medicine and director of the medical toxicology fellowship program at the New York University School of Medicine and the New York City Poison Control Center. He is also associate editor, toxicology, of the EMERGENCY MEDICINE editorial board. Dr Henretig is an attending toxicologist, department of emergency medicine, Children’s Hospital of Philadelphia, Pennsylvania.

References

 

 

  1. Mowry JB, Spyker DA, Cantilena LR Jr, Bailey JE, Ford M. 2012 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 30th Annual Report. Clin Toxicol (Phila). 2013;51(10):949-1229.
  2. Wood JN, Pecker LH, Russo ME, Henretig F, Christian CW. Evaluation and referral for child maltreatment in pediatric poisoning victims. Child Abuse Negl. 2012;36(4):362-369.
  3. Lamminpää A. Alcohol intoxication in childhood and adolescence. Alcohol Alcohol. 1995;30(1):5-12.
  4. Malouf R, Brust JC. Hypoglycemia: causes, neurological manifestations, and outcome. Ann Neurol.1985;17(5):421-430.
  5. Chikava K, Lower DR, Frangiskakis SH, Sepulveda JL, Virji MA, Rao KN. Acute ethanol intoxication in a 7-month old-infant. Pediatr Dev Pathol. 2004;7(4):400-402.
  6. Ford JB, Wayment MT, Albertson TE, Owen KP, Radke JB, Sutter ME. Elimination kinetics of ethanol in a 5-week-old infant and a literature review of infant ethanol pharmacokinetics. Case Rep Med. 2013;2013:250716. doi:10.1155/2013/250716
  7. McCormick T, Levine M, Knox O, Claudius I. Ethanol ingestion in two infants under 2 months old: a previously unreported cause of ALTE. Pediatrics. 2013;131(2);e604-e607.
  8. Fong HF, Muller AA. An unexpected clinical course in a 29-day-old infant with ethanol exposure. Pediatr Emerg Care. 2014;30(2):111-113.
  9. Iyer SS, Haupt A, Henretig FM. Pick your poison: straight from the spring? Ped Emerg Care. 2009;25(3):194-196.
  10. Edmunds SM, Ajizian SJ, Liguori A. Acute obtundation in a 9-month-old patient: ethanol ingestion. Pediatr Emerg Care. 2014;30(10):739-741.
  11. Simon HK, Cox JM, Sucov A, Linakis JG. Serum ethanol clearance in intoxicated children and adolescents presenting to the ED. Acad Emerg Med. 1994;1(6):520-524.
Issue
Emergency Medicine - 47(6)
Publications
Topics
Page Number
272-274
Sections
A 4-month-old infant was brought to the ED by her father after a reported unintentional ethanol exposure.
A 4-month-old infant was brought to the ED by her father after a reported unintentional ethanol exposure.

Case

A previously healthy 4-month-old girl was brought into the ED for concerns of alcohol ingestion. Reportedly, the infant’s father reconstituted 4 ounces of powdered formula using what he thought was water from an unmarked bottle in his refrigerator. He later realized that the bottle contained rum, although he still let the child finish the 4 ounces of formula in the hopes that she would vomit—which did not occur.

Upon arrival to the ED, the infant’s vital signs were: blood pressure, 100/61 mm Hg; heart rate, 155 beats/minute; respiratory rate, 36 breaths/minute; and temperature, normal. Oxygen saturation was 98% on room air. A rapid bedside blood glucose test was 89 mg/dL. The infant’s physical examination was unremarkable. She appeared active but hungry, had a strong cry, and had a developmentally appropriate gross neurological examination.

How does ethanol exposure in children typically occur?

Recent reports from the American Association of Poison Control Centers’ National Poison Data System demonstrate that ethanol exposures comprise 1% to 3% of total exposures in children aged ≤5 years.

The most common sources are ethanol-containing beverages, mouthwash, and cologne/perfume.1 Ethanol can also be found as a solvent for certain pediatric liquid medications (eg, ranitidine) or in flavor extracts (eg, vanilla extract, orange extract). Any clear alcohol (eg, vodka, gin, rum) stored in an accessible site, such as a refrigerator, may be mistaken for water. In many reports, a caregiver unintentionally used the alcohol to reconstitute formula; however, intentional provision of alcohol to toddlers, usually as a sedative, is a recurring concern.2

What are the clinical concerns in children with ethanol intoxication?

An understanding of the pathways of ethanol metabolism frames the key issues surrounding ethanol exposure in small children. Ethanol is metabolized in the liver primarily through sequential oxidation by alcohol-dehydrogenase (ADH) and aldehyde-dehydrogenase (ALDH), which reduce nicotinamide adenine dinucleotide (NAD+) to NAD plus hydrogen (NADH) in each step. The final product of this pathway, acetate, is then converted to acetyl coenzyme A (acetyl-CoA), which enters into the Krebs cycle for thiamine-dependent metabolism to carbon dioxide and water (Figure). With substantial exposures to ethanol, the accumulation of NADH creates an imbalance in the body’s reducing potential, resulting in metabolic disturbances such as alcoholic ketoacidosis.

Under usual conditions, a normal serum glucose concentration is maintained from ingested carbohydrates and via glycogenolysis of hepatic glycogen stores. Such glycogen reserves can sustain normal blood glucose concentrations for several hours in adults but for a shorter period in children. Once glycogen is depleted, as is common after an overnight fast, glucose can be generated through gluconeogenesis.

However, in the presence of ethanol (Figure), the excessive reducing potential (ie, NADH) that results from ethanol metabolism shunts pyruvate away from the gluconeogenic pathway (toward lactate), inhibiting glucose production. Unlike adults, children and infants, who have relatively low glycogen reserves, are at significant risk for hypoglycemia following ethanol exposure. This represents the largest contributor to morbidity and mortality of children with ethanol intoxication.3 Patients with hypoglycemia can have a highly variable clinical presentation including agitation, seizures, focality, or coma.4

Case Continuation

Intravenous (IV) access was obtained, and the patient was placed on a dextrose-containing fluid at 1.5 times the maintenance flow rate. Pertinent laboratory studies revealed a serum glucose level of 90 mg/dL, normal electrolyte panel, and an initial blood alcohol concentration of 337 mg/dL (approximately 30 minutes postingestion).

How do children with ethanol intoxication present?

While there is some variation in clinical effects among nontolerant adults, acute ethanol intoxication with a serum concentration >250 mg/dL is frequently associated with stupor, respiratory depression, and hypotension. A concentration >400 mg/dL may be associated with coma or apnea. Although similar clinical effects are expected in adolescents and children, infants often have counterintuitive clinical findings.

To date, eight cases of significant infant ethanol exposure exist in the literature (age range, 29 days to 9 months; ethanol concentration, 183-524 mg/dL). Respiratory depression was absent in all cases.5-9 In all but two cases, the neurological examination revealed only subtle decreases in interaction or tone. The remaining two children were described as obtunded and flaccid (ethanol levels, 405 mg/dL and 524 mg/dL, respectively) and were intubated for airway protection despite normal respiratory rates.7,10

The incongruence between the clinical findings (both the neurological examination and respiratory effects) and the ethanol concentration is difficult to explain. It may be due to age-related neurological immaturity or a limited ability to perform the required detailed neurological examinations in children. In particular, the relatively preserved level of consciousness, despite an otherwise coma-inducing ethanol concentration, is unique to infants. Accordingly, there should be a low threshold to check ethanol concentrations in infants presenting with apparent life-threatening events, altered mental status, decreased tone, or unexplained hypoglycemia or hypothermia.

 

 

What is the estimated time to sobriety in infants?

Ethanol is eliminated via a hepatic enzymatic oxidation pathway that becomes saturated at low serum levels. In nontolerant adults, this results in a zero-order kinetic elimination pattern with an ethanol elimination rate of approximately 20 mg/dL per hour. Anecdotally, it had been thought that children clear ethanol at roughly double this rate via unclear mechanisms. However, a review of published kinetic data suggests the actual rate of clearance may not differ substantially from adults (range, 19-34 mg/dL per hour).5-7,10,11

Case Conclusion

The patient was transferred to a tertiary care pediatric hospital for continued management, where the markedly elevated serum ethanol concentration was confirmed.  She was maintained on a dextrose-containing IV fluid and observed overnight without development of any complications. Serial serum ethanol concentrations were performed and complete clearance was achieved approximately 20 hours postingestion, suggesting a metabolic rate of 16 mg/dL per hour. The infant was discharged home with supervision by child protective services.

Dr Boroughf is a toxicology fellow, department of emergency medicine, Albert Einstein Medical Center, Philadelphia, Pennsylvania. Dr Nelson, editor of “Case Studies in Toxicology,” is a professor in the department of emergency medicine and director of the medical toxicology fellowship program at the New York University School of Medicine and the New York City Poison Control Center. He is also associate editor, toxicology, of the EMERGENCY MEDICINE editorial board. Dr Henretig is an attending toxicologist, department of emergency medicine, Children’s Hospital of Philadelphia, Pennsylvania.

Case

A previously healthy 4-month-old girl was brought into the ED for concerns of alcohol ingestion. Reportedly, the infant’s father reconstituted 4 ounces of powdered formula using what he thought was water from an unmarked bottle in his refrigerator. He later realized that the bottle contained rum, although he still let the child finish the 4 ounces of formula in the hopes that she would vomit—which did not occur.

Upon arrival to the ED, the infant’s vital signs were: blood pressure, 100/61 mm Hg; heart rate, 155 beats/minute; respiratory rate, 36 breaths/minute; and temperature, normal. Oxygen saturation was 98% on room air. A rapid bedside blood glucose test was 89 mg/dL. The infant’s physical examination was unremarkable. She appeared active but hungry, had a strong cry, and had a developmentally appropriate gross neurological examination.

How does ethanol exposure in children typically occur?

Recent reports from the American Association of Poison Control Centers’ National Poison Data System demonstrate that ethanol exposures comprise 1% to 3% of total exposures in children aged ≤5 years.

The most common sources are ethanol-containing beverages, mouthwash, and cologne/perfume.1 Ethanol can also be found as a solvent for certain pediatric liquid medications (eg, ranitidine) or in flavor extracts (eg, vanilla extract, orange extract). Any clear alcohol (eg, vodka, gin, rum) stored in an accessible site, such as a refrigerator, may be mistaken for water. In many reports, a caregiver unintentionally used the alcohol to reconstitute formula; however, intentional provision of alcohol to toddlers, usually as a sedative, is a recurring concern.2

What are the clinical concerns in children with ethanol intoxication?

An understanding of the pathways of ethanol metabolism frames the key issues surrounding ethanol exposure in small children. Ethanol is metabolized in the liver primarily through sequential oxidation by alcohol-dehydrogenase (ADH) and aldehyde-dehydrogenase (ALDH), which reduce nicotinamide adenine dinucleotide (NAD+) to NAD plus hydrogen (NADH) in each step. The final product of this pathway, acetate, is then converted to acetyl coenzyme A (acetyl-CoA), which enters into the Krebs cycle for thiamine-dependent metabolism to carbon dioxide and water (Figure). With substantial exposures to ethanol, the accumulation of NADH creates an imbalance in the body’s reducing potential, resulting in metabolic disturbances such as alcoholic ketoacidosis.

Under usual conditions, a normal serum glucose concentration is maintained from ingested carbohydrates and via glycogenolysis of hepatic glycogen stores. Such glycogen reserves can sustain normal blood glucose concentrations for several hours in adults but for a shorter period in children. Once glycogen is depleted, as is common after an overnight fast, glucose can be generated through gluconeogenesis.

However, in the presence of ethanol (Figure), the excessive reducing potential (ie, NADH) that results from ethanol metabolism shunts pyruvate away from the gluconeogenic pathway (toward lactate), inhibiting glucose production. Unlike adults, children and infants, who have relatively low glycogen reserves, are at significant risk for hypoglycemia following ethanol exposure. This represents the largest contributor to morbidity and mortality of children with ethanol intoxication.3 Patients with hypoglycemia can have a highly variable clinical presentation including agitation, seizures, focality, or coma.4

Case Continuation

Intravenous (IV) access was obtained, and the patient was placed on a dextrose-containing fluid at 1.5 times the maintenance flow rate. Pertinent laboratory studies revealed a serum glucose level of 90 mg/dL, normal electrolyte panel, and an initial blood alcohol concentration of 337 mg/dL (approximately 30 minutes postingestion).

How do children with ethanol intoxication present?

While there is some variation in clinical effects among nontolerant adults, acute ethanol intoxication with a serum concentration >250 mg/dL is frequently associated with stupor, respiratory depression, and hypotension. A concentration >400 mg/dL may be associated with coma or apnea. Although similar clinical effects are expected in adolescents and children, infants often have counterintuitive clinical findings.

To date, eight cases of significant infant ethanol exposure exist in the literature (age range, 29 days to 9 months; ethanol concentration, 183-524 mg/dL). Respiratory depression was absent in all cases.5-9 In all but two cases, the neurological examination revealed only subtle decreases in interaction or tone. The remaining two children were described as obtunded and flaccid (ethanol levels, 405 mg/dL and 524 mg/dL, respectively) and were intubated for airway protection despite normal respiratory rates.7,10

The incongruence between the clinical findings (both the neurological examination and respiratory effects) and the ethanol concentration is difficult to explain. It may be due to age-related neurological immaturity or a limited ability to perform the required detailed neurological examinations in children. In particular, the relatively preserved level of consciousness, despite an otherwise coma-inducing ethanol concentration, is unique to infants. Accordingly, there should be a low threshold to check ethanol concentrations in infants presenting with apparent life-threatening events, altered mental status, decreased tone, or unexplained hypoglycemia or hypothermia.

 

 

What is the estimated time to sobriety in infants?

Ethanol is eliminated via a hepatic enzymatic oxidation pathway that becomes saturated at low serum levels. In nontolerant adults, this results in a zero-order kinetic elimination pattern with an ethanol elimination rate of approximately 20 mg/dL per hour. Anecdotally, it had been thought that children clear ethanol at roughly double this rate via unclear mechanisms. However, a review of published kinetic data suggests the actual rate of clearance may not differ substantially from adults (range, 19-34 mg/dL per hour).5-7,10,11

Case Conclusion

The patient was transferred to a tertiary care pediatric hospital for continued management, where the markedly elevated serum ethanol concentration was confirmed.  She was maintained on a dextrose-containing IV fluid and observed overnight without development of any complications. Serial serum ethanol concentrations were performed and complete clearance was achieved approximately 20 hours postingestion, suggesting a metabolic rate of 16 mg/dL per hour. The infant was discharged home with supervision by child protective services.

Dr Boroughf is a toxicology fellow, department of emergency medicine, Albert Einstein Medical Center, Philadelphia, Pennsylvania. Dr Nelson, editor of “Case Studies in Toxicology,” is a professor in the department of emergency medicine and director of the medical toxicology fellowship program at the New York University School of Medicine and the New York City Poison Control Center. He is also associate editor, toxicology, of the EMERGENCY MEDICINE editorial board. Dr Henretig is an attending toxicologist, department of emergency medicine, Children’s Hospital of Philadelphia, Pennsylvania.

References

 

 

  1. Mowry JB, Spyker DA, Cantilena LR Jr, Bailey JE, Ford M. 2012 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 30th Annual Report. Clin Toxicol (Phila). 2013;51(10):949-1229.
  2. Wood JN, Pecker LH, Russo ME, Henretig F, Christian CW. Evaluation and referral for child maltreatment in pediatric poisoning victims. Child Abuse Negl. 2012;36(4):362-369.
  3. Lamminpää A. Alcohol intoxication in childhood and adolescence. Alcohol Alcohol. 1995;30(1):5-12.
  4. Malouf R, Brust JC. Hypoglycemia: causes, neurological manifestations, and outcome. Ann Neurol.1985;17(5):421-430.
  5. Chikava K, Lower DR, Frangiskakis SH, Sepulveda JL, Virji MA, Rao KN. Acute ethanol intoxication in a 7-month old-infant. Pediatr Dev Pathol. 2004;7(4):400-402.
  6. Ford JB, Wayment MT, Albertson TE, Owen KP, Radke JB, Sutter ME. Elimination kinetics of ethanol in a 5-week-old infant and a literature review of infant ethanol pharmacokinetics. Case Rep Med. 2013;2013:250716. doi:10.1155/2013/250716
  7. McCormick T, Levine M, Knox O, Claudius I. Ethanol ingestion in two infants under 2 months old: a previously unreported cause of ALTE. Pediatrics. 2013;131(2);e604-e607.
  8. Fong HF, Muller AA. An unexpected clinical course in a 29-day-old infant with ethanol exposure. Pediatr Emerg Care. 2014;30(2):111-113.
  9. Iyer SS, Haupt A, Henretig FM. Pick your poison: straight from the spring? Ped Emerg Care. 2009;25(3):194-196.
  10. Edmunds SM, Ajizian SJ, Liguori A. Acute obtundation in a 9-month-old patient: ethanol ingestion. Pediatr Emerg Care. 2014;30(10):739-741.
  11. Simon HK, Cox JM, Sucov A, Linakis JG. Serum ethanol clearance in intoxicated children and adolescents presenting to the ED. Acad Emerg Med. 1994;1(6):520-524.
References

 

 

  1. Mowry JB, Spyker DA, Cantilena LR Jr, Bailey JE, Ford M. 2012 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 30th Annual Report. Clin Toxicol (Phila). 2013;51(10):949-1229.
  2. Wood JN, Pecker LH, Russo ME, Henretig F, Christian CW. Evaluation and referral for child maltreatment in pediatric poisoning victims. Child Abuse Negl. 2012;36(4):362-369.
  3. Lamminpää A. Alcohol intoxication in childhood and adolescence. Alcohol Alcohol. 1995;30(1):5-12.
  4. Malouf R, Brust JC. Hypoglycemia: causes, neurological manifestations, and outcome. Ann Neurol.1985;17(5):421-430.
  5. Chikava K, Lower DR, Frangiskakis SH, Sepulveda JL, Virji MA, Rao KN. Acute ethanol intoxication in a 7-month old-infant. Pediatr Dev Pathol. 2004;7(4):400-402.
  6. Ford JB, Wayment MT, Albertson TE, Owen KP, Radke JB, Sutter ME. Elimination kinetics of ethanol in a 5-week-old infant and a literature review of infant ethanol pharmacokinetics. Case Rep Med. 2013;2013:250716. doi:10.1155/2013/250716
  7. McCormick T, Levine M, Knox O, Claudius I. Ethanol ingestion in two infants under 2 months old: a previously unreported cause of ALTE. Pediatrics. 2013;131(2);e604-e607.
  8. Fong HF, Muller AA. An unexpected clinical course in a 29-day-old infant with ethanol exposure. Pediatr Emerg Care. 2014;30(2):111-113.
  9. Iyer SS, Haupt A, Henretig FM. Pick your poison: straight from the spring? Ped Emerg Care. 2009;25(3):194-196.
  10. Edmunds SM, Ajizian SJ, Liguori A. Acute obtundation in a 9-month-old patient: ethanol ingestion. Pediatr Emerg Care. 2014;30(10):739-741.
  11. Simon HK, Cox JM, Sucov A, Linakis JG. Serum ethanol clearance in intoxicated children and adolescents presenting to the ED. Acad Emerg Med. 1994;1(6):520-524.
Issue
Emergency Medicine - 47(6)
Issue
Emergency Medicine - 47(6)
Page Number
272-274
Page Number
272-274
Publications
Publications
Topics
Article Type
Display Headline
Case Studies in Toxicology: Babies and Booze—Pediatric Considerations in the Management of Ethanol Intoxication
Display Headline
Case Studies in Toxicology: Babies and Booze—Pediatric Considerations in the Management of Ethanol Intoxication
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica

Knee Extensor Mechanism Reconstruction With Complete Extensor Allograft After Failure of Patellar Tendon Repair

Article Type
Changed
Thu, 09/19/2019 - 13:34
Display Headline
Knee Extensor Mechanism Reconstruction With Complete Extensor Allograft After Failure of Patellar Tendon Repair

The extensor mechanism of the knee comprises the quadriceps tendon, the patella, and the patellar tendon. The extensor mechanism may be damaged by injury to these structures, with consequences such as the inability to actively extend the knee and hemarthrosis.1,2 Disruption of this mechanism is rare, and the most common injury pattern is an eccentric contraction of the quadriceps tendon on a flexed knee causing a tendon (quadriceps or patellar) rupture or a patella fracture.1,2

Patellar tendon ruptures are more common in persons younger than 40 years.1 Treatment is surgical, regardless of age and physical activity. In the acute setting, repair can be end-to-end suture or transosseous tunnel insertion. End-to-end suturing is difficult in chronic patellar tendon ruptures because of patella alta secondary to quadriceps contraction.3 Treatment options for chronic ruptures may involve transpatellar traction4 or tendon reinforcement with fascia lata, a semitendinosus band, or synthetic materials.3-5 Alternatively, tendon autograft and allografts have also been recommended, especially in extreme situations.1,6 Furthermore, animal experiments have shown that a compact platelet-rich fibrin scaffold (CPFS) has the potential to accelerate healing of patellar tendon defects and to act as a bioscaffold for graft augmentation.7

We describe the case of a 30-year-old man who underwent extensor mechanism reconstruction with cadaveric tendon–patellar tendon–bone allograft for failure of an infected primary end-to-end repair. The patient provided written informed consent for print and electronic publication of this case report.

Case Report

A 30-year-old healthy man landed on an empty glass fish tank, resulting in a traumatic right-knee arthrotomy. On initial evaluation, the patient had a negative straight-leg-raise test and impaired knee extension. The patient was taken urgently to the operating room for irrigation and débridement and concurrent repair of the patellar tendon laceration. Antibiotic prophylaxis with 2 g of intravenous (IV) cefazolin was given in the emergency room.

Intraoperatively, after visualizing the patellar tendon laceration and excluding any associated chondral lesions, we proceeded with extensive débridement and irrigation using 9 L of normal saline pulse lavage. After we achieved a clean site, we proceeded to repair the patellar tendon using No. 2 FiberWire sutures (Arthrex, Naples, Florida) with a classic Krackow repair8 consisting of 2 sutures run in a 4-row fashion through the patella and the patellar tendon. The suture was securely tightened and then tested for stability to at least 90° of knee flexion. The retinaculum was repaired using No. 0 Vicryl sutures (Ethicon, Somerville, New Jersey). After wound closure and dressing, the patient was placed in a hinged knee brace locked in extension at all times after surgery. Antibiotic treatment with IV cefazolin was administered for 48 hours.

Postoperative management consisted of weight-bearing as tolerated on the operative limb and appropriate deep venous thrombosis prophylaxis. The patient followed up in clinic 2 weeks and 4 weeks after surgery. At 4 weeks, the patient was noted to have a secondary wound infection with superficial dehiscence and serosanguineous drainage. No wound opening was noticed, and local wound care was performed with a 1-week course of oral cephalexin. The patient was scheduled to follow up a few weeks later but did not follow up for a year.

At 1-year follow-up, the patient reported that he had had a steady progression of his knee range of motion (ROM) with decreased pain. However, over time, the patient noted subjective instability of the knee, with frequent falls occurring close to his 1-year follow-up. Examination of his knee showed that his active ROM ranged from 20° in extension to 120° in flexion, with a weak extensor mechanism. Passively, his knee could be brought to full extension. His incision was well healed, but it had an area of bogginess in the middle. Radiographs showed patella alta on the affected knee, with a lengthening of the patellar tendon of 7.70 cm on the right compared with 5.18 cm on the left. Magnetic resonance imaging (MRI) showed moderate-to-severe patellar tendinosis with small fluid pockets around the surgical material and evidence of acute patellar enthesopathy. The laboratory values showed a white blood cell count of 7580/μL (normal, 4500-11,000/μL), an erythrocyte sedimentation rate of 2 mm/h (normal, 1-15 mm/h), and a C-reactive protein level of 1.93 mg/dL (normal, 0.00-0.29 mg/dL). Based on the clinical examination and imaging findings, there was a concern for a possible chronic deep-tissue infection, in addition to failure of the primary patellar tendon repair. Operative versus nonoperative management options were discussed with the patient, and he elected to undergo surgery.

During surgery, the patellar laxity was confirmed, and the patellar tendon was noticed to be chronically thickened and surrounded by unhealthy tissue. Initially, an extensive soft-tissue débridement was performed, and all patellar tendon loculations visualized on the preoperative MRI were drained; a solid purulent-like fluid was expressed. Unfortunately, the extensive and required débridement did not allow the preservation of the patellar tendon. Appropriate cultures were taken and sent for immediate Gram-stain analysis, which returned negative. Tissue samples from the patellar tendon were also sent to the pathology department for analysis. Intraoperatively, the infrapatellar defect was filled temporarily with a tobramycin cement spacer mixed with 2 g of vancomycin in a manner similar to that of the Masquelet technique used for infected long-bone nonunions with bone loss.9,10 This technique is a 2-stage procedure that promotes the formation of a biologic membrane that allows bone healing in the reconstruction of long-bone defects. The first stage consists of a radical débridement with soft-tissue repair by flaps when needed, with the insertion of a polymethylmethacrylate cement spacer into the bone defect. The second stage is usually performed 6 to 8 weeks later, with removal of the spacer and preservation of the induced membrane, which is filled with iliac crest bone autograft augmented (if necessary) with demineralized allograft.

 

 

The incision was closed primarily, and after surgery, the patient was allowed to bear weight as tolerated in a hinged knee brace locked in extension. Final laboratory analysis from cultures and tissue samples revealed acute and chronic inflammation with more than 20 neutrophils per high-powered field. No organisms grew from aerobic, anaerobic, fungal, or mycobacterial cultures. The infectious disease service was consulted and recommended oral cephalexin.

Because all cultures were negative, all laboratory examinations did not indicate any residual infections, and no bony involvement was noticed intraoperatively or in the preoperative knee MRI, we decided to proceed with the second stage of the Masquelet technique after 2 weeks. The patient returned to the operating room for final reconstruction of his patellar tendon using a custom-ordered cadaveric tendon–patellar tendon–bone allograft, the length of which was determined by measuring the contralateral patellar tendon, ie, 5.18 cm (Figure 1A). The previous anterior knee incision was reopened and extended distally past the tibial tuberosity and proximally toward the quadriceps tendon. The antibiotic spacer was removed. We proceeded with a repeat irrigation and débridement and the allograft transfer. The selected allograft was customized by reducing the tibial bone component to an approximately 1×2-cm bone block and by reducing the allograft patellar thickness with an oscillating saw, leaving an approximately 2-mm thick patellar bone graft attached to the patellar tendon. In a similar technique using an oscillating saw, we shaved off the anterior cortex of the patient’s patella to accommodate, in a sandwich fashion, the patellar allograft. Proximally, the quadriceps tendon insertion was split longitudinally and partially separated from the superior pole of the patellar tendon to allow seating and fixation of the modified quadriceps allograft tendon component.

We proceeded with the fixation of the allograft first distally on the patella. The anterior cortex of the tibial tuberosity was resected to allow the perfect seating of the bone block allograft. The graft was secured with a 4.0-mm fully threaded cancellous lag screw and reinforced with a 2.4-mm, 3-hole T-volar buttress plate (Synthes, Paoli, Pennsylvania). The plate was contoured to better fit the patient’s tibia. We sutured the patellar allograft tendon to the patella using two No. 2-0 FiberWire sutures in Krackow suture technique8 (Figures 1B, 1C). We obtained good fixation of the patellar tendon, and the distance between the patellar insertion and the inferior patellar pole was the same as before surgery: 5.57 cm and comparable to the contralateral side (Figures 2A-2C). The patellar allograft and autograft sandwich were secured with additional No. 2-0 FiberWire sutures, and the quadriceps allograft and autograft were secured with the cross-stitch technique with the same material. Fine suturing of the quadriceps tendon was done with No. 0 Vicryl sutures. After the fixation was completed, we tested the stability of the reconstruction and found good flexion up to 120°.

The postoperative protocol consisted of weight-bearing as tolerated in full extension and passive knee ROM, using a continuous passive ROM machine from 0° to 45° for the first 4 weeks, followed by active ROM, increased as tolerated, during the next 8 weeks.

The patient was seen in clinic 3 and 9 months after surgery. At the 3-month follow-up appointment, the patient’s examination showed knee ROM from 0° extension to 130° of flexion, no secondary infection signs, and radiographic evidence of a well-healing patellar allograft with symmetric patellar tendon length to the contralateral side. At 9-month follow-up, the patient’s active ROM was from 0° extension to 140° flexion (Figures 3A, 3B), and he had returned to his preinjury level of functioning.

Discussion

This case report describes the successful reconstruction of a patellar tendon defect with cadaveric tendon–patellar tendon–bone allograft. Extensor mechanism injuries are uncommon in general, and the incidence of patellar tendon injury is higher in men than in women.2 Patellar tendon tears occur frequently in active patients younger than 40 years, usually as a result of sudden quadriceps contraction with the knee slightly flexed.1 Treatment of patellar tendon injury is surgical, and functional outcomes for patients with this injury are equivalent to those of patients with quadriceps tendon injuries or patellar fractures.2 Acute patellar tendon tears can be repaired by end-to-end suturing or transosseous tunnel insertion in the tibia or patella.1 Reinforcement is often added between the patella and tibial tuberosity, using a semitendinosus band or wire.1 End-to-end suture is performed using a thick resorbable suture. It is important to avoid patella alta during suturing, comparing the position of the patella with the contralateral patella with the knee in 45° of flexion. In proximal avulsion, the tendon is anchored to the bone by 2 thick nonresorbable sutures through 2 parallel bone tunnels to the proximal pole of the patella. Distal avulsion is rare in adults, but it can be managed by using staples or suture anchors.1

 

 

End-to-end suturing of chronic patellar tendon defects is difficult more than 45 days after injury primarily because of difficulties in correcting patella alta secondary to the upward force exerted by the quadriceps tendon.1,3 Extreme situations similar to the case we present warrant Achilles or patellar tendon allograft for reconstruction of the extensor mechanism.1,3,6,9

Extensor mechanism allograft also provides an effective remedy for severe quadriceps deficiency caused by loss of the patella, patellar tendon, and quadriceps tendon in total knee arthroplasty.10 However, in such cases, late failure is common, and major quadriceps deficiency occurs after removal of the allograft material.10 To improve outcome, a novel technique using the medial gastrocnemius muscle transferred to the muscular portion of the vastus medialis and lateralis flaps provides a secure and strong closure of the anterior knee, thereby restoring the extensor mechanism of the knee.10

Patellar tendon reconstruction with allograft tissue has been successfully used, especially in cases related to chronic patellar tendon ruptures11 and total knee arthroplasty.6,12-14 Crossett and colleagues12 showed that, at 2-year follow-up, the average knee score for pain, ROM, and stability had improved from 26 points (range, 6-39 points) before surgery to 81 points (range, 40-92 points). The average knee score for function had also improved: 14 points (range, 0-35 points) before surgery to 53 points (range, 30-90 points).12 Primary repair may succeed in early intervention, but in an established rupture, allograft reconstruction is often necessary. Achilles tendon is the preferred allograft, with the calcaneus fragment embedded into the proximal tibia as a new tubercle and the tendon sutured into the remaining extensor mechanism.1,11 The repair is further protected using a cable loop from the superior pole of the patella to a drill hole in the upper tibia.9 Techniques have also been described involving passage of the proximal aspect of the allograft tendon through patellar bone tunnels and suture fixation to the native quadriceps tendon.11,15 However, in our technique, we shaved off the anterior cortex of the patient’s patella to allow a sandwich-type over-position of the allograft to secure fixation to the patella.

Another alternative to allograft reconstruction involves biocompatible scaffolds. Such scaffolds incorporate the use of platelets in a fibrin framework. A CPFS, produced from blood and calcium gluconate to improve healing of patellar tendon defects, has been described in animal studies.7 In the rabbit model, CPFS acts as a provisional bioscaffold that can accelerate healing of an injured patellar tendon repair, potentially secondary to several growth factors derived from platelets.7 Platelets are biocompatible sources of growth factors, and CPFS can act as a scaffold to restore the mechanical integrity of injured soft tissue.7,16 In addition, CPFS can act to lower donor-site morbidity associated with harvesting tissue autograft.7 However, to our knowledge, such scaffolds have not been used in human trials. The LARS biocompatible ligament (Corin Group PLC, Cirencester, United Kingdom), currently not approved by the US Food and Drug Administration, is used for reconstructions of isolated or multiple knee ligament injuries.17 This graft requires the presence of healthy tissue with good blood supply from which new tendon or ligament can grow in. Sometimes it is also used for extensor mechanism reconstruction after radical tumor resection around the knee; however, good results are achieved in only 59% of cases,18 and to our knowledge, only 1 case of primary repair of a patellar tendon rupture has been published.19

Techniques involving the use of tendon–patellar tendon–bone graft with fixation via the sandwich-type over-position of the allograft for chronic patellar tendon rupture have not been described in the literature. In our patient, given the extensive patellar tendon lesion and inflammation with chronic tissue degeneration, there was no option but to use allograft. To improve the patient’s outcome, we chose the strongest possible allograft, tendon–patellar tendon–bone graft.

Conclusion

Revision patellar tendon reconstruction is a challenging, but necessary, procedure to restore the extensor mechanism of the knee, especially in young, active individuals. Various options to reconstruct the tissue defects are available. Our patient was successfully treated with a tendon–patellar tendon–bone allograft reconstruction.

References

1.    Saragaglia D, Pison A, Rubens-Duval B. Acute and old ruptures of the extensor apparatus of the knee in adults (excluding knee replacement). Orthop Traumatol Surg Res. 2013;99(1 suppl):S67-S76.

2.    Tejwani NC, Lekic N, Bechtel C, Montero N, Egol KA. Outcomes after knee joint extensor mechanism disruptions: is it better to fracture the patella or rupture the tendon? J Orthop Trauma. 2012;26(11):648-651.

3.    Ecker ML, Lotke PA, Glazer RM. Late reconstruction of the patellar tendon. J Bone Joint Surg Am. 1979;61(6):884-886.

4.    Siwek CW, Rao JP. Ruptures of the extensor mechanism of the knee joint. J Bone Joint Surg Am. 1981;63(6):932-937.

5.    Levy M, Goldstein J, Rosner M. A method of repair for quadriceps tendon or patellar ligament (tendon) ruptures without cast immobilization. Preliminary report. Clin Orthop Relat Res. 1987;218:297-301.

6.    Burks RT, Edelson RH. Allograft reconstruction of the patellar ligament. A case report. J Bone Joint Surg Am. 1994;76(7):1077-1079.

7.    Matsunaga D, Akizuki S, Takizawa T, Omae S, Kato H. Compact platelet-rich fibrin scaffold to improve healing of patellar tendon defects and for medial collateral ligament reconstruction. Knee. 2013;20(6):545-550.

8.    Krackow KA, Thomas SC, Jones LC. Ligament-tendon fixation: analysis of a new stitch and comparison with standard techniques. Orthopedics. 1988;11(6):909-917.

9.    Brooks P. Extensor mechanism ruptures. Orthopedics. 2009;32(9):683-684.

10.  Whiteside LA. Surgical technique: muscle transfer restores extensor function after failed patella-patellar tendon allograft. Clin Orthop Relat Res. 2014;472(1):218-226.

11.  Farmer K, Cosgarea AJ. Procedure 25. Acute and chronic patellar tendon ruptures. In: Miller MD, Cole BJ, Cosgarea AJ, Sekiya JK, eds. Operative Techniques: Sports Knee Surgery. Philadelphia, PA: Saunders (Elsevier); 2008:397-417.

12.  Crossett LS, Sinha RK, Sechriest VF, Rubash HE. Reconstruction of a ruptured patellar tendon with achilles tendon allograft following total knee arthroplasty. J Bone Joint Surg Am. 2002;84(8):1354-1361.

13.  Lahav A, Burks RT, Scholl MD. Allograft reconstruction of the patellar tendon: 12-year follow-up. Am J Orthop. 2004;33(12):623-624.

14.  Yoo JH, Chang JD, Seo YJ, Baek SW. Reconstruction of a patellar tendon with Achilles tendon allograft for severe patellar infera--a case report. Knee. 2011;18(5):350-353.

15.  Saldua NS, Mazurek MT. Procedure 37. Quadriceps and patellar tendon repair. In: Reider B, Terry MA, Provencher MT, eds. Operative Techniques: Sports Medicine Surgery. Philadelphia, PA: Saunders (Elsevier); 2010:623-640.

16.  Anitua E, Andia I, Ardanza B, Nurden P, Nurden AT. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost. 2004;91(1):4-15.

17.  Ibrahim SAR, Ahmad FHF, Salah M, Al Misfer ARK, Ghaffer SA, Khirat S. Surgical management of traumatic knee dislocation. Arthroscopy. 2008;24(2):178-187.

18.  Dominkus M, Sabeti M, Toma C, Abdolvahab F, Trieb K, Kotz RI. Reconstructing the extensor apparatus with a new polyester ligament. Clin Orthop Relat Res. 2006;453:328-334.

19.  Naim S, Gougoulias N, Griffiths D. Patellar tendon reconstruction using LARS ligament: surgical technique and case report. Strategies Trauma Limb Reconstr. 2011;6(1):39-41.

Article PDF
Author and Disclosure Information

Savyasachi C. Thakkar, MD, Nigel Hsu, MD, and Erik A. Hasenboehler, MD

Authors’ Disclosure Statement: The authors report no actual or potential conflict of interest in relation to this article.

Issue
The American Journal of Orthopedics - 44(6)
Publications
Topics
Page Number
E199-E201
Legacy Keywords
american journal of orthopedics, AJO, case report and literature review, case report, online exclusive, knee, mechanism, reconstruction, allograft, patellar, tendon, repair, limb, imaging, thakkar, hsu, hasenboehler
Sections
Author and Disclosure Information

Savyasachi C. Thakkar, MD, Nigel Hsu, MD, and Erik A. Hasenboehler, MD

Authors’ Disclosure Statement: The authors report no actual or potential conflict of interest in relation to this article.

Author and Disclosure Information

Savyasachi C. Thakkar, MD, Nigel Hsu, MD, and Erik A. Hasenboehler, MD

Authors’ Disclosure Statement: The authors report no actual or potential conflict of interest in relation to this article.

Article PDF
Article PDF

The extensor mechanism of the knee comprises the quadriceps tendon, the patella, and the patellar tendon. The extensor mechanism may be damaged by injury to these structures, with consequences such as the inability to actively extend the knee and hemarthrosis.1,2 Disruption of this mechanism is rare, and the most common injury pattern is an eccentric contraction of the quadriceps tendon on a flexed knee causing a tendon (quadriceps or patellar) rupture or a patella fracture.1,2

Patellar tendon ruptures are more common in persons younger than 40 years.1 Treatment is surgical, regardless of age and physical activity. In the acute setting, repair can be end-to-end suture or transosseous tunnel insertion. End-to-end suturing is difficult in chronic patellar tendon ruptures because of patella alta secondary to quadriceps contraction.3 Treatment options for chronic ruptures may involve transpatellar traction4 or tendon reinforcement with fascia lata, a semitendinosus band, or synthetic materials.3-5 Alternatively, tendon autograft and allografts have also been recommended, especially in extreme situations.1,6 Furthermore, animal experiments have shown that a compact platelet-rich fibrin scaffold (CPFS) has the potential to accelerate healing of patellar tendon defects and to act as a bioscaffold for graft augmentation.7

We describe the case of a 30-year-old man who underwent extensor mechanism reconstruction with cadaveric tendon–patellar tendon–bone allograft for failure of an infected primary end-to-end repair. The patient provided written informed consent for print and electronic publication of this case report.

Case Report

A 30-year-old healthy man landed on an empty glass fish tank, resulting in a traumatic right-knee arthrotomy. On initial evaluation, the patient had a negative straight-leg-raise test and impaired knee extension. The patient was taken urgently to the operating room for irrigation and débridement and concurrent repair of the patellar tendon laceration. Antibiotic prophylaxis with 2 g of intravenous (IV) cefazolin was given in the emergency room.

Intraoperatively, after visualizing the patellar tendon laceration and excluding any associated chondral lesions, we proceeded with extensive débridement and irrigation using 9 L of normal saline pulse lavage. After we achieved a clean site, we proceeded to repair the patellar tendon using No. 2 FiberWire sutures (Arthrex, Naples, Florida) with a classic Krackow repair8 consisting of 2 sutures run in a 4-row fashion through the patella and the patellar tendon. The suture was securely tightened and then tested for stability to at least 90° of knee flexion. The retinaculum was repaired using No. 0 Vicryl sutures (Ethicon, Somerville, New Jersey). After wound closure and dressing, the patient was placed in a hinged knee brace locked in extension at all times after surgery. Antibiotic treatment with IV cefazolin was administered for 48 hours.

Postoperative management consisted of weight-bearing as tolerated on the operative limb and appropriate deep venous thrombosis prophylaxis. The patient followed up in clinic 2 weeks and 4 weeks after surgery. At 4 weeks, the patient was noted to have a secondary wound infection with superficial dehiscence and serosanguineous drainage. No wound opening was noticed, and local wound care was performed with a 1-week course of oral cephalexin. The patient was scheduled to follow up a few weeks later but did not follow up for a year.

At 1-year follow-up, the patient reported that he had had a steady progression of his knee range of motion (ROM) with decreased pain. However, over time, the patient noted subjective instability of the knee, with frequent falls occurring close to his 1-year follow-up. Examination of his knee showed that his active ROM ranged from 20° in extension to 120° in flexion, with a weak extensor mechanism. Passively, his knee could be brought to full extension. His incision was well healed, but it had an area of bogginess in the middle. Radiographs showed patella alta on the affected knee, with a lengthening of the patellar tendon of 7.70 cm on the right compared with 5.18 cm on the left. Magnetic resonance imaging (MRI) showed moderate-to-severe patellar tendinosis with small fluid pockets around the surgical material and evidence of acute patellar enthesopathy. The laboratory values showed a white blood cell count of 7580/μL (normal, 4500-11,000/μL), an erythrocyte sedimentation rate of 2 mm/h (normal, 1-15 mm/h), and a C-reactive protein level of 1.93 mg/dL (normal, 0.00-0.29 mg/dL). Based on the clinical examination and imaging findings, there was a concern for a possible chronic deep-tissue infection, in addition to failure of the primary patellar tendon repair. Operative versus nonoperative management options were discussed with the patient, and he elected to undergo surgery.

During surgery, the patellar laxity was confirmed, and the patellar tendon was noticed to be chronically thickened and surrounded by unhealthy tissue. Initially, an extensive soft-tissue débridement was performed, and all patellar tendon loculations visualized on the preoperative MRI were drained; a solid purulent-like fluid was expressed. Unfortunately, the extensive and required débridement did not allow the preservation of the patellar tendon. Appropriate cultures were taken and sent for immediate Gram-stain analysis, which returned negative. Tissue samples from the patellar tendon were also sent to the pathology department for analysis. Intraoperatively, the infrapatellar defect was filled temporarily with a tobramycin cement spacer mixed with 2 g of vancomycin in a manner similar to that of the Masquelet technique used for infected long-bone nonunions with bone loss.9,10 This technique is a 2-stage procedure that promotes the formation of a biologic membrane that allows bone healing in the reconstruction of long-bone defects. The first stage consists of a radical débridement with soft-tissue repair by flaps when needed, with the insertion of a polymethylmethacrylate cement spacer into the bone defect. The second stage is usually performed 6 to 8 weeks later, with removal of the spacer and preservation of the induced membrane, which is filled with iliac crest bone autograft augmented (if necessary) with demineralized allograft.

 

 

The incision was closed primarily, and after surgery, the patient was allowed to bear weight as tolerated in a hinged knee brace locked in extension. Final laboratory analysis from cultures and tissue samples revealed acute and chronic inflammation with more than 20 neutrophils per high-powered field. No organisms grew from aerobic, anaerobic, fungal, or mycobacterial cultures. The infectious disease service was consulted and recommended oral cephalexin.

Because all cultures were negative, all laboratory examinations did not indicate any residual infections, and no bony involvement was noticed intraoperatively or in the preoperative knee MRI, we decided to proceed with the second stage of the Masquelet technique after 2 weeks. The patient returned to the operating room for final reconstruction of his patellar tendon using a custom-ordered cadaveric tendon–patellar tendon–bone allograft, the length of which was determined by measuring the contralateral patellar tendon, ie, 5.18 cm (Figure 1A). The previous anterior knee incision was reopened and extended distally past the tibial tuberosity and proximally toward the quadriceps tendon. The antibiotic spacer was removed. We proceeded with a repeat irrigation and débridement and the allograft transfer. The selected allograft was customized by reducing the tibial bone component to an approximately 1×2-cm bone block and by reducing the allograft patellar thickness with an oscillating saw, leaving an approximately 2-mm thick patellar bone graft attached to the patellar tendon. In a similar technique using an oscillating saw, we shaved off the anterior cortex of the patient’s patella to accommodate, in a sandwich fashion, the patellar allograft. Proximally, the quadriceps tendon insertion was split longitudinally and partially separated from the superior pole of the patellar tendon to allow seating and fixation of the modified quadriceps allograft tendon component.

We proceeded with the fixation of the allograft first distally on the patella. The anterior cortex of the tibial tuberosity was resected to allow the perfect seating of the bone block allograft. The graft was secured with a 4.0-mm fully threaded cancellous lag screw and reinforced with a 2.4-mm, 3-hole T-volar buttress plate (Synthes, Paoli, Pennsylvania). The plate was contoured to better fit the patient’s tibia. We sutured the patellar allograft tendon to the patella using two No. 2-0 FiberWire sutures in Krackow suture technique8 (Figures 1B, 1C). We obtained good fixation of the patellar tendon, and the distance between the patellar insertion and the inferior patellar pole was the same as before surgery: 5.57 cm and comparable to the contralateral side (Figures 2A-2C). The patellar allograft and autograft sandwich were secured with additional No. 2-0 FiberWire sutures, and the quadriceps allograft and autograft were secured with the cross-stitch technique with the same material. Fine suturing of the quadriceps tendon was done with No. 0 Vicryl sutures. After the fixation was completed, we tested the stability of the reconstruction and found good flexion up to 120°.

The postoperative protocol consisted of weight-bearing as tolerated in full extension and passive knee ROM, using a continuous passive ROM machine from 0° to 45° for the first 4 weeks, followed by active ROM, increased as tolerated, during the next 8 weeks.

The patient was seen in clinic 3 and 9 months after surgery. At the 3-month follow-up appointment, the patient’s examination showed knee ROM from 0° extension to 130° of flexion, no secondary infection signs, and radiographic evidence of a well-healing patellar allograft with symmetric patellar tendon length to the contralateral side. At 9-month follow-up, the patient’s active ROM was from 0° extension to 140° flexion (Figures 3A, 3B), and he had returned to his preinjury level of functioning.

Discussion

This case report describes the successful reconstruction of a patellar tendon defect with cadaveric tendon–patellar tendon–bone allograft. Extensor mechanism injuries are uncommon in general, and the incidence of patellar tendon injury is higher in men than in women.2 Patellar tendon tears occur frequently in active patients younger than 40 years, usually as a result of sudden quadriceps contraction with the knee slightly flexed.1 Treatment of patellar tendon injury is surgical, and functional outcomes for patients with this injury are equivalent to those of patients with quadriceps tendon injuries or patellar fractures.2 Acute patellar tendon tears can be repaired by end-to-end suturing or transosseous tunnel insertion in the tibia or patella.1 Reinforcement is often added between the patella and tibial tuberosity, using a semitendinosus band or wire.1 End-to-end suture is performed using a thick resorbable suture. It is important to avoid patella alta during suturing, comparing the position of the patella with the contralateral patella with the knee in 45° of flexion. In proximal avulsion, the tendon is anchored to the bone by 2 thick nonresorbable sutures through 2 parallel bone tunnels to the proximal pole of the patella. Distal avulsion is rare in adults, but it can be managed by using staples or suture anchors.1

 

 

End-to-end suturing of chronic patellar tendon defects is difficult more than 45 days after injury primarily because of difficulties in correcting patella alta secondary to the upward force exerted by the quadriceps tendon.1,3 Extreme situations similar to the case we present warrant Achilles or patellar tendon allograft for reconstruction of the extensor mechanism.1,3,6,9

Extensor mechanism allograft also provides an effective remedy for severe quadriceps deficiency caused by loss of the patella, patellar tendon, and quadriceps tendon in total knee arthroplasty.10 However, in such cases, late failure is common, and major quadriceps deficiency occurs after removal of the allograft material.10 To improve outcome, a novel technique using the medial gastrocnemius muscle transferred to the muscular portion of the vastus medialis and lateralis flaps provides a secure and strong closure of the anterior knee, thereby restoring the extensor mechanism of the knee.10

Patellar tendon reconstruction with allograft tissue has been successfully used, especially in cases related to chronic patellar tendon ruptures11 and total knee arthroplasty.6,12-14 Crossett and colleagues12 showed that, at 2-year follow-up, the average knee score for pain, ROM, and stability had improved from 26 points (range, 6-39 points) before surgery to 81 points (range, 40-92 points). The average knee score for function had also improved: 14 points (range, 0-35 points) before surgery to 53 points (range, 30-90 points).12 Primary repair may succeed in early intervention, but in an established rupture, allograft reconstruction is often necessary. Achilles tendon is the preferred allograft, with the calcaneus fragment embedded into the proximal tibia as a new tubercle and the tendon sutured into the remaining extensor mechanism.1,11 The repair is further protected using a cable loop from the superior pole of the patella to a drill hole in the upper tibia.9 Techniques have also been described involving passage of the proximal aspect of the allograft tendon through patellar bone tunnels and suture fixation to the native quadriceps tendon.11,15 However, in our technique, we shaved off the anterior cortex of the patient’s patella to allow a sandwich-type over-position of the allograft to secure fixation to the patella.

Another alternative to allograft reconstruction involves biocompatible scaffolds. Such scaffolds incorporate the use of platelets in a fibrin framework. A CPFS, produced from blood and calcium gluconate to improve healing of patellar tendon defects, has been described in animal studies.7 In the rabbit model, CPFS acts as a provisional bioscaffold that can accelerate healing of an injured patellar tendon repair, potentially secondary to several growth factors derived from platelets.7 Platelets are biocompatible sources of growth factors, and CPFS can act as a scaffold to restore the mechanical integrity of injured soft tissue.7,16 In addition, CPFS can act to lower donor-site morbidity associated with harvesting tissue autograft.7 However, to our knowledge, such scaffolds have not been used in human trials. The LARS biocompatible ligament (Corin Group PLC, Cirencester, United Kingdom), currently not approved by the US Food and Drug Administration, is used for reconstructions of isolated or multiple knee ligament injuries.17 This graft requires the presence of healthy tissue with good blood supply from which new tendon or ligament can grow in. Sometimes it is also used for extensor mechanism reconstruction after radical tumor resection around the knee; however, good results are achieved in only 59% of cases,18 and to our knowledge, only 1 case of primary repair of a patellar tendon rupture has been published.19

Techniques involving the use of tendon–patellar tendon–bone graft with fixation via the sandwich-type over-position of the allograft for chronic patellar tendon rupture have not been described in the literature. In our patient, given the extensive patellar tendon lesion and inflammation with chronic tissue degeneration, there was no option but to use allograft. To improve the patient’s outcome, we chose the strongest possible allograft, tendon–patellar tendon–bone graft.

Conclusion

Revision patellar tendon reconstruction is a challenging, but necessary, procedure to restore the extensor mechanism of the knee, especially in young, active individuals. Various options to reconstruct the tissue defects are available. Our patient was successfully treated with a tendon–patellar tendon–bone allograft reconstruction.

The extensor mechanism of the knee comprises the quadriceps tendon, the patella, and the patellar tendon. The extensor mechanism may be damaged by injury to these structures, with consequences such as the inability to actively extend the knee and hemarthrosis.1,2 Disruption of this mechanism is rare, and the most common injury pattern is an eccentric contraction of the quadriceps tendon on a flexed knee causing a tendon (quadriceps or patellar) rupture or a patella fracture.1,2

Patellar tendon ruptures are more common in persons younger than 40 years.1 Treatment is surgical, regardless of age and physical activity. In the acute setting, repair can be end-to-end suture or transosseous tunnel insertion. End-to-end suturing is difficult in chronic patellar tendon ruptures because of patella alta secondary to quadriceps contraction.3 Treatment options for chronic ruptures may involve transpatellar traction4 or tendon reinforcement with fascia lata, a semitendinosus band, or synthetic materials.3-5 Alternatively, tendon autograft and allografts have also been recommended, especially in extreme situations.1,6 Furthermore, animal experiments have shown that a compact platelet-rich fibrin scaffold (CPFS) has the potential to accelerate healing of patellar tendon defects and to act as a bioscaffold for graft augmentation.7

We describe the case of a 30-year-old man who underwent extensor mechanism reconstruction with cadaveric tendon–patellar tendon–bone allograft for failure of an infected primary end-to-end repair. The patient provided written informed consent for print and electronic publication of this case report.

Case Report

A 30-year-old healthy man landed on an empty glass fish tank, resulting in a traumatic right-knee arthrotomy. On initial evaluation, the patient had a negative straight-leg-raise test and impaired knee extension. The patient was taken urgently to the operating room for irrigation and débridement and concurrent repair of the patellar tendon laceration. Antibiotic prophylaxis with 2 g of intravenous (IV) cefazolin was given in the emergency room.

Intraoperatively, after visualizing the patellar tendon laceration and excluding any associated chondral lesions, we proceeded with extensive débridement and irrigation using 9 L of normal saline pulse lavage. After we achieved a clean site, we proceeded to repair the patellar tendon using No. 2 FiberWire sutures (Arthrex, Naples, Florida) with a classic Krackow repair8 consisting of 2 sutures run in a 4-row fashion through the patella and the patellar tendon. The suture was securely tightened and then tested for stability to at least 90° of knee flexion. The retinaculum was repaired using No. 0 Vicryl sutures (Ethicon, Somerville, New Jersey). After wound closure and dressing, the patient was placed in a hinged knee brace locked in extension at all times after surgery. Antibiotic treatment with IV cefazolin was administered for 48 hours.

Postoperative management consisted of weight-bearing as tolerated on the operative limb and appropriate deep venous thrombosis prophylaxis. The patient followed up in clinic 2 weeks and 4 weeks after surgery. At 4 weeks, the patient was noted to have a secondary wound infection with superficial dehiscence and serosanguineous drainage. No wound opening was noticed, and local wound care was performed with a 1-week course of oral cephalexin. The patient was scheduled to follow up a few weeks later but did not follow up for a year.

At 1-year follow-up, the patient reported that he had had a steady progression of his knee range of motion (ROM) with decreased pain. However, over time, the patient noted subjective instability of the knee, with frequent falls occurring close to his 1-year follow-up. Examination of his knee showed that his active ROM ranged from 20° in extension to 120° in flexion, with a weak extensor mechanism. Passively, his knee could be brought to full extension. His incision was well healed, but it had an area of bogginess in the middle. Radiographs showed patella alta on the affected knee, with a lengthening of the patellar tendon of 7.70 cm on the right compared with 5.18 cm on the left. Magnetic resonance imaging (MRI) showed moderate-to-severe patellar tendinosis with small fluid pockets around the surgical material and evidence of acute patellar enthesopathy. The laboratory values showed a white blood cell count of 7580/μL (normal, 4500-11,000/μL), an erythrocyte sedimentation rate of 2 mm/h (normal, 1-15 mm/h), and a C-reactive protein level of 1.93 mg/dL (normal, 0.00-0.29 mg/dL). Based on the clinical examination and imaging findings, there was a concern for a possible chronic deep-tissue infection, in addition to failure of the primary patellar tendon repair. Operative versus nonoperative management options were discussed with the patient, and he elected to undergo surgery.

During surgery, the patellar laxity was confirmed, and the patellar tendon was noticed to be chronically thickened and surrounded by unhealthy tissue. Initially, an extensive soft-tissue débridement was performed, and all patellar tendon loculations visualized on the preoperative MRI were drained; a solid purulent-like fluid was expressed. Unfortunately, the extensive and required débridement did not allow the preservation of the patellar tendon. Appropriate cultures were taken and sent for immediate Gram-stain analysis, which returned negative. Tissue samples from the patellar tendon were also sent to the pathology department for analysis. Intraoperatively, the infrapatellar defect was filled temporarily with a tobramycin cement spacer mixed with 2 g of vancomycin in a manner similar to that of the Masquelet technique used for infected long-bone nonunions with bone loss.9,10 This technique is a 2-stage procedure that promotes the formation of a biologic membrane that allows bone healing in the reconstruction of long-bone defects. The first stage consists of a radical débridement with soft-tissue repair by flaps when needed, with the insertion of a polymethylmethacrylate cement spacer into the bone defect. The second stage is usually performed 6 to 8 weeks later, with removal of the spacer and preservation of the induced membrane, which is filled with iliac crest bone autograft augmented (if necessary) with demineralized allograft.

 

 

The incision was closed primarily, and after surgery, the patient was allowed to bear weight as tolerated in a hinged knee brace locked in extension. Final laboratory analysis from cultures and tissue samples revealed acute and chronic inflammation with more than 20 neutrophils per high-powered field. No organisms grew from aerobic, anaerobic, fungal, or mycobacterial cultures. The infectious disease service was consulted and recommended oral cephalexin.

Because all cultures were negative, all laboratory examinations did not indicate any residual infections, and no bony involvement was noticed intraoperatively or in the preoperative knee MRI, we decided to proceed with the second stage of the Masquelet technique after 2 weeks. The patient returned to the operating room for final reconstruction of his patellar tendon using a custom-ordered cadaveric tendon–patellar tendon–bone allograft, the length of which was determined by measuring the contralateral patellar tendon, ie, 5.18 cm (Figure 1A). The previous anterior knee incision was reopened and extended distally past the tibial tuberosity and proximally toward the quadriceps tendon. The antibiotic spacer was removed. We proceeded with a repeat irrigation and débridement and the allograft transfer. The selected allograft was customized by reducing the tibial bone component to an approximately 1×2-cm bone block and by reducing the allograft patellar thickness with an oscillating saw, leaving an approximately 2-mm thick patellar bone graft attached to the patellar tendon. In a similar technique using an oscillating saw, we shaved off the anterior cortex of the patient’s patella to accommodate, in a sandwich fashion, the patellar allograft. Proximally, the quadriceps tendon insertion was split longitudinally and partially separated from the superior pole of the patellar tendon to allow seating and fixation of the modified quadriceps allograft tendon component.

We proceeded with the fixation of the allograft first distally on the patella. The anterior cortex of the tibial tuberosity was resected to allow the perfect seating of the bone block allograft. The graft was secured with a 4.0-mm fully threaded cancellous lag screw and reinforced with a 2.4-mm, 3-hole T-volar buttress plate (Synthes, Paoli, Pennsylvania). The plate was contoured to better fit the patient’s tibia. We sutured the patellar allograft tendon to the patella using two No. 2-0 FiberWire sutures in Krackow suture technique8 (Figures 1B, 1C). We obtained good fixation of the patellar tendon, and the distance between the patellar insertion and the inferior patellar pole was the same as before surgery: 5.57 cm and comparable to the contralateral side (Figures 2A-2C). The patellar allograft and autograft sandwich were secured with additional No. 2-0 FiberWire sutures, and the quadriceps allograft and autograft were secured with the cross-stitch technique with the same material. Fine suturing of the quadriceps tendon was done with No. 0 Vicryl sutures. After the fixation was completed, we tested the stability of the reconstruction and found good flexion up to 120°.

The postoperative protocol consisted of weight-bearing as tolerated in full extension and passive knee ROM, using a continuous passive ROM machine from 0° to 45° for the first 4 weeks, followed by active ROM, increased as tolerated, during the next 8 weeks.

The patient was seen in clinic 3 and 9 months after surgery. At the 3-month follow-up appointment, the patient’s examination showed knee ROM from 0° extension to 130° of flexion, no secondary infection signs, and radiographic evidence of a well-healing patellar allograft with symmetric patellar tendon length to the contralateral side. At 9-month follow-up, the patient’s active ROM was from 0° extension to 140° flexion (Figures 3A, 3B), and he had returned to his preinjury level of functioning.

Discussion

This case report describes the successful reconstruction of a patellar tendon defect with cadaveric tendon–patellar tendon–bone allograft. Extensor mechanism injuries are uncommon in general, and the incidence of patellar tendon injury is higher in men than in women.2 Patellar tendon tears occur frequently in active patients younger than 40 years, usually as a result of sudden quadriceps contraction with the knee slightly flexed.1 Treatment of patellar tendon injury is surgical, and functional outcomes for patients with this injury are equivalent to those of patients with quadriceps tendon injuries or patellar fractures.2 Acute patellar tendon tears can be repaired by end-to-end suturing or transosseous tunnel insertion in the tibia or patella.1 Reinforcement is often added between the patella and tibial tuberosity, using a semitendinosus band or wire.1 End-to-end suture is performed using a thick resorbable suture. It is important to avoid patella alta during suturing, comparing the position of the patella with the contralateral patella with the knee in 45° of flexion. In proximal avulsion, the tendon is anchored to the bone by 2 thick nonresorbable sutures through 2 parallel bone tunnels to the proximal pole of the patella. Distal avulsion is rare in adults, but it can be managed by using staples or suture anchors.1

 

 

End-to-end suturing of chronic patellar tendon defects is difficult more than 45 days after injury primarily because of difficulties in correcting patella alta secondary to the upward force exerted by the quadriceps tendon.1,3 Extreme situations similar to the case we present warrant Achilles or patellar tendon allograft for reconstruction of the extensor mechanism.1,3,6,9

Extensor mechanism allograft also provides an effective remedy for severe quadriceps deficiency caused by loss of the patella, patellar tendon, and quadriceps tendon in total knee arthroplasty.10 However, in such cases, late failure is common, and major quadriceps deficiency occurs after removal of the allograft material.10 To improve outcome, a novel technique using the medial gastrocnemius muscle transferred to the muscular portion of the vastus medialis and lateralis flaps provides a secure and strong closure of the anterior knee, thereby restoring the extensor mechanism of the knee.10

Patellar tendon reconstruction with allograft tissue has been successfully used, especially in cases related to chronic patellar tendon ruptures11 and total knee arthroplasty.6,12-14 Crossett and colleagues12 showed that, at 2-year follow-up, the average knee score for pain, ROM, and stability had improved from 26 points (range, 6-39 points) before surgery to 81 points (range, 40-92 points). The average knee score for function had also improved: 14 points (range, 0-35 points) before surgery to 53 points (range, 30-90 points).12 Primary repair may succeed in early intervention, but in an established rupture, allograft reconstruction is often necessary. Achilles tendon is the preferred allograft, with the calcaneus fragment embedded into the proximal tibia as a new tubercle and the tendon sutured into the remaining extensor mechanism.1,11 The repair is further protected using a cable loop from the superior pole of the patella to a drill hole in the upper tibia.9 Techniques have also been described involving passage of the proximal aspect of the allograft tendon through patellar bone tunnels and suture fixation to the native quadriceps tendon.11,15 However, in our technique, we shaved off the anterior cortex of the patient’s patella to allow a sandwich-type over-position of the allograft to secure fixation to the patella.

Another alternative to allograft reconstruction involves biocompatible scaffolds. Such scaffolds incorporate the use of platelets in a fibrin framework. A CPFS, produced from blood and calcium gluconate to improve healing of patellar tendon defects, has been described in animal studies.7 In the rabbit model, CPFS acts as a provisional bioscaffold that can accelerate healing of an injured patellar tendon repair, potentially secondary to several growth factors derived from platelets.7 Platelets are biocompatible sources of growth factors, and CPFS can act as a scaffold to restore the mechanical integrity of injured soft tissue.7,16 In addition, CPFS can act to lower donor-site morbidity associated with harvesting tissue autograft.7 However, to our knowledge, such scaffolds have not been used in human trials. The LARS biocompatible ligament (Corin Group PLC, Cirencester, United Kingdom), currently not approved by the US Food and Drug Administration, is used for reconstructions of isolated or multiple knee ligament injuries.17 This graft requires the presence of healthy tissue with good blood supply from which new tendon or ligament can grow in. Sometimes it is also used for extensor mechanism reconstruction after radical tumor resection around the knee; however, good results are achieved in only 59% of cases,18 and to our knowledge, only 1 case of primary repair of a patellar tendon rupture has been published.19

Techniques involving the use of tendon–patellar tendon–bone graft with fixation via the sandwich-type over-position of the allograft for chronic patellar tendon rupture have not been described in the literature. In our patient, given the extensive patellar tendon lesion and inflammation with chronic tissue degeneration, there was no option but to use allograft. To improve the patient’s outcome, we chose the strongest possible allograft, tendon–patellar tendon–bone graft.

Conclusion

Revision patellar tendon reconstruction is a challenging, but necessary, procedure to restore the extensor mechanism of the knee, especially in young, active individuals. Various options to reconstruct the tissue defects are available. Our patient was successfully treated with a tendon–patellar tendon–bone allograft reconstruction.

References

1.    Saragaglia D, Pison A, Rubens-Duval B. Acute and old ruptures of the extensor apparatus of the knee in adults (excluding knee replacement). Orthop Traumatol Surg Res. 2013;99(1 suppl):S67-S76.

2.    Tejwani NC, Lekic N, Bechtel C, Montero N, Egol KA. Outcomes after knee joint extensor mechanism disruptions: is it better to fracture the patella or rupture the tendon? J Orthop Trauma. 2012;26(11):648-651.

3.    Ecker ML, Lotke PA, Glazer RM. Late reconstruction of the patellar tendon. J Bone Joint Surg Am. 1979;61(6):884-886.

4.    Siwek CW, Rao JP. Ruptures of the extensor mechanism of the knee joint. J Bone Joint Surg Am. 1981;63(6):932-937.

5.    Levy M, Goldstein J, Rosner M. A method of repair for quadriceps tendon or patellar ligament (tendon) ruptures without cast immobilization. Preliminary report. Clin Orthop Relat Res. 1987;218:297-301.

6.    Burks RT, Edelson RH. Allograft reconstruction of the patellar ligament. A case report. J Bone Joint Surg Am. 1994;76(7):1077-1079.

7.    Matsunaga D, Akizuki S, Takizawa T, Omae S, Kato H. Compact platelet-rich fibrin scaffold to improve healing of patellar tendon defects and for medial collateral ligament reconstruction. Knee. 2013;20(6):545-550.

8.    Krackow KA, Thomas SC, Jones LC. Ligament-tendon fixation: analysis of a new stitch and comparison with standard techniques. Orthopedics. 1988;11(6):909-917.

9.    Brooks P. Extensor mechanism ruptures. Orthopedics. 2009;32(9):683-684.

10.  Whiteside LA. Surgical technique: muscle transfer restores extensor function after failed patella-patellar tendon allograft. Clin Orthop Relat Res. 2014;472(1):218-226.

11.  Farmer K, Cosgarea AJ. Procedure 25. Acute and chronic patellar tendon ruptures. In: Miller MD, Cole BJ, Cosgarea AJ, Sekiya JK, eds. Operative Techniques: Sports Knee Surgery. Philadelphia, PA: Saunders (Elsevier); 2008:397-417.

12.  Crossett LS, Sinha RK, Sechriest VF, Rubash HE. Reconstruction of a ruptured patellar tendon with achilles tendon allograft following total knee arthroplasty. J Bone Joint Surg Am. 2002;84(8):1354-1361.

13.  Lahav A, Burks RT, Scholl MD. Allograft reconstruction of the patellar tendon: 12-year follow-up. Am J Orthop. 2004;33(12):623-624.

14.  Yoo JH, Chang JD, Seo YJ, Baek SW. Reconstruction of a patellar tendon with Achilles tendon allograft for severe patellar infera--a case report. Knee. 2011;18(5):350-353.

15.  Saldua NS, Mazurek MT. Procedure 37. Quadriceps and patellar tendon repair. In: Reider B, Terry MA, Provencher MT, eds. Operative Techniques: Sports Medicine Surgery. Philadelphia, PA: Saunders (Elsevier); 2010:623-640.

16.  Anitua E, Andia I, Ardanza B, Nurden P, Nurden AT. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost. 2004;91(1):4-15.

17.  Ibrahim SAR, Ahmad FHF, Salah M, Al Misfer ARK, Ghaffer SA, Khirat S. Surgical management of traumatic knee dislocation. Arthroscopy. 2008;24(2):178-187.

18.  Dominkus M, Sabeti M, Toma C, Abdolvahab F, Trieb K, Kotz RI. Reconstructing the extensor apparatus with a new polyester ligament. Clin Orthop Relat Res. 2006;453:328-334.

19.  Naim S, Gougoulias N, Griffiths D. Patellar tendon reconstruction using LARS ligament: surgical technique and case report. Strategies Trauma Limb Reconstr. 2011;6(1):39-41.

References

1.    Saragaglia D, Pison A, Rubens-Duval B. Acute and old ruptures of the extensor apparatus of the knee in adults (excluding knee replacement). Orthop Traumatol Surg Res. 2013;99(1 suppl):S67-S76.

2.    Tejwani NC, Lekic N, Bechtel C, Montero N, Egol KA. Outcomes after knee joint extensor mechanism disruptions: is it better to fracture the patella or rupture the tendon? J Orthop Trauma. 2012;26(11):648-651.

3.    Ecker ML, Lotke PA, Glazer RM. Late reconstruction of the patellar tendon. J Bone Joint Surg Am. 1979;61(6):884-886.

4.    Siwek CW, Rao JP. Ruptures of the extensor mechanism of the knee joint. J Bone Joint Surg Am. 1981;63(6):932-937.

5.    Levy M, Goldstein J, Rosner M. A method of repair for quadriceps tendon or patellar ligament (tendon) ruptures without cast immobilization. Preliminary report. Clin Orthop Relat Res. 1987;218:297-301.

6.    Burks RT, Edelson RH. Allograft reconstruction of the patellar ligament. A case report. J Bone Joint Surg Am. 1994;76(7):1077-1079.

7.    Matsunaga D, Akizuki S, Takizawa T, Omae S, Kato H. Compact platelet-rich fibrin scaffold to improve healing of patellar tendon defects and for medial collateral ligament reconstruction. Knee. 2013;20(6):545-550.

8.    Krackow KA, Thomas SC, Jones LC. Ligament-tendon fixation: analysis of a new stitch and comparison with standard techniques. Orthopedics. 1988;11(6):909-917.

9.    Brooks P. Extensor mechanism ruptures. Orthopedics. 2009;32(9):683-684.

10.  Whiteside LA. Surgical technique: muscle transfer restores extensor function after failed patella-patellar tendon allograft. Clin Orthop Relat Res. 2014;472(1):218-226.

11.  Farmer K, Cosgarea AJ. Procedure 25. Acute and chronic patellar tendon ruptures. In: Miller MD, Cole BJ, Cosgarea AJ, Sekiya JK, eds. Operative Techniques: Sports Knee Surgery. Philadelphia, PA: Saunders (Elsevier); 2008:397-417.

12.  Crossett LS, Sinha RK, Sechriest VF, Rubash HE. Reconstruction of a ruptured patellar tendon with achilles tendon allograft following total knee arthroplasty. J Bone Joint Surg Am. 2002;84(8):1354-1361.

13.  Lahav A, Burks RT, Scholl MD. Allograft reconstruction of the patellar tendon: 12-year follow-up. Am J Orthop. 2004;33(12):623-624.

14.  Yoo JH, Chang JD, Seo YJ, Baek SW. Reconstruction of a patellar tendon with Achilles tendon allograft for severe patellar infera--a case report. Knee. 2011;18(5):350-353.

15.  Saldua NS, Mazurek MT. Procedure 37. Quadriceps and patellar tendon repair. In: Reider B, Terry MA, Provencher MT, eds. Operative Techniques: Sports Medicine Surgery. Philadelphia, PA: Saunders (Elsevier); 2010:623-640.

16.  Anitua E, Andia I, Ardanza B, Nurden P, Nurden AT. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost. 2004;91(1):4-15.

17.  Ibrahim SAR, Ahmad FHF, Salah M, Al Misfer ARK, Ghaffer SA, Khirat S. Surgical management of traumatic knee dislocation. Arthroscopy. 2008;24(2):178-187.

18.  Dominkus M, Sabeti M, Toma C, Abdolvahab F, Trieb K, Kotz RI. Reconstructing the extensor apparatus with a new polyester ligament. Clin Orthop Relat Res. 2006;453:328-334.

19.  Naim S, Gougoulias N, Griffiths D. Patellar tendon reconstruction using LARS ligament: surgical technique and case report. Strategies Trauma Limb Reconstr. 2011;6(1):39-41.

Issue
The American Journal of Orthopedics - 44(6)
Issue
The American Journal of Orthopedics - 44(6)
Page Number
E199-E201
Page Number
E199-E201
Publications
Publications
Topics
Article Type
Display Headline
Knee Extensor Mechanism Reconstruction With Complete Extensor Allograft After Failure of Patellar Tendon Repair
Display Headline
Knee Extensor Mechanism Reconstruction With Complete Extensor Allograft After Failure of Patellar Tendon Repair
Legacy Keywords
american journal of orthopedics, AJO, case report and literature review, case report, online exclusive, knee, mechanism, reconstruction, allograft, patellar, tendon, repair, limb, imaging, thakkar, hsu, hasenboehler
Legacy Keywords
american journal of orthopedics, AJO, case report and literature review, case report, online exclusive, knee, mechanism, reconstruction, allograft, patellar, tendon, repair, limb, imaging, thakkar, hsu, hasenboehler
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Intra-Articular Dislocation of the Patella With Associated Hoffa Fracture in a Skeletally Immature Patient

Article Type
Changed
Thu, 09/19/2019 - 13:34
Display Headline
Intra-Articular Dislocation of the Patella With Associated Hoffa Fracture in a Skeletally Immature Patient

In 1887, Midelfart1 first reported on an intra-articular dislocation of the patella, and since then approximately 50 cases have been reported in the worldwide literature.2 Also known as an inferior patellar dislocation, these rare traumatic events occur when the patella dislocates intra-articularly. Because the patella commonly rotates about its horizontal axis, the articular surface is facing proximally or distally. The patella becomes lodged within the trochlea and locks the knee joint. Most cases described in the literature involved adolescent boys, with the patella difficult to reduce. Most patients required open reduction, while those who underwent successful closed reduction often needed general anesthesia.3

Similarly, coronal shear fractures of the femoral condyle (ie, Hoffa fractures) are an uncommon fracture pattern typically seen in adults. These fractures are even more infrequent in skeletally immature patients, with fewer than 5 cases documented in the literature.4-7 In our case report, we present a 14-year-old boy with a coronal shear fracture of the femoral condyle associated with an intra-articular patellar dislocation. To our knowledge, this constellation of injuries has not been reported. Additionally, closed reduction of the patella was successful after intra-articular lidocaine injection, without the need for sedation or general anesthesia. The patient’s guardian provided written informed consent for print and electronic publication of this case report.

Case Report

A 14-year-old boy presented to our institution after sustaining a direct blow to his left knee. The injury occurred as he jumped and landed on a flexed knee while playing with friends. The patient was unable to ambulate after the injury, and his left knee was locked in a slightly flexed position. Examination in the emergency department showed the knee to be held in approximately 60º of flexion, with an obvious bony prominence noted anteriorly over the femoral condyles. The patient was unable to perform a straight leg raise or any active range of motion (ROM) at the knee. Radiographs performed with the knee maintained in flexion confirmed that the patella was displaced into the knee joint and was rotated with the articular surface facing distally. Also noted was a coronal shear fracture of the lateral femoral condyle (Figures 1A, 1B).

The patient received pain medication and an intra-articular lidocaine injection prior to a reduction attempt by the orthopedic resident. With the patient supine, the hip was gently flexed to relax the quadriceps muscle. As the knee was flexed up to 110º, the prominent patella was gripped between the thumb and fingers to gently free and elevate the patella out of the intercondylar notch.

After reduction, an immediate return of normal patellar contour and patellofemoral tracking was observed as the knee was gently extended. There was no obvious defect to the patellar or quadriceps tendons, and the patient was able to perform a straight-leg raise, confirming the integrity of the extensor mechanism. Radiographs performed after the reduction confirmed relocation of the patella in correct anatomic position, as well as a lateral femoral condyle fracture (Figures 2A, 2B). Magnetic resonance imaging (MRI) of the knee confirmed no full-thickness quadriceps or patellar tendon tear. A computed tomography (CT) scan of the knee showed a comminuted fracture of the lateral femoral condyle in the coronal plane, as well as multiple bone fragments within the joint (Figures 3A, 3B). The patient was placed in a bulky soft dressing and underwent open reduction and internal fixation of the fracture.

 

A 10-cm incision was made over the anterior aspect of the knee, and after dissection to the level of the retinaculum, a lateral parapatellar arthrotomy was performed. The patella was retracted medially to identify and free the fracture fragments. The fracture fragments were provisionally reduced and stabilized with three 0.065-in Kirschner wires. An area of osteochondral impaction proximal to the fracture was elevated and allograft bone was incorporated below the articular surface (Figures 4A, 4B). Rigid fixation of the fracture was achieved using 3 screws (2 Bio-Compression Screws [Arthrex Inc., Naples, Florida] and 1 Synthes cannulated screw [Synthes, West Chester, Pennsylvania]). The screws were placed in posteroanterior (PA) direction and inserted into the weight-bearing articular surface of the femoral condyle (Figures 4C, 4D). The screws were countersunk, and stable fixation with compression of the fracture was achieved. Reduction and screw position were verified with fluoroscopic views. The wound was closed in layers, and the patient was discharged home the next day.

Postoperatively, the patient was non-weight-bearing on the affected limb with a hinged-knee brace to allow for knee ROM exercises immediately. He was also given a continuous passive motion device to maintain knee motion. At the 6-week mark, the patient’s fracture alignment appeared to be well-maintained and showed interval healing. Clinically, the patient was noted to have limited knee ROM. The decision was made to take the patient to the operating room primarily for a manipulation under anesthesia and resection of scar tissue from postoperative arthrofibrosis. Arthroscopic screw removal was also planned as a secondary procedure at the same time in order to prevent the possibility of chondral injury from screw migration. During the procedure, the patient was noted to have improved ROM from 5º to 85º premanipulation to 5º to 110º postoperatively. At 3 months after the initial injury, the patient was allowed to begin progressive weight-bearing on the left knee. At most recent follow-up, after 12 months, the patient was able to ambulate and bear weight on the left leg without pain. Plain radiographs show a well-healed fracture with no evidence of collapse of the femoral condyle (Figures 5A, 5B). His active ROM of the left knee was 5º to 110º without pain (Figures 5C, 5D).

 

 

Discussion

In the vast majority of patellar dislocations, the patella dislocates laterally over the trochlear groove. Inferior, or intra-articular, dislocations of the patella are rare. The mechanism of injury is usually a blow onto the patella with a flexed knee. The 2 groups commonly involved are adolescent boys and the elderly.8,9 In young men, it is thought that lax patellar attachments place adolescents at higher risk for this type of injury.10-12 While patella fractures and frank extensor mechanism ruptures are uncommon in this age group, the same mechanism of injury can lead to stripping of the deep fibers of the patellar tendon from the superior pole of the patella.3,13 The intact superficial fibers of the tendon allow the patella to hinge and displace into the joint.14

Inferior dislocations of the patella are classified into 2 types based on the orientation of the articular surface and the presence of osteophytes.15 Type I inferior dislocations occur after a direct blow to a flexed knee forces the superior pole of the patella into the intercondylar notch. Type II dislocations are caused by osteophytes on the superior pole of the patella that become wedged in the intercondylar notch and dislocate the patella inferiorly. In type I dislocations, the patella is rotated in the horizontal plane and the articular surface often faces inferiorly, but type II dislocations do not involve rotation of the articular surface. Type II injuries are seen more commonly in the elderly.

Our patient was able to tolerate a closed reduction of the patella after an intra-articular lidocaine injection, and a successful reduction was achieved without great difficulty. However, the majority of reports describe the need for an open reduction of inferior patellar dislocations.3,8 When closed reductions were a success, they were performed under general anesthesia or conscious sedation.3 It is thought that the difficulty of reduction results from the tension of the quadriceps muscle pulling the patella superiorly into intercondylar notch.11,16 However, successful closed reduction may be more likely in patients with less patellar rotation and entrapment within the intercondylar notch, as well as in patients whose knee is near full extension at presentation.17-19 Successful closed reduction is also seen in elderly patients, where dislocation is generally caused by less forceful impact and held by osteophytes. In these patients, the knee is commonly held in extension.12,15,20-22

The fracture pattern seen in this case also shows a rare fracture in skeletally immature patients, with only a few case reports in the literature. Isolated coronal plane femur fractures account for 0.65% of all femur fractures and are usually seen in adults after high-energy trauma.23 In the skeletally immature, the fracture can occur with lower-energy mechanisms. The typical mechanism is thought to be a shearing force to the femur caused by an axial load to the knee in 90° or more of flexion.4,24 A CT scan is recommended for better identification of the fracture and to plan treatment.25,26 Because of their intra-articular nature and tenuous blood supply, Hoffa fractures tend to do poorly with nonoperative treatment and are prone to displacement and nonunion.27,28 The goal of operative treatment is to obtain anatomic reduction and rigid fixation. While operative fixation techniques are varied, screw fixation with multiple smaller diameter screws has equal pullout strength compared to larger screws and may minimize damage to the articular cartilage.29-31 By preserving blood supply to the fracture, and allowing for early active mobilization, operative treatment generally provides good long-term functional outcomes in these fracture patterns.24

Conclusion

We describe a case in which the patella of an adolescent boy dislocated inferiorly into the knee joint, with an associated coronal shear fracture of the lateral femoral condyle. To our knowledge, this constellation of injuries has not been reported. For this uncommon injury pattern, we recommend a sequential treatment algorithm to minimize morbidity. We recommend first attempting a closed reduction of the patella with adequate pain control to avoid the morbidity associated with general anesthesia. After a successful reduction, an advanced imaging study (eg, MRI) is advisable to assess for concomitant soft-tissue injuries and preoperative planning, if necessary. The mechanism of injury and force required to cause a patellar dislocation of this nature leaves a high likelihood of other injuries. When a fracture is noted on plain radiographs after reduction, a CT scan can provide important information for planning surgical fixation of the fracture. Even in a skeletally immature patient, the principle of direct reduction and stable interfragmentary fixation of an articular fracture is critical for long-term function, even after a significant trauma to the knee.

References

1.    Midelfart V. En sjelden luxation of patella. Norsk Magazin for Laegevidenskaben. 1887;4:588.

2.    Kramer DE, Simoni MK. Horizontal intra-articular patellar dislocation resulting in quadriceps avulsion and medial patellofemoral ligament tear: a case report. J Pediatr Orthop B. 2013;22(4):329-332.

3.    van den Broek TA, Moll PJ. Horizontal rotation of the patella. A case report with review of the literature. Acta Orthop Scand. 1985;56(5):436-438.

4.    Flanagin BA, Cruz AI, Medvecky MJ. Hoffa fracture in a 14-year-old. Orthopedics. 2011;34(2):138.

5.    Strauss E, Nelson JM, Abdelwahab IF. Fracture of the lateral femoral condyle. A case report. Bull Hosp Jt Dis Orthop Inst. 1984;44(1):86-90.

6.    Biau DJ, Schranz PJ. Transverse Hoffa’s or deep osteochondral fracture? An unusual fracture of the lateral femoral condyle in a child. Injury. 2005;36(7):862-865.

7.    McDonough PW, Bernstein RM. Nonunion of a Hoffa fracture in a child. J Orthop Trauma. 2000;14(7):519-521.

8.    Brady TA, Russell D. Interarticular horizontal dislocation of the patella. A case report. J Bone Joint Surg Am. 1965;47(7):1393-1396.

9.    Yuguero M, Gonzalez JA, Carma A, Huguet J. Intra-articular patellar dislocation. Orthopedics. 2003;26(5):517-518.

10.  Frangakis EK. Intra-articular dislocation of the patella. A case report. J Bone Joint Surg Am. 1974;56(2):423-424.

11.  Nanda R, Yadav RS, Thakur M. Intra-articular dislocation of the patella. J Trauma. 2000;48(1):159-160.

12.  Choudhary RK, Tice JW. Intra-articular dislocation of the patella with incomplete rotation--two case reports and a review of the literature. Knee. 2004;11(2):125-127.

13.  Chatziantoniou I, Diakos G, Pantelelli M. Horizontal dislocation of the patella. Case report. EEXOT. 2008;59(2):112-114.

14.  McHugh G, Ryan E, Cleary M, Kenny P, O’Flanagan S, Keogh P. Intra-articular dislocation of the patella. Case Rep Orthop. 2013;2013:535803.

15.  Bankes MJ, Eastwood DM. Inferior dislocation of the patella in the degenerate knee. Injury. 2002;33(6):528-529.

16.  Theodorides A, Guo S, Case R. Intra-articular dislocation of the patella: A case report and review of the literature. Injury Extra. 2010;41(10):103-105.

17.  Dimentberg RA. Intra-articular dislocation of the patella: case report and literature review. Clin J Sport Med. 1997;7(2):126-128.

18.  Morin WD, Steadman JR. Case report of a successful closed reduction without anesthesia. Clin Orthop. 1993(297):179-181.

19.  Murakami Y. Intra-articular dislocation of the patella. A case report. Clin Orthop. 1982;171:137-139.

20.  Joshi RP. Inferior dislocation of the patella. Injury. 1997;28(5-6):389-390.

21.  Garner JP, Pike JM, George CD. Intra-articular dislocation of the patella: two cases and literature review. J Trauma. 1999;47(4):780-783.

22.  McCarthy TA, Quinn B, Pegum JM. Inferior dislocation of the patella: an unusual cause of a locked knee. Ir J Med Sci. 2001;170(3):209-210.

23.  Manfredini M, Gildone A, Ferrante R, Bernasconi S, Massari L. Unicondylar femoral fractures: therapeutic strategy and long-term results. A review of 23 patients. Acta Orthop Belg. 2001;67(2):132-138.

24.  Holmes SM, Bomback D, Baumgaertner MR. Coronal fractures of the femoral condyle: a brief report of five cases. J Orthop Trauma. 2004;18(5):316-319.

25.  Nork SE, Segina DN, Aflatoon K, et al. The association between supracondylar-intercondylar distal femoral fractures and coronal plane fractures. J Bone Joint Surg Am. 2005;87(3):564-569.

26.  Allmann KH, Altehoefer C, Wildanger G, et al. Hoffa fracture--a radiologic diagnostic approach. J Belge Radiol. 1996;79(5):201-202.

27.  Oztürk A, Ozkan Y, Ozdemir RM. Nonunion of a Hoffa fracture in an adult. Chir Organi Mov. 2009;93(3):183-185.

28.  Lewis SL, Pozo JL, Muirhead-Allwood WF. Coronal fractures of the lateral femoral condyle. J Bone Joint Surg Br. 1989;71(1):118-120.

29.  Arastu MH, Kokke MC, Duffy PJ, Korley RE, Buckley RE. Coronal plane partial articular fractures of the distal femoral condyle: current concepts in management. Bone Joint J. 2013;95-B(9):1165-1171.

30.  Westmoreland GL, McLaurin TM, Hutton WC. Screw pullout strength: a biomechanical comparison of large-fragment and small-fragment fixation in the tibial plateau. J Orthop Trauma. 2002;16(3):178-181.

31.  Jarit GJ, Kummer FJ, Gibber MJ, Egol KA. A mechanical evaluation of two fixation methods using cancellous screws for coronal fractures of the lateral condyle of the distal femur (OTA type 33B). J Orthop Trauma. 2006;20(4):273-276.

Article PDF
Author and Disclosure Information

Vishnu C. Potini, MD, and Robin M. Gehrmann, MD

Authors’ Disclosure Statement: The authors report no actual or potential conflict of interest in relation to this article.

Issue
The American Journal of Orthopedics - 44(6)
Publications
Topics
Page Number
E195-E198
Legacy Keywords
american journal of orthopedics, AJO, case report and literature review, case report, online exclusive, intra-articular, dislocation, patella, knee, hoffa fracture, fracture, fracture management, trauma, joint, potini, gehrmann
Sections
Author and Disclosure Information

Vishnu C. Potini, MD, and Robin M. Gehrmann, MD

Authors’ Disclosure Statement: The authors report no actual or potential conflict of interest in relation to this article.

Author and Disclosure Information

Vishnu C. Potini, MD, and Robin M. Gehrmann, MD

Authors’ Disclosure Statement: The authors report no actual or potential conflict of interest in relation to this article.

Article PDF
Article PDF

In 1887, Midelfart1 first reported on an intra-articular dislocation of the patella, and since then approximately 50 cases have been reported in the worldwide literature.2 Also known as an inferior patellar dislocation, these rare traumatic events occur when the patella dislocates intra-articularly. Because the patella commonly rotates about its horizontal axis, the articular surface is facing proximally or distally. The patella becomes lodged within the trochlea and locks the knee joint. Most cases described in the literature involved adolescent boys, with the patella difficult to reduce. Most patients required open reduction, while those who underwent successful closed reduction often needed general anesthesia.3

Similarly, coronal shear fractures of the femoral condyle (ie, Hoffa fractures) are an uncommon fracture pattern typically seen in adults. These fractures are even more infrequent in skeletally immature patients, with fewer than 5 cases documented in the literature.4-7 In our case report, we present a 14-year-old boy with a coronal shear fracture of the femoral condyle associated with an intra-articular patellar dislocation. To our knowledge, this constellation of injuries has not been reported. Additionally, closed reduction of the patella was successful after intra-articular lidocaine injection, without the need for sedation or general anesthesia. The patient’s guardian provided written informed consent for print and electronic publication of this case report.

Case Report

A 14-year-old boy presented to our institution after sustaining a direct blow to his left knee. The injury occurred as he jumped and landed on a flexed knee while playing with friends. The patient was unable to ambulate after the injury, and his left knee was locked in a slightly flexed position. Examination in the emergency department showed the knee to be held in approximately 60º of flexion, with an obvious bony prominence noted anteriorly over the femoral condyles. The patient was unable to perform a straight leg raise or any active range of motion (ROM) at the knee. Radiographs performed with the knee maintained in flexion confirmed that the patella was displaced into the knee joint and was rotated with the articular surface facing distally. Also noted was a coronal shear fracture of the lateral femoral condyle (Figures 1A, 1B).

The patient received pain medication and an intra-articular lidocaine injection prior to a reduction attempt by the orthopedic resident. With the patient supine, the hip was gently flexed to relax the quadriceps muscle. As the knee was flexed up to 110º, the prominent patella was gripped between the thumb and fingers to gently free and elevate the patella out of the intercondylar notch.

After reduction, an immediate return of normal patellar contour and patellofemoral tracking was observed as the knee was gently extended. There was no obvious defect to the patellar or quadriceps tendons, and the patient was able to perform a straight-leg raise, confirming the integrity of the extensor mechanism. Radiographs performed after the reduction confirmed relocation of the patella in correct anatomic position, as well as a lateral femoral condyle fracture (Figures 2A, 2B). Magnetic resonance imaging (MRI) of the knee confirmed no full-thickness quadriceps or patellar tendon tear. A computed tomography (CT) scan of the knee showed a comminuted fracture of the lateral femoral condyle in the coronal plane, as well as multiple bone fragments within the joint (Figures 3A, 3B). The patient was placed in a bulky soft dressing and underwent open reduction and internal fixation of the fracture.

 

A 10-cm incision was made over the anterior aspect of the knee, and after dissection to the level of the retinaculum, a lateral parapatellar arthrotomy was performed. The patella was retracted medially to identify and free the fracture fragments. The fracture fragments were provisionally reduced and stabilized with three 0.065-in Kirschner wires. An area of osteochondral impaction proximal to the fracture was elevated and allograft bone was incorporated below the articular surface (Figures 4A, 4B). Rigid fixation of the fracture was achieved using 3 screws (2 Bio-Compression Screws [Arthrex Inc., Naples, Florida] and 1 Synthes cannulated screw [Synthes, West Chester, Pennsylvania]). The screws were placed in posteroanterior (PA) direction and inserted into the weight-bearing articular surface of the femoral condyle (Figures 4C, 4D). The screws were countersunk, and stable fixation with compression of the fracture was achieved. Reduction and screw position were verified with fluoroscopic views. The wound was closed in layers, and the patient was discharged home the next day.

Postoperatively, the patient was non-weight-bearing on the affected limb with a hinged-knee brace to allow for knee ROM exercises immediately. He was also given a continuous passive motion device to maintain knee motion. At the 6-week mark, the patient’s fracture alignment appeared to be well-maintained and showed interval healing. Clinically, the patient was noted to have limited knee ROM. The decision was made to take the patient to the operating room primarily for a manipulation under anesthesia and resection of scar tissue from postoperative arthrofibrosis. Arthroscopic screw removal was also planned as a secondary procedure at the same time in order to prevent the possibility of chondral injury from screw migration. During the procedure, the patient was noted to have improved ROM from 5º to 85º premanipulation to 5º to 110º postoperatively. At 3 months after the initial injury, the patient was allowed to begin progressive weight-bearing on the left knee. At most recent follow-up, after 12 months, the patient was able to ambulate and bear weight on the left leg without pain. Plain radiographs show a well-healed fracture with no evidence of collapse of the femoral condyle (Figures 5A, 5B). His active ROM of the left knee was 5º to 110º without pain (Figures 5C, 5D).

 

 

Discussion

In the vast majority of patellar dislocations, the patella dislocates laterally over the trochlear groove. Inferior, or intra-articular, dislocations of the patella are rare. The mechanism of injury is usually a blow onto the patella with a flexed knee. The 2 groups commonly involved are adolescent boys and the elderly.8,9 In young men, it is thought that lax patellar attachments place adolescents at higher risk for this type of injury.10-12 While patella fractures and frank extensor mechanism ruptures are uncommon in this age group, the same mechanism of injury can lead to stripping of the deep fibers of the patellar tendon from the superior pole of the patella.3,13 The intact superficial fibers of the tendon allow the patella to hinge and displace into the joint.14

Inferior dislocations of the patella are classified into 2 types based on the orientation of the articular surface and the presence of osteophytes.15 Type I inferior dislocations occur after a direct blow to a flexed knee forces the superior pole of the patella into the intercondylar notch. Type II dislocations are caused by osteophytes on the superior pole of the patella that become wedged in the intercondylar notch and dislocate the patella inferiorly. In type I dislocations, the patella is rotated in the horizontal plane and the articular surface often faces inferiorly, but type II dislocations do not involve rotation of the articular surface. Type II injuries are seen more commonly in the elderly.

Our patient was able to tolerate a closed reduction of the patella after an intra-articular lidocaine injection, and a successful reduction was achieved without great difficulty. However, the majority of reports describe the need for an open reduction of inferior patellar dislocations.3,8 When closed reductions were a success, they were performed under general anesthesia or conscious sedation.3 It is thought that the difficulty of reduction results from the tension of the quadriceps muscle pulling the patella superiorly into intercondylar notch.11,16 However, successful closed reduction may be more likely in patients with less patellar rotation and entrapment within the intercondylar notch, as well as in patients whose knee is near full extension at presentation.17-19 Successful closed reduction is also seen in elderly patients, where dislocation is generally caused by less forceful impact and held by osteophytes. In these patients, the knee is commonly held in extension.12,15,20-22

The fracture pattern seen in this case also shows a rare fracture in skeletally immature patients, with only a few case reports in the literature. Isolated coronal plane femur fractures account for 0.65% of all femur fractures and are usually seen in adults after high-energy trauma.23 In the skeletally immature, the fracture can occur with lower-energy mechanisms. The typical mechanism is thought to be a shearing force to the femur caused by an axial load to the knee in 90° or more of flexion.4,24 A CT scan is recommended for better identification of the fracture and to plan treatment.25,26 Because of their intra-articular nature and tenuous blood supply, Hoffa fractures tend to do poorly with nonoperative treatment and are prone to displacement and nonunion.27,28 The goal of operative treatment is to obtain anatomic reduction and rigid fixation. While operative fixation techniques are varied, screw fixation with multiple smaller diameter screws has equal pullout strength compared to larger screws and may minimize damage to the articular cartilage.29-31 By preserving blood supply to the fracture, and allowing for early active mobilization, operative treatment generally provides good long-term functional outcomes in these fracture patterns.24

Conclusion

We describe a case in which the patella of an adolescent boy dislocated inferiorly into the knee joint, with an associated coronal shear fracture of the lateral femoral condyle. To our knowledge, this constellation of injuries has not been reported. For this uncommon injury pattern, we recommend a sequential treatment algorithm to minimize morbidity. We recommend first attempting a closed reduction of the patella with adequate pain control to avoid the morbidity associated with general anesthesia. After a successful reduction, an advanced imaging study (eg, MRI) is advisable to assess for concomitant soft-tissue injuries and preoperative planning, if necessary. The mechanism of injury and force required to cause a patellar dislocation of this nature leaves a high likelihood of other injuries. When a fracture is noted on plain radiographs after reduction, a CT scan can provide important information for planning surgical fixation of the fracture. Even in a skeletally immature patient, the principle of direct reduction and stable interfragmentary fixation of an articular fracture is critical for long-term function, even after a significant trauma to the knee.

In 1887, Midelfart1 first reported on an intra-articular dislocation of the patella, and since then approximately 50 cases have been reported in the worldwide literature.2 Also known as an inferior patellar dislocation, these rare traumatic events occur when the patella dislocates intra-articularly. Because the patella commonly rotates about its horizontal axis, the articular surface is facing proximally or distally. The patella becomes lodged within the trochlea and locks the knee joint. Most cases described in the literature involved adolescent boys, with the patella difficult to reduce. Most patients required open reduction, while those who underwent successful closed reduction often needed general anesthesia.3

Similarly, coronal shear fractures of the femoral condyle (ie, Hoffa fractures) are an uncommon fracture pattern typically seen in adults. These fractures are even more infrequent in skeletally immature patients, with fewer than 5 cases documented in the literature.4-7 In our case report, we present a 14-year-old boy with a coronal shear fracture of the femoral condyle associated with an intra-articular patellar dislocation. To our knowledge, this constellation of injuries has not been reported. Additionally, closed reduction of the patella was successful after intra-articular lidocaine injection, without the need for sedation or general anesthesia. The patient’s guardian provided written informed consent for print and electronic publication of this case report.

Case Report

A 14-year-old boy presented to our institution after sustaining a direct blow to his left knee. The injury occurred as he jumped and landed on a flexed knee while playing with friends. The patient was unable to ambulate after the injury, and his left knee was locked in a slightly flexed position. Examination in the emergency department showed the knee to be held in approximately 60º of flexion, with an obvious bony prominence noted anteriorly over the femoral condyles. The patient was unable to perform a straight leg raise or any active range of motion (ROM) at the knee. Radiographs performed with the knee maintained in flexion confirmed that the patella was displaced into the knee joint and was rotated with the articular surface facing distally. Also noted was a coronal shear fracture of the lateral femoral condyle (Figures 1A, 1B).

The patient received pain medication and an intra-articular lidocaine injection prior to a reduction attempt by the orthopedic resident. With the patient supine, the hip was gently flexed to relax the quadriceps muscle. As the knee was flexed up to 110º, the prominent patella was gripped between the thumb and fingers to gently free and elevate the patella out of the intercondylar notch.

After reduction, an immediate return of normal patellar contour and patellofemoral tracking was observed as the knee was gently extended. There was no obvious defect to the patellar or quadriceps tendons, and the patient was able to perform a straight-leg raise, confirming the integrity of the extensor mechanism. Radiographs performed after the reduction confirmed relocation of the patella in correct anatomic position, as well as a lateral femoral condyle fracture (Figures 2A, 2B). Magnetic resonance imaging (MRI) of the knee confirmed no full-thickness quadriceps or patellar tendon tear. A computed tomography (CT) scan of the knee showed a comminuted fracture of the lateral femoral condyle in the coronal plane, as well as multiple bone fragments within the joint (Figures 3A, 3B). The patient was placed in a bulky soft dressing and underwent open reduction and internal fixation of the fracture.

 

A 10-cm incision was made over the anterior aspect of the knee, and after dissection to the level of the retinaculum, a lateral parapatellar arthrotomy was performed. The patella was retracted medially to identify and free the fracture fragments. The fracture fragments were provisionally reduced and stabilized with three 0.065-in Kirschner wires. An area of osteochondral impaction proximal to the fracture was elevated and allograft bone was incorporated below the articular surface (Figures 4A, 4B). Rigid fixation of the fracture was achieved using 3 screws (2 Bio-Compression Screws [Arthrex Inc., Naples, Florida] and 1 Synthes cannulated screw [Synthes, West Chester, Pennsylvania]). The screws were placed in posteroanterior (PA) direction and inserted into the weight-bearing articular surface of the femoral condyle (Figures 4C, 4D). The screws were countersunk, and stable fixation with compression of the fracture was achieved. Reduction and screw position were verified with fluoroscopic views. The wound was closed in layers, and the patient was discharged home the next day.

Postoperatively, the patient was non-weight-bearing on the affected limb with a hinged-knee brace to allow for knee ROM exercises immediately. He was also given a continuous passive motion device to maintain knee motion. At the 6-week mark, the patient’s fracture alignment appeared to be well-maintained and showed interval healing. Clinically, the patient was noted to have limited knee ROM. The decision was made to take the patient to the operating room primarily for a manipulation under anesthesia and resection of scar tissue from postoperative arthrofibrosis. Arthroscopic screw removal was also planned as a secondary procedure at the same time in order to prevent the possibility of chondral injury from screw migration. During the procedure, the patient was noted to have improved ROM from 5º to 85º premanipulation to 5º to 110º postoperatively. At 3 months after the initial injury, the patient was allowed to begin progressive weight-bearing on the left knee. At most recent follow-up, after 12 months, the patient was able to ambulate and bear weight on the left leg without pain. Plain radiographs show a well-healed fracture with no evidence of collapse of the femoral condyle (Figures 5A, 5B). His active ROM of the left knee was 5º to 110º without pain (Figures 5C, 5D).

 

 

Discussion

In the vast majority of patellar dislocations, the patella dislocates laterally over the trochlear groove. Inferior, or intra-articular, dislocations of the patella are rare. The mechanism of injury is usually a blow onto the patella with a flexed knee. The 2 groups commonly involved are adolescent boys and the elderly.8,9 In young men, it is thought that lax patellar attachments place adolescents at higher risk for this type of injury.10-12 While patella fractures and frank extensor mechanism ruptures are uncommon in this age group, the same mechanism of injury can lead to stripping of the deep fibers of the patellar tendon from the superior pole of the patella.3,13 The intact superficial fibers of the tendon allow the patella to hinge and displace into the joint.14

Inferior dislocations of the patella are classified into 2 types based on the orientation of the articular surface and the presence of osteophytes.15 Type I inferior dislocations occur after a direct blow to a flexed knee forces the superior pole of the patella into the intercondylar notch. Type II dislocations are caused by osteophytes on the superior pole of the patella that become wedged in the intercondylar notch and dislocate the patella inferiorly. In type I dislocations, the patella is rotated in the horizontal plane and the articular surface often faces inferiorly, but type II dislocations do not involve rotation of the articular surface. Type II injuries are seen more commonly in the elderly.

Our patient was able to tolerate a closed reduction of the patella after an intra-articular lidocaine injection, and a successful reduction was achieved without great difficulty. However, the majority of reports describe the need for an open reduction of inferior patellar dislocations.3,8 When closed reductions were a success, they were performed under general anesthesia or conscious sedation.3 It is thought that the difficulty of reduction results from the tension of the quadriceps muscle pulling the patella superiorly into intercondylar notch.11,16 However, successful closed reduction may be more likely in patients with less patellar rotation and entrapment within the intercondylar notch, as well as in patients whose knee is near full extension at presentation.17-19 Successful closed reduction is also seen in elderly patients, where dislocation is generally caused by less forceful impact and held by osteophytes. In these patients, the knee is commonly held in extension.12,15,20-22

The fracture pattern seen in this case also shows a rare fracture in skeletally immature patients, with only a few case reports in the literature. Isolated coronal plane femur fractures account for 0.65% of all femur fractures and are usually seen in adults after high-energy trauma.23 In the skeletally immature, the fracture can occur with lower-energy mechanisms. The typical mechanism is thought to be a shearing force to the femur caused by an axial load to the knee in 90° or more of flexion.4,24 A CT scan is recommended for better identification of the fracture and to plan treatment.25,26 Because of their intra-articular nature and tenuous blood supply, Hoffa fractures tend to do poorly with nonoperative treatment and are prone to displacement and nonunion.27,28 The goal of operative treatment is to obtain anatomic reduction and rigid fixation. While operative fixation techniques are varied, screw fixation with multiple smaller diameter screws has equal pullout strength compared to larger screws and may minimize damage to the articular cartilage.29-31 By preserving blood supply to the fracture, and allowing for early active mobilization, operative treatment generally provides good long-term functional outcomes in these fracture patterns.24

Conclusion

We describe a case in which the patella of an adolescent boy dislocated inferiorly into the knee joint, with an associated coronal shear fracture of the lateral femoral condyle. To our knowledge, this constellation of injuries has not been reported. For this uncommon injury pattern, we recommend a sequential treatment algorithm to minimize morbidity. We recommend first attempting a closed reduction of the patella with adequate pain control to avoid the morbidity associated with general anesthesia. After a successful reduction, an advanced imaging study (eg, MRI) is advisable to assess for concomitant soft-tissue injuries and preoperative planning, if necessary. The mechanism of injury and force required to cause a patellar dislocation of this nature leaves a high likelihood of other injuries. When a fracture is noted on plain radiographs after reduction, a CT scan can provide important information for planning surgical fixation of the fracture. Even in a skeletally immature patient, the principle of direct reduction and stable interfragmentary fixation of an articular fracture is critical for long-term function, even after a significant trauma to the knee.

References

1.    Midelfart V. En sjelden luxation of patella. Norsk Magazin for Laegevidenskaben. 1887;4:588.

2.    Kramer DE, Simoni MK. Horizontal intra-articular patellar dislocation resulting in quadriceps avulsion and medial patellofemoral ligament tear: a case report. J Pediatr Orthop B. 2013;22(4):329-332.

3.    van den Broek TA, Moll PJ. Horizontal rotation of the patella. A case report with review of the literature. Acta Orthop Scand. 1985;56(5):436-438.

4.    Flanagin BA, Cruz AI, Medvecky MJ. Hoffa fracture in a 14-year-old. Orthopedics. 2011;34(2):138.

5.    Strauss E, Nelson JM, Abdelwahab IF. Fracture of the lateral femoral condyle. A case report. Bull Hosp Jt Dis Orthop Inst. 1984;44(1):86-90.

6.    Biau DJ, Schranz PJ. Transverse Hoffa’s or deep osteochondral fracture? An unusual fracture of the lateral femoral condyle in a child. Injury. 2005;36(7):862-865.

7.    McDonough PW, Bernstein RM. Nonunion of a Hoffa fracture in a child. J Orthop Trauma. 2000;14(7):519-521.

8.    Brady TA, Russell D. Interarticular horizontal dislocation of the patella. A case report. J Bone Joint Surg Am. 1965;47(7):1393-1396.

9.    Yuguero M, Gonzalez JA, Carma A, Huguet J. Intra-articular patellar dislocation. Orthopedics. 2003;26(5):517-518.

10.  Frangakis EK. Intra-articular dislocation of the patella. A case report. J Bone Joint Surg Am. 1974;56(2):423-424.

11.  Nanda R, Yadav RS, Thakur M. Intra-articular dislocation of the patella. J Trauma. 2000;48(1):159-160.

12.  Choudhary RK, Tice JW. Intra-articular dislocation of the patella with incomplete rotation--two case reports and a review of the literature. Knee. 2004;11(2):125-127.

13.  Chatziantoniou I, Diakos G, Pantelelli M. Horizontal dislocation of the patella. Case report. EEXOT. 2008;59(2):112-114.

14.  McHugh G, Ryan E, Cleary M, Kenny P, O’Flanagan S, Keogh P. Intra-articular dislocation of the patella. Case Rep Orthop. 2013;2013:535803.

15.  Bankes MJ, Eastwood DM. Inferior dislocation of the patella in the degenerate knee. Injury. 2002;33(6):528-529.

16.  Theodorides A, Guo S, Case R. Intra-articular dislocation of the patella: A case report and review of the literature. Injury Extra. 2010;41(10):103-105.

17.  Dimentberg RA. Intra-articular dislocation of the patella: case report and literature review. Clin J Sport Med. 1997;7(2):126-128.

18.  Morin WD, Steadman JR. Case report of a successful closed reduction without anesthesia. Clin Orthop. 1993(297):179-181.

19.  Murakami Y. Intra-articular dislocation of the patella. A case report. Clin Orthop. 1982;171:137-139.

20.  Joshi RP. Inferior dislocation of the patella. Injury. 1997;28(5-6):389-390.

21.  Garner JP, Pike JM, George CD. Intra-articular dislocation of the patella: two cases and literature review. J Trauma. 1999;47(4):780-783.

22.  McCarthy TA, Quinn B, Pegum JM. Inferior dislocation of the patella: an unusual cause of a locked knee. Ir J Med Sci. 2001;170(3):209-210.

23.  Manfredini M, Gildone A, Ferrante R, Bernasconi S, Massari L. Unicondylar femoral fractures: therapeutic strategy and long-term results. A review of 23 patients. Acta Orthop Belg. 2001;67(2):132-138.

24.  Holmes SM, Bomback D, Baumgaertner MR. Coronal fractures of the femoral condyle: a brief report of five cases. J Orthop Trauma. 2004;18(5):316-319.

25.  Nork SE, Segina DN, Aflatoon K, et al. The association between supracondylar-intercondylar distal femoral fractures and coronal plane fractures. J Bone Joint Surg Am. 2005;87(3):564-569.

26.  Allmann KH, Altehoefer C, Wildanger G, et al. Hoffa fracture--a radiologic diagnostic approach. J Belge Radiol. 1996;79(5):201-202.

27.  Oztürk A, Ozkan Y, Ozdemir RM. Nonunion of a Hoffa fracture in an adult. Chir Organi Mov. 2009;93(3):183-185.

28.  Lewis SL, Pozo JL, Muirhead-Allwood WF. Coronal fractures of the lateral femoral condyle. J Bone Joint Surg Br. 1989;71(1):118-120.

29.  Arastu MH, Kokke MC, Duffy PJ, Korley RE, Buckley RE. Coronal plane partial articular fractures of the distal femoral condyle: current concepts in management. Bone Joint J. 2013;95-B(9):1165-1171.

30.  Westmoreland GL, McLaurin TM, Hutton WC. Screw pullout strength: a biomechanical comparison of large-fragment and small-fragment fixation in the tibial plateau. J Orthop Trauma. 2002;16(3):178-181.

31.  Jarit GJ, Kummer FJ, Gibber MJ, Egol KA. A mechanical evaluation of two fixation methods using cancellous screws for coronal fractures of the lateral condyle of the distal femur (OTA type 33B). J Orthop Trauma. 2006;20(4):273-276.

References

1.    Midelfart V. En sjelden luxation of patella. Norsk Magazin for Laegevidenskaben. 1887;4:588.

2.    Kramer DE, Simoni MK. Horizontal intra-articular patellar dislocation resulting in quadriceps avulsion and medial patellofemoral ligament tear: a case report. J Pediatr Orthop B. 2013;22(4):329-332.

3.    van den Broek TA, Moll PJ. Horizontal rotation of the patella. A case report with review of the literature. Acta Orthop Scand. 1985;56(5):436-438.

4.    Flanagin BA, Cruz AI, Medvecky MJ. Hoffa fracture in a 14-year-old. Orthopedics. 2011;34(2):138.

5.    Strauss E, Nelson JM, Abdelwahab IF. Fracture of the lateral femoral condyle. A case report. Bull Hosp Jt Dis Orthop Inst. 1984;44(1):86-90.

6.    Biau DJ, Schranz PJ. Transverse Hoffa’s or deep osteochondral fracture? An unusual fracture of the lateral femoral condyle in a child. Injury. 2005;36(7):862-865.

7.    McDonough PW, Bernstein RM. Nonunion of a Hoffa fracture in a child. J Orthop Trauma. 2000;14(7):519-521.

8.    Brady TA, Russell D. Interarticular horizontal dislocation of the patella. A case report. J Bone Joint Surg Am. 1965;47(7):1393-1396.

9.    Yuguero M, Gonzalez JA, Carma A, Huguet J. Intra-articular patellar dislocation. Orthopedics. 2003;26(5):517-518.

10.  Frangakis EK. Intra-articular dislocation of the patella. A case report. J Bone Joint Surg Am. 1974;56(2):423-424.

11.  Nanda R, Yadav RS, Thakur M. Intra-articular dislocation of the patella. J Trauma. 2000;48(1):159-160.

12.  Choudhary RK, Tice JW. Intra-articular dislocation of the patella with incomplete rotation--two case reports and a review of the literature. Knee. 2004;11(2):125-127.

13.  Chatziantoniou I, Diakos G, Pantelelli M. Horizontal dislocation of the patella. Case report. EEXOT. 2008;59(2):112-114.

14.  McHugh G, Ryan E, Cleary M, Kenny P, O’Flanagan S, Keogh P. Intra-articular dislocation of the patella. Case Rep Orthop. 2013;2013:535803.

15.  Bankes MJ, Eastwood DM. Inferior dislocation of the patella in the degenerate knee. Injury. 2002;33(6):528-529.

16.  Theodorides A, Guo S, Case R. Intra-articular dislocation of the patella: A case report and review of the literature. Injury Extra. 2010;41(10):103-105.

17.  Dimentberg RA. Intra-articular dislocation of the patella: case report and literature review. Clin J Sport Med. 1997;7(2):126-128.

18.  Morin WD, Steadman JR. Case report of a successful closed reduction without anesthesia. Clin Orthop. 1993(297):179-181.

19.  Murakami Y. Intra-articular dislocation of the patella. A case report. Clin Orthop. 1982;171:137-139.

20.  Joshi RP. Inferior dislocation of the patella. Injury. 1997;28(5-6):389-390.

21.  Garner JP, Pike JM, George CD. Intra-articular dislocation of the patella: two cases and literature review. J Trauma. 1999;47(4):780-783.

22.  McCarthy TA, Quinn B, Pegum JM. Inferior dislocation of the patella: an unusual cause of a locked knee. Ir J Med Sci. 2001;170(3):209-210.

23.  Manfredini M, Gildone A, Ferrante R, Bernasconi S, Massari L. Unicondylar femoral fractures: therapeutic strategy and long-term results. A review of 23 patients. Acta Orthop Belg. 2001;67(2):132-138.

24.  Holmes SM, Bomback D, Baumgaertner MR. Coronal fractures of the femoral condyle: a brief report of five cases. J Orthop Trauma. 2004;18(5):316-319.

25.  Nork SE, Segina DN, Aflatoon K, et al. The association between supracondylar-intercondylar distal femoral fractures and coronal plane fractures. J Bone Joint Surg Am. 2005;87(3):564-569.

26.  Allmann KH, Altehoefer C, Wildanger G, et al. Hoffa fracture--a radiologic diagnostic approach. J Belge Radiol. 1996;79(5):201-202.

27.  Oztürk A, Ozkan Y, Ozdemir RM. Nonunion of a Hoffa fracture in an adult. Chir Organi Mov. 2009;93(3):183-185.

28.  Lewis SL, Pozo JL, Muirhead-Allwood WF. Coronal fractures of the lateral femoral condyle. J Bone Joint Surg Br. 1989;71(1):118-120.

29.  Arastu MH, Kokke MC, Duffy PJ, Korley RE, Buckley RE. Coronal plane partial articular fractures of the distal femoral condyle: current concepts in management. Bone Joint J. 2013;95-B(9):1165-1171.

30.  Westmoreland GL, McLaurin TM, Hutton WC. Screw pullout strength: a biomechanical comparison of large-fragment and small-fragment fixation in the tibial plateau. J Orthop Trauma. 2002;16(3):178-181.

31.  Jarit GJ, Kummer FJ, Gibber MJ, Egol KA. A mechanical evaluation of two fixation methods using cancellous screws for coronal fractures of the lateral condyle of the distal femur (OTA type 33B). J Orthop Trauma. 2006;20(4):273-276.

Issue
The American Journal of Orthopedics - 44(6)
Issue
The American Journal of Orthopedics - 44(6)
Page Number
E195-E198
Page Number
E195-E198
Publications
Publications
Topics
Article Type
Display Headline
Intra-Articular Dislocation of the Patella With Associated Hoffa Fracture in a Skeletally Immature Patient
Display Headline
Intra-Articular Dislocation of the Patella With Associated Hoffa Fracture in a Skeletally Immature Patient
Legacy Keywords
american journal of orthopedics, AJO, case report and literature review, case report, online exclusive, intra-articular, dislocation, patella, knee, hoffa fracture, fracture, fracture management, trauma, joint, potini, gehrmann
Legacy Keywords
american journal of orthopedics, AJO, case report and literature review, case report, online exclusive, intra-articular, dislocation, patella, knee, hoffa fracture, fracture, fracture management, trauma, joint, potini, gehrmann
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media